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The role of abnormal DNA methylation in the progression of disease is a growing 
area of research that relies upon the establishment of sound statistical methods. The 
common method for declaring there is differential methylation between two groups at a 
given CpG site, as summarized by the difference between proportions methylated ∆β=β1-
β2, has been through use of a Filtered Two Sample t-test, using the recommended filter of 
0.17 (Bibikova et al., 2006b). In this dissertation, we performed a re-analysis of the data 
used in recommending the threshold by fitting a mixed-effects ANOVA model. It was 
determined that the 0.17 filter is not accurate and conjectured that application of a Filtered 
xii 
Two Sample t-test likely leads to loss of power. Further, the Two Sample t-test assumes 
that data arise from an underlying distribution encompassing the entire real number line, 
whereas β1 and β2 are constrained on the interval [ ]1,0 . Additionally, the imposition of a 
filter at a level signifying the minimum level of detectable difference to a Two Sample t-
test likely reduces power for smaller but truly differentially methylated CpG sites.  
Therefore, we compared the Two Sample t-test and the Filtered Two Sample t-test, which 
are widely used but largely untested with respect to their performance, to three proposed 
methods.  These three proposed methods are a Beta distribution test, a Likelihood ratio 
test, and a Bootstrap test, where each was designed to address distributional concerns 
present in the current testing methods.  It was ultimately shown through simulations 
comparing Type I and Type II error rates that the (unfiltered) Two Sample t-test and the 
Beta distribution test performed comparatively well. 
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CHAPTER 1 Overview of DNA Methylation and the Illumina Technology 
 
Cancer is a class of diseases marked by a continuing increase in aberrant gene 
function.  This aberrant gene function likely arises from either a genetic mutation or an 
epigenetic change.  An epigenetic change is a modification to genomic DNA that has only 
implications in gene expression capacity but leaves the primary sequence of the DNA 
unchanged.  Research has long recognized the role of genetic mutations, whether inherited 
through the germ line or arising in somatic tissues later in life, in contributing to cancer.  
However, more recent studies evidencing their role in the progression of tumors have 
brought epigenetic changes to the forefront of cancer research (Jones, 2002).    
 
1.1 Genetic Packaging and Epigenetic Modifications 
 
To understand the role of epigenetic changes in contribution to cancer, one must first take a 
deeper look at the mechanisms of genetic packaging and expression.  The genetic 
information of eukaryotic cells is stored as DNA in their nucleus.  The enormous amount 
of DNA is compactly stored in the nucleus of each cell by means of a complex 
combination with proteins to form chromatin.  The fundamental repeating storage unit of 
this chromatin is called a nucleosome; each nucleosome contains approximately 146 base 
pairs of DNA wrapped around it.  In addition to providing a compact storage mechanism 
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of DNA, chromatin also preserves the appropriate access to it through the interaction of the 
nucleosome with specific protein complexes that associate with, manipulate and 
epigenetically modify the nucleosome (Rountree, 2001).  These epigenetic modifications, 
while not affecting the primary structure of the genetic code, can have implications in the 
secondary interactions that are critical to the regulation of gene expression.  The interaction 
of specific interest here is transcription status. 
Transcription is the process of forming an equivalent RNA copy of a sequence of 
DNA (MedicineNet.com, 2010).  The regulation of transcription by means of an epigenetic 
modification could have the ability to alter a wide range of gene function from high-level 
expression to complete silencing (Rountree, 2001).  Two epigenetic modifications, in 
particular, have garnered much interest in their inverse roles in transcriptional regulation 
and hence in their role in the progression of cancer.  The first epigenetic modification, 
histone acetylation involves the acetylation of the amino-terminal tails of histones H3 and 
H4 by histone acetyltransferases (HATs) and is implicated in transcriptional activation.  
The second epigenetic modification, which is of primary concern for study here, is DNA 
methylation. 
 
1.2 DNA Methylation: An Overview 
 
DNA methylation is the addition of a methyl group to the 5′-carbon of a cytosine.  
The only methylated base in human DNA is a 5-methylcytosine located in a cytosine-
guanine (CG) dinucleotide, also referred to as a CpG site. DNA methylation occurs by 
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means of an S-adenosyl-methionine acting as a methyl donor by means of adding a methyl 
group to the cytosine ring to form methyl cytosine (Eng, 2000).  This reaction is catalyzed 
by DNA methyltransferases (DNMTs), of which there are three types: Dnmt1, Dnmt3a, 
and Dnmt3b (Rountree, 2001).  Through the interplay of these three enzymes and their 
associated factors which target and regulate their enzymatic activity, genomic methylation 
patterns are established during embryogenesis.  
CpG sites, and consequently DNA methylation sites, are not distributed evenly 
throughout the genome.  Rather, CpG sites are relatively scarce throughout the genome as 
a whole, and  they are clustered in regions of the DNA strand called “CpG islands,” 
broadly defined as CG rich regions of DNA (Herman, 2003).    More specifically, CpG 
islands are characterized as sequences longer than 200 base pairs in length with a CG 
dinucleotide content of greater than 50% and an observed over expected ratio of CpG 
dinucleotides of at least 0.6 (Gardiner-Garden and Frommer, 1987, Takai and Jones, 2002).  
CpG islands are primarily found in the 5′-regions of housekeeping genes, spanning from 
the promoter region to the first exon.  The rationale behind the existence of CpG islands is 
as follows: it has been shown that most (~80%) of CpG dinucleotides that are located 
outside the bounds of a CpG island are methylated (Herman, 2003). Over time, this 
methylation has reduced the overall frequency of CpGs in the genome as a whole due to 
the fact that methylated cytosines have an increased vulnerability to deamination (Bird, 
1980).  On the other hand, most of the CpG dinucleotides within the bounds of CpG 
islands are unmethylated, rendering them less vulnerable to deamination, hence preserving 
the expected frequency of CpG dinucleotides in these regions (Rountree, 2001).  However, 
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while most CpG islands are normally unmethylated, areas of dense DNA methylation do 
naturally occur in these regions and are primarily associated with germ line differentiation 
through the inactivation of genes on the X-chromosome in somatic cells and with the 
silencing of alleles of imprinted genes. 
 
1.3 Aberrant DNA methylation 
 
The condition of study here for its role in the progression of cancer was aberrant 
DNA methylation and its effect on the transcription of RNA.  Abnormal DNA methylation 
in gene promoter regions is shown to interfere in the transcription of DNA to RNA, 
ultimately suppressing gene expression (Michalowsky, 1989).  When gene expression is 
suppressed in a gene responsible for inhibiting the progression to cancer, like the tumor 
suppressor gene, the chance for the development of a cancerous lesion increases.  The 
interaction of methylcytosine binding proteins with other structural components of the 
chromatin renders the DNA inaccessible to transcription factors through histone 
deacetylation and chromatin structure changes, thereby accomplishing this gene silencing 
effect.   
 
1.4 The role of environmental toxins in aberrant DNA methylation 
 
 While its exact cause is not always known, DNA methylation can be either 
heritable or as a novel response to toxins (Dolinoy et al., 2007; Illumina, 2006; Liu et al., 
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2008).  The incidence of aberrant DNA methylation as a response to environmental toxins 
is well documented, and three recent and important studies are here highlighted.  
 In Dolinoy et al. (2007), the effects of maternal exposure to the estrogenic 
xenobiotic chemical bisphenol A (BPA) on the fetal epigenome was explored by studying 
the Agouti gene in viable yellow agouti mice.  The Agouti gene controls hair color and was 
studied because it is a metastable epiallele, an allele that, owing to differential methylation 
patterns, can be expressed variably in genetically identical individuals.  Female mice were 
fed food supplemented with BPA beginning two weeks prior to mating through pregnancy 
and lactation.  Dolinoy et al. examined the coat color of the litter and measured DNA 
methylation at nine sites in the Agouti gene.  Compared to a control litter, the litter of mice 
exposed maternally to BPA exhibited a different distribution of coat color that was skewed 
towards a lighter coat.  Furthermore, they showed that BPA exposure reduced the 
percentage of cells with methylation at the nine measured sites in the Agouti gene.  It was 
also found that greater variability in methylation patterns existed between animals than 
within a range of tissue types of a single mouse which suggested that the methylation 
patterns were likely to have been established early in the embryonic development. 
As a second example of the role of an environmental toxin in aberrant DNA 
methylation we turn to Weihrauch et al. (2001).  Here, the mechanism of the effect of 
Vinyl chloride (VC) exposure on hepatocellular carcinomas (HCC) was examined.  VC is 
a colorless toxic gas widely employed as a refrigerant and intermediate in organic 
synthesis.  It is well-documented both that in VC-associated liver angiosarcomas (LAS), 
mutations of the K-ras-2 gene exist and that K-ras-2 mutations induce p16 methylation 
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accompanied by the inactivation of the p16 gene, i.e., the tumor suppressor gene.  
Weihrauch et al. hypothesized that there was a similar relation between VC-associated 
HCC and mutations of the K-ras-2 gene and subsequent methylation of the p16 gene.  In 
comparing a sample of patients with VC associated HCCs against a control group of 
patients with HCC due to other demonstrated factors, it was determined that there was 
indeed an increased proportion of K-ras-2 gene mutation and abnormal hypermethylation 
of the p16 gene in the test sample.  This suggested that exposure to the toxin VC does, in 
fact, play an important role in the pathogenesis of VC-associated HCC by means of K-ras-
2 mutations and resulting p16 gene methylation. 
 Finally, in Liu et al. (2008), the effect of combined exposure to the inhaled diesel 
exhaust particles toxin and a fungus allergen Aspergillus fumigatus on methylation levels 
was observed.  Resulting from a 3-week course of inhaled diesel exhaust particle exposure 
while undergoing intranasal sensitization to A. fumigates, hypermethylation was induced 
at CpG-45, CpG--53, and CpG-205 sites of the cytokine interferon (IFN)-γ   promoter and 
hypomethylation at CpG-408 of the T helper (Th) 2  interleukin (IL)-4 cytokine promoter. 
The induced methylation changes of the promoters in both genes were significantly 
correlated with changes in immunoglobin (Ig) E levels.  While much research has 
demonstrated both the role of Th 2 IL-4 cytokines in promoting allergic sensitization and 
asthma and the role of Th1 cytokine IFN-γ in protecting against allergic sensitization and 
asthma, this study was the first to show that inhaled environmental exposures can affect 
asthma pathogenesis by altering methylation patterns of Th genes in vivo. 
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Therefore, as demonstrated by the aforementioned articles, aberrant DNA 
methylation is a research topic of current and specific interest.  DNA methylation has been 
implicated in several cancers ranging from breast cancer to Acute Lymphoblastic 
Leukemia and colon cancer by means of silencing the tumor suppressor gene (Yan et al., 
2000; Roman-Gomez et al., 2002; Suzuki et al., 2002).  In this thesis, aberrant DNA 
methylation was examined as it relates the hepatocellular carcinoma due to hepatitis C 
infection.   
 
1.5 The Illumina Technology 
 
Of particular interest here was the detection of methylation sites for the quantitative 
analysis of differential methylation patterns.  Thus, the need for a technology to accurately 
and completely asses the methylation status of the large number of existing CpG sites 
arises.  The GoldenGate Methylation BeadArray Cancer Panel I platform is technology 
developed by Illumina for cancer-focused methylation analysis.  It enables the 
simultaneous analysis of up to 1,505 CpG loci selected from 807 genes, and it runs two or 
more CpG assays for over 74% of these genes (Illumina, 2006).  This GoldenGate 
BeadArray begins with a bisulfite treatment to DNA that converts unmethylated cytosines 
to uracils while leaving methylated cytosines unchanged. This bisulfite treated genomic 
DNA is then immobilized on paramagnetic beads.  Then, for each CpG site, an allele-
specific oligonucleotide and a locus specific oligonucleotide are assembled for each the 
methylated and unmethylated state, where separate labels (red and green, respectively) are 
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used to design each of the two states. Thus, two pairs of probes are designed for each site.  
For all loci simultaneously, the pooled oligonucleotides are assayed by annealing to the 
target sequence and then washed to remove excess or mishybridized oligonucleotides.  
Extension of the allele specific oligonucleotides to the locus specific oligonucleotides and 
subsequent ligation creates PCR templates, which are amplified with fluorescently labeled 
universal primers.  The resulting products are ultimately hybridized to a beadarray bearing 
the complementary address sequences.  The fluorescent expression for each the methylated 
and unmethylated states are quantified and reported as two channel array data.  Therefore, 
each array consists of expression values for the methylated target sequence (Red) as well 
as expression values for the unmethylated target sequence (Green). 
 The Illumina assay represents each CpG site as a specific beadtype, and it 
incorporates approximately 30 beads (e.g. oligonucleotides) per beadtype to ensure the 
assay’s reproducibility.  As some examples, the Illumina GoldenGate BeadArray  platform 
has been used in studies to show that human embryonic stem cells are distinguished from 
all other cell types by their methylation profile (Bibikova et al., 2006a), to differentiate 
methylation patterns between lung adenocarcinomas and normal lung tissues (Bibikova et 
al., 2006b), to identify genes that show aberrant DNA methylation in hematologic 
neoplasms (Martin-Subero et al., 2009), and to identify CpG loci exhibiting de novo DNA 
methylation in two molecular subtypes of diffuse large B-cell lymphoma (Wang et al., 
2010).    
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CHAPTER 2 Current Methods for Analyzing DNA Methylation Data 
 
 In this chapter, we introduce the application dataset that motivated this research, 
identifying differentially methylated CpG sites in HCV-induced hepatocellular carcinoma. 
We then describe the two current inferential methods commonly applied when comparing 
two groups with respect to DNA methylation, the Two Sample t-test and the Filtered Two 
Sample t-test.  At the conclusion of this chapter, we also highlight their perceived 
deficiencies.   
 
2.1 Hepatitis C Virus (HCV) Data Set 
 
 Hepatitis C is an infectious disease caused by the Hepatitis C virus (HCV).  The 
Hepatitis C virus is an RNA virus belonging to the family of flaviviruses, which primarily 
targets the hepatocytes, the main tissue of the liver (Lauer, 2001).  HCV is spread by blood 
to blood contact, most often through injection drug use, blood transfusion (although 
increasingly unlikely), and in rare cases, sexual contact.  Acute Hepatitis C, referring to the 
first six months after infection with HCV, is relatively asymptomatic, with only vague 
symptoms including jaundice, malaise, and nausea.  This silent onset of HCV makes the 
assessment of this infection difficult.  In the majority of cases, the Hepatitis C virus 
produces a chronic infection lasting longer than six months.   Most chronic infections 
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result in some degree of fibrosis of the liver, while 15 to 20 percent of those infected 
develop cirrhosis. 
 The time frame in which the various stages of liver disease develop, as a result of 
HCV, varies widely from patient to patient.  In approximately one third of patients, serious 
liver disease develops 20 years or less after infection, while in another third, serious liver 
disease takes 30 years or longer to develop.  Several factors have been proposed to 
accelerate the clinical progression of HCV including alcohol intake, coinfection with HIV-
1 or HBV, male gender, or an older age at infection.  However, once cirrhosis is 
established, the risk of hepatocellular carcinoma (HCC) is approximately 1 to 4 percent per 
year.  Broadly speaking, treatment for HCV infection consists of a combination therapy of 
interferon and ribavirin, although liver transplantation remains the only viable treatment 
option for patients with either decompensated HCV-related cirrhosis or early stage HCC.  
Current studies, such as the methylation data set used here, focus on identifying molecular 
events that may be useful in the early diagnosis of the progression from HCV cirrhosis to 
HCC. 
This research was motivated by a subset of a published methylation data set 
(Archer et al., 2010) which is publicly available at Gene Expression Omnibus, accession 
number GSE 18081  (Edgar et al., 2002; Barrett et al., 2009).  The subset considered in this 
thesis consists of methylation data for 36 patients with either HCV cirrhosis without 
concomintant Hepatocellular Carcinoma (HCC) (N=16) or HCV cirrhosis with 
concomitant HCC (N=20). Each patient’s DNA sample was prepared according to the 
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Illumina technology with primers for the Methylated (Red) and Unmethylated (Green) 
channels. 
 
2.2 Analysis of Methylation Data 
 
In methylation studies such as the one studied here, data are presented as 
expression levels for both the methylated (Red) and unmethylated (Green) channels across 
multiple samples for a given collection of CpG sites.  The data are further divided between 
samples originating from two groups of patients, one group of which presents a certain 
disease.  Then, it is of clinical interest to analyze differences in methylation patterns 
between the two groups.  Here, the first group was comprised of the samples which 
demonstrated HCV cirrhosis without concomitant HCC versus the second group that was 
comprised of samples which demonstrated HCV cirrhosis with concomitant HCC.  These 
CpG sites, once identified, would be marked for future study as locations which could 
factor in the progression of HCV cirrhosis to the development of HCC. 
All of the raw data were read into the R programming environment. Neither 
background correction nor normalization steps were implemented on this initial read-in.  
Bead summary data were created according to the default method used by Illumina as 
follows: 
 First, beads which had intensities greater than 3 median absolute deviations 
(MADs) from the bead median intensity on the original (un-logged) scale were removed 
for each bead type on each array.  Once outliers were removed, the mean intensity of the 
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remaining beads was calculated for each the red and green channels using the unlogged 
scale.  More specifically, for each array (i) and beadtype (i.e. CpG site) (j), beadtype 
expression for the red (methylated) and green (unmethylated) channels was estimated by 
averaging the intensities over the beads within the beadtype, 
∑∑ ==
k
ijk
k
ijijkij gk
Gr
k
R 1,1          (2.1) 
where i=1,2,…,36 indexes the samples, j=1,2,…,1624 indexes the beadtypes, k indexes the 
number of beads per beadtype (k ), and ijkr  and ijkg  are the red and green bead 
intensities, respectively, for the ith sample, jth beadtype, and kth bead.   
Illumina BeadArrays contain approximately 77 blank beadtypes which do not have 
associated gene annotation data.  Therefore only those 1,547 beadtypes with associated 
gene information files were retained for future analyses.  Note that as previously stated, the 
Illumina platform enables the simultaneous analysis of up to 1,505 CpG loci, not including 
control beadtypes.  Thus these 1,547 retained beadtypes indeed include control beadtypes. 
 
2.3 Hypothesis testing using the Two Sample t-test 
 
Upon the collection and preprocessing of methylation data, it was of interest to 
conduct hypothesis testing to deduce differences in methylation patterns between groups.  
CpG sites with differential methylation between the two groups mark sites for future 
studies as sites which possibly contributed to the progression of disease.  Hypothesis tests 
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were performed on a beadtype level summary statistic measuring “proportion methylated” 
which is often computed as 
)0,max()0,max(
)0,max(
ijlijl
ijl
ijl GR
R
+
=β .                     (2.2) 
Again i indexes the array (i=1,…,36), j indexes the beadtype (j=1,…,1547), and here, l 
indexes outcome group (l=1,2).  Note that for the purposes of this paper, no background 
subtraction was performed in this portion of the analysis.  Hypothesis tests for identifying 
differentially expressed CpG sites were performed using the random variable, ‘proportion 
methylated.’  Currently, the two-sample t-test is a widely accepted test in this scenario.  So, 
for each beadtype, a two-sample t-test was applied to the sample proportion methylated to 
test the null hypothesis of the equality of methylation levels in two groups of samples.  
More specifically, letting 1j⋅β  and 2j⋅β  represent the mean population proportion 
methylated across arrays in each group for the jth CpG site, the null hypothesis is 
     210 : jjH ⋅⋅ = ββ                       (2.3) 
which is tested against the alternative hypothesis, 
     211 : jjH ⋅⋅ ≠ ββ .                    (2.4) 
The test statistic for the two-sample t-test is  
2
2
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1
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                  (2.5) 
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 where 1. jβ , 21.ˆ jσ , and 1n   are the sample mean proportion methylated, the sample variance, 
and the sample size, respectively, of the group 1 samples, and 2. jβ , 22.ˆ jσ , and 2n  are those 
corresponding to the group 2 samples for the jth CpG site summarized over the arrays in 
the group.  Next, the degrees of freedom (df) assuming unequal variances in the two 
groups are calculated as 
2
4
2
1
4
1
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.                    (2.6) 
The two-sided p-value is calculated, 
jdfj tFp j ⋅⋅−= 1(2 )                    (2.7) 
where F is the cumulative distribution function of a t distribution. 
Results of a t-test are commonly expressed in terms of a p-value, or the probability 
that a test statistic computed under the condition that the null hypothesis is true is at least 
as extreme as the value of the test statistic that was actually obtained.  A large p-value 
(close to 1) indicates a high probability that the obtained test statistic is aligned with one 
that would typically be computed if the null hypothesis were true. So this is considered as 
evidence in favor of not rejecting the null hypothesis.  A small p-value, on the other hand, 
supports rejection of the null hypothesis and the conclusion that the two means are not 
equivalent. 
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2.4 Filtered Two Sample T-test  
 
  In the landmark paper describing Illumina’s GoldenGate Methylation BeadArray 
assay, Bibikova et al. (2006b) introduced the  Filtered t-test, and this testing framework 
quickly gained in popularity.  Under this testing framework, a CpG site would be identified 
as differentially methylated between two groups of arrays if both the p-value of the Two 
Sample t-test was less than some pre-determined threshold and the difference between the 
mean proportion methylated values, 21 jjj ⋅⋅ −=∆ βββ , was larger than an additionally 
specified threshold.  Bibikova, et al. (2006b) estimated that the Illumina technology can 
discriminate between levels of differentiation that differ by 0.17 or greater, so they used ∆β  
= 0.17 as the threshold for the filtered t-test.  However, since this threshold 
recommendation, more stringent thresholds have been used.  For example, in Richter et al. 
(2009), a two sample t-test was conducted at the α = 0.001 level with an additional filter of 
∆β  > 0.30.  Additionally, responding to a concern of too little statistical power of a 
performed Mann-Whitney U test, Martin-Subero et al. (2009) filtered ∆β at 0.50.   
 
2.5 Limitations of current analysis methods 
 
Despite a lack of study into the performance quality of these two tests on this data 
type, the Two Sample t-test and the Filtered Two Sample t-test have attained widespread 
use.  However, the Two Sample t-test assumes that the sample data follow a normal 
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distribution ranging the entire real number line.  Although, considering the scale of the 
proportion methylated variable (i.e., βijl∈[0,1]∀ i, j, and l), one could argue that a two-
sample t-test is not statistically rigorous.  Furthermore, the application of a Filtered Two 
Sample t-test is only as good as the accuracy of the filter.  That is, applying a filter to the 
two sample t-test may reduce power for many CpG sites with smaller but truly different 
proportions, where power is defined as the probability that a test will reject a false null 
hypothesis.  Thus, in this thesis we performed a detailed analysis into the accuracy of the 
0.17 estimated level of minimum discrimination between methylation levels. We also 
proposed alternative inferential methods for comparing two groups with respect to 
proportion methylated that utilize the scale of the proportion methylated variable (i.e., 
βijl∈[0,1]∀ i, j, and l), and to thus fully consider all known facets of the distribution. In so 
doing, we both propose a new computed minimum level of discrimination, and we further 
solidify recommendations for future testing methodology.   
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CHAPTER 3 Determination of Minimum Level of Discernable Differential Methylation 
According to the Illumina Technology 
 
The application of a Filtered Two Sample t-test hinges on the task of identifying an 
appropriate filter to apply to the delta beta, β∆ , values in conjunction with the Two 
Sample t-test.   Bibikova, et al. (2006b) estimated that the Illumina technology can 
discriminate between levels of differentiation that differ by 0.17 or greater, so often 
17.0=∆β has been used as a threshold for the filtered t-test.  The determination of a 0.17 
threshold was based on a dilution study performed by diluting female genomic DNA to 
male genomic DNA at ratios of 100:0, 50:50, 20:80, 10:90, 5:95, and 0:100 prior to 
bisulfite conversion. This dataset consists of 47 samples from an Illumina Universal Array 
Matrix wherein the GoldenGate Methylation Cancer Panel I was used as the methylation 
assay. Specifically, the 47 samples were derived by mixing male and female genomic 
DNA in the previously specified proportions. Two unique female and 2 unique male 
samples were used in creating the mixtures that were subsequently hybridized: Female 1 
and Male 1 dilutions were each technically replicated 4 times (with exception of the 95:5 
which was replicated 3 times) and Female 2 and Male 2 dilutions were each replicated 4 
times.  17 CpG sites associated with X-linked genes were examined on the X chromosome 
to assess methylation levels.  For each of 17 genes on the X chromosome, Bibikova et al. 
computed the maximum standard deviation over the replicate runs and found that the 
standard deviation of the β- value obtained across the four replicates was <0.06 in 99% of 
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cases.  They concluded that the Illumina technology could thus discriminate levels of 
methylation that differ by at least .17.006.0296.1 ≅××    
Moreover, since this threshold recommendation, more stringent thresholds have 
been used.  For example, in Richter et al., a two sample t-test was conducted at the 
001.0=α  level with an additional filter of 30.0>∆β  (2009).  Additionally, responding to 
a concern of too little statistical power of a performed Mann-Whitney U test, Martin-
Subero et al. (2009) filtered β∆  at 0.50.   
However, we conjecture that a Filtered Two-Sample t-test may severely reduce 
power for CpG sites with small but truly differential ∆β’s.  Nevertheless, if a filter is to be 
applied, the level of the filter should be computed as a function of the analyzed data since 
various factors such tissue type and handling can affect the amount of variability in CpG 
site methylation across technical replicates.  Therefore, the application of a standard 
filtering level such as that developed by Bibikova et. al. or a more “conservative” filter 
level as seen in other research studies could in actuality be missing very real differential 
methylation patterns present in the data. 
To investigate the proposed filter, herein we perform a re-analysis of the dilution 
data (Bibikova et al., 2006).  This data set provided what was needed to compute a 
minimum discernable level of differential methylation because it is essentially a clinical 
data set in which the true outcome is known.  As alluded to in Chapter 1, DNA methylation 
is the means by which one of the two X chromosomes in a female is inactivated for germ 
line differentiation in somatic cells.  Because males only possess one X chromosome, 
methylation for this purpose does not occur.  Therefore, for genes linked to the X 
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chromosome, one could expect approximately 50% methylation of these genes in a sample 
arising from a female and 0% methylation of these genes in a sample arising from a male.  
The dilution data set of Bibikova et al. consisted of 17 X linked genes measured in 
mixtures of female and male genomic DNA samples where the mixtures were according to 
specific proportions.  It can then be expected that a sample with 100% Female: 0% Male 
would exhibit approximately 50% methylation, and so on, as summarized in Table 3.1 
below.  
Mixing Ratio  
Expected 
approximate 
methylation level 
1. 100% Female: 0% Male 50% 
2. 50% Female: 50% Male 25% 
3. 20% Female: 80% Male 10% 
4. 10% Female: 90% Male 5% 
      5.     5% Female: 95% Male 2.5% 
      6.     0% Female: 100% Male 0% 
Table 3.1 Expected approximate methylation level for X linked  
genes given mixing ratio. 
 
To conclude a minimum level of discernable differential methylation, we sought to make 
the following five comparisons to determine if differential methylation could be detected:  
MaleFemaleMaleFemale
MaleFemaleMaleFemale
MaleFemaleMaleFemale
MaleFemaleMaleFemale
MaleFemaleMaleFemale
%100:%0versus%95:%5
%95:%5versus%90:%10
%90:%10versus%80:%20
%80:%20versus%50:%50
%50:%50versus%0:%100
BRatio MixingversusARatio Mixing
 
Briefly, across the 17 X-chromosome linked CpG sites, it was sought to model methylation 
levels as a function of the mixing ratio of female to male DNA.  By means of this resulting 
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model, we both obtained an accurate description of and established the significance of the 
relationship between the proportion methylation level and the mixing ratio.  Additionally, a 
mixed ANOVA model was employed to the perform five pairwise comparisons listed 
above testing for differences in the mean methylation levels between two mixing ratios.  In 
so doing, we can determine that differential methylation can be identified at values as 
small as the minimum mixing ratio comparison showing a significant difference in 
methylation.  This chapter concludes with a summary of the results of these hypothesis 
tests and the conclusions drawn. 
 
3.1 Motivation and Methods: Hierarchical model building to Bibikova et al. dilution data 
 
We sought a model to appropriately define the relationship of the proportion of 
methylation across CpG sites as a function of the mixing ratio.  As evidenced in Figure 3.1, 
the ratio of Female to Male DNA in a sample possesses a nonlinear relation with 
methylation level. 
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Figure 3.1. Boxplot of proportion methylation by percent of female  
genomic DNA in the hybridized sample 
 
Moreover, it is also graphically observed that this nonlinear relation appears to depend 
both on dilution order (Female 1: Male 1 vs. Female 2: Male 2; see Figure 3.2) and on the 
particular CpG site within this dilution order that the methylation is measured (see Figure 
3.3). 
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Figure 3.2 Mean proportion methylated level across CpG site by 
percent of  female genomic DNA in sample for the first dilution 
order (top panel) and the second dilution order (bottom panel) 
 
 
 
 
Figure 3.3 Proportion methylated level by Percent of female genomic DNA 
for each CpG site (1-17) within dilution order (1-2) 
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By design, while neither the CpG site nor the dilution order should affect the 
relationship between mixing ratio and methylation level, Figures 3.2 and 3.3 demonstrate 
evidence of random differences within these grouping levels.  Therefore, owing to these 
differing nonlinear shapes at both the dilution order level and the CpG site level, it was 
concluded that a nonlinear mixed effects model was the most appropriate model building 
procedure with which to progress.  Additionally, owing to the fact that four technical 
replicates were produced for each mixing ratio (with exception of the 95:5 which was 
replicated 3 times), we hypothesized that random differences among the order of the 
replicates could potentially exist.  Therefore, we chose to fit a nonlinear mixed effects 
model summarizing the mean proportion of methylation at each mixing ratio while 
employing random effects for the dilution order (1 or 2), the technical replicate order (1, 2, 
3, or 4) nested within each dilution order, and the particular CpG site (1,…,17) within each 
replicate order that was nested within each dilution order.  
Given that the nature of the data was CpG site methylation from each of 17 sites 
within each of two females and two males, one would expect the proportion of methylation 
across each of the 17 CpG sites to be correlated.  Indeed, this is the case, as illustrated in 
Table 3.2, and the presence of such correlations further motivates the construction of a 
single nonlinear model to summarize the proportion of methylation across the 17 CpG 
sites. 
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EFNB1-645 EFNB1-672 ELK1-1163ELK1-1306ELK1-1495ELK1-877FMR1-1182 FMR1-1440 G6PD-1076 G6PD-1304 G6PD-834 GLA-1158 GLA-1294 GLA-1306 GLA-1388 GLA-881 GPC3-1182
EFNB1-645 1.00 0.98 0.97 0.96 0.99 0.98 0.97 0.99 0.98 0.99 0.96 0.99 0.81 0.68 0.99 0.73 0.95
EFNB1-672 0.98 1.00 0.99 0.97 0.98 0.99 0.99 0.99 0.98 0.98 0.96 0.99 0.86 0.74 0.99 0.78 0.98
ELK1-1163 0.97 0.99 1.00 0.97 0.95 0.99 0.99 0.98 0.98 0.96 0.96 0.97 0.84 0.72 0.98 0.77 0.98
ELK1-1306 0.96 0.97 0.97 1.00 0.94 0.97 0.96 0.96 0.99 0.95 0.99 0.97 0.72 0.59 0.96 0.65 0.95
ELK1-1495 0.99 0.98 0.95 0.94 1.00 0.98 0.96 0.99 0.96 0.99 0.93 0.99 0.82 0.69 0.99 0.74 0.94
ELK1-877 0.98 0.99 0.99 0.97 0.98 1.00 0.99 0.99 0.99 0.98 0.97 0.99 0.83 0.70 0.99 0.75 0.97
FMR1-1182 0.97 0.99 0.99 0.96 0.96 0.99 1.00 0.99 0.98 0.97 0.96 0.98 0.86 0.74 0.98 0.79 0.98
FMR1-1440 0.99 0.99 0.98 0.96 0.99 0.99 0.99 1.00 0.98 0.99 0.95 0.99 0.85 0.72 1.00 0.77 0.97
G6PD-1076 0.98 0.98 0.98 0.99 0.96 0.99 0.98 0.98 1.00 0.97 0.99 0.98 0.77 0.63 0.98 0.69 0.96
G6PD-1304 0.99 0.98 0.96 0.95 0.99 0.98 0.97 0.99 0.97 1.00 0.95 0.99 0.81 0.68 0.99 0.73 0.94
G6PD-834 0.96 0.96 0.96 0.99 0.93 0.97 0.96 0.95 0.99 0.95 1.00 0.97 0.70 0.57 0.96 0.62 0.94
GLA-1158 0.99 0.99 0.97 0.97 0.99 0.99 0.98 0.99 0.98 0.99 0.97 1.00 0.81 0.68 0.99 0.73 0.96
GLA-1294 0.81 0.86 0.84 0.72 0.82 0.83 0.86 0.85 0.77 0.81 0.70 0.81 1.00 0.96 0.83 0.97 0.86
GLA-1306 0.68 0.74 0.72 0.59 0.69 0.70 0.74 0.72 0.63 0.68 0.57 0.68 0.96 1.00 0.71 0.98 0.77
GLA-1388 0.99 0.99 0.98 0.96 0.99 0.99 0.98 1.00 0.98 0.99 0.96 0.99 0.83 0.71 1.00 0.76 0.96
GLA-881 0.73 0.78 0.77 0.65 0.74 0.75 0.79 0.77 0.69 0.73 0.62 0.73 0.97 0.98 0.76 1.00 0.82
GPC3-1182 0.95 0.98 0.98 0.95 0.94 0.97 0.98 0.97 0.96 0.94 0.94 0.96 0.86 0.77 0.96 0.82 1.00
 
Table 3.2 Correlation among 17 CpG sites. 
 
The model building procedure was performed using the nlme library in R version 
2.11.1 (R Development Core Team, 2010).  Owing to the shape of the methylation curves 
in Figure 3.3, a Logistic Regression model was chosen for our model building procedure.  
Model formulation for the mixed Logistic Regression model is as follows. 
 
3.1(a) Nonlinear Mixed Model Formulation: Logistic Regression Model 
 
An initial model (Equation 3.1) was fit including independent random effects for 
the jth CpG site within the mth dilution order level and the nth technical replicate order.  
Generally, the nonlinear mixed model employing three nested random effects is 
represented 
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where y summarizes the mean proportion of methylation as a function of x, mixing ratio 
(Pinheiro and Bates, 2000).  Here, β is a vector of fixed effects, with design matrix mnjA .  
The first level random effects, mb , those corresponding to the mth dilution order, are 
independently distributed vectors with variance-covariance matrix 1Ψ and a corresponding 
design matrix, njm,B .  The second level random effects, mnb , those corresponding to the nth 
technical replicate within the mth dilution order, are independently distributed vectors with 
variance-covariance matrix 2Ψ and a corresponding design matrix, jmn,B .  And, the third 
level random effects, mnjb , those corresponding to the jth CpG site nested within the mth 
dilution order and the nth technical replicate, are independently distributed vectors with 
variance-covariance matrix 3Ψ and a corresponding design matrix, mnjB .    
Using the framework of the Logistic regression model, this model is expressed  
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and the random coefficients are modeled 
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Note that in Equation 3.2, the asymptote as the percent of Female genomic DNA 
approaches 100 is fixed at 0.5 because, biologically, this is the expected proportion of 
methylation for this mixing ratio level.  Furthermore, 2ϕ represents the value of percent of 
Female genomic DNA present in the mixture at the inflection point of the curve and 3ϕ is a 
scale parameter on the x-axis quantifying the relationship between mixing ratio and 
proportion of methylation. 
 
3.1(b) Model Selection 
 
Now that the methodology underlying the candidate model has been outlaid, the 
model was estimated and the adequacy of the model fit was evaluated by means of a 
residual plot.  A plot of the standardized residuals plotted as a function of the fitted values 
revealed systematic departures from zero as demonstrated in Figure 3.4. 
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Figure 3.4 Standardized residuals plotted  
as a function of the fitted values for the  
original Logistic regression model 
 
In response to these systematic departures, an alternative Logistic regression model was fit 
employing an alternative variance structure of the within group errors.  This variance 
model was in the form in which the variance at each CpG site increases exponentially with 
the percent of Female DNA present in the mixture.  This property can be graphically 
observed in Figure 3.3 by noting that the curves describing the expected proportion of 
methylation become much more highly variable as the percent of Female DNA increases.  
Indeed the application of this structure yielded a more appropriate plot of the standardized 
residuals plotted as a function of the fitted values: 
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Figure 3.5 Standardized residuals plotted as a  
function of the fitted values using an exponential  
variance structure. 
 
As a final verification of model adequacy, a plot of the fitted methylation values overlaid 
upon the observed methylation values in the mixture data set for the updated model using 
the exponential variance structure is included in Figure 3.6 below.  Given that the fitted 
mean curve adheres well to observed data, we concluded that the model provides an 
appropriate fit. 
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   Figure 3.6 Mean fitted proportion methylated  
curve overlaid upon observed proportion methylated  
values.  
 
Our model building procedure concluded with significance testing for the inclusion of the 
three random effects in the model.  We began with significance testing for the random 
component associated with the jth CpG site, which was nested within the mth dilution 
order and the nth technical replicate.  This was assessed by fitting a new Logistic 
regression model where the random effects associated with CpG site were dropped from 
the model.  The resulting reduced model was compared to the original full model by means 
of a Likelihood Ratio Test, where the test statistic is computed 






−= )(
)(ln2
1
0
HL
HL
D         (3.4) 
Here, )( 0HL is the likelihood of the of the Logistic Regression model under the null 
hypothesis of a full model containing a random term for the nested CpG site effect in the 
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model.  And, )( AHL is the likelihood under the alternative hypothesis of a reduced model 
where either .0 and 0 32 == mnjmnj bb   The likelihood ratio test statistic was compared to a 
chi-squared distribution with 21 nn −  degrees of freedom, where 1n  and 2n  are the degrees 
of freedom of the full and reduced models, respectively.  The p-value of the performed 
Likelihood Ratio test was 0.06 which was considered only marginally significant.  
Therefore, it was concluded that evidence for dropping the random components for the 
nested CpG site effect did not exist. 
 
3.1(c) Establishment of a significant relationship between Proportion of Methylation and 
Mixing Ratio 
 
 By means of this resulting model, we obtained an accurate description of the 
relationship between the proportion methylation level and the mixing ratio.  We used the 
fitted mixed Logistic regression model to establish the significance of this dose-response 
relationship.  We examined the 3ϕ parameter from the fitted model because this parameter 
defines the slope of our nonlinear model, and thus, it describes the nature of the relation 
between our independent and dependent variables.  In the estimated model, 40.8ˆ3 =ϕ , 
with a 95% confidence interval ( ..2ˆ3 es∗±ϕ ) of (5.61, 11.89).  Because this confidence 
interval does not include zero, we conclude there is a significant relationship between 
percent of female genomic (dose) and proportion methylation level (response). Therefore 
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we proceeded in performing pairwise comparisons of adjacent levels for better discerning 
the minimum level of detectable differential methylation, 
 
3.2 Establishing a Minimum Level of Detectable Differentiation 
 
Upon establishing both the nature and the significance of the relationship between 
mixing ratio and the mean level of proportion of methylation at each CpG site, we wished 
to establish a minimum level of detectable differentiation for the Illumina technology.  In 
this manner, we evaluated whether the threshold of 0.17 established in Bibikova et al. 
(2006b) that was claimed to be the minimum level of differentiation that the Illumina 
technology could detect was appropriate.   
 In establishing the minimum level of discrimination, we sought to perform the five 
comparisons previously outlined, and listed again here: 
MaleFemaleMaleFemale
MaleFemaleMaleFemale
MaleFemaleMaleFemale
MaleFemaleMaleFemale
MaleFemaleMaleFemale
BRatioMixingARatioMixing
%100:%0versus%95:%5
%95:%5versus%90:%10
%90:%10versus%80:%20
%80:%20versus%50:%50
%50:%50versus%0:%100
versus
 
A mixed ANOVA model was employed to perform these five pairwise comparisons testing 
for differences in the mean methylation levels between two mixing ratios.  Because, by 
biological principle, we could anticipate the methylation levels present at each mixing ratio 
(see Table 3.1), we could also anticipate the differential level of methylation present for 
each of the five pairwise comparisons.  For example, for the comparison of 100% Female: 
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0% Male versus 50% Female: 50% Male, we could have expected a difference in mean 
methylation of approximately 0.50-0.25=0.25, and so on, down to the last pairwise 
comparison designed to query a difference in mean methylation of 0.025.  The minimum 
level of discernable discrimination was then concluded to be the minimum queried 
difference in mean methylation for which the pairwise comparison determined 
significantly differentially methylated between the two mixing ratios. 
The form of the mixed ANOVA model was as follows: 
rmnjmnjmnmrrmnjy εδγβαµ +++++= ⋅⋅⋅⋅ )()(      (Eq. 3.5) 
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(Kutner et al., 2005). 
A likelihood ratio test for the significance of the CpG site nested effect 
( 0:.0: )()(0 ≠= mnjAmnj HvsH δδ ) demonstrated that we rejected the null hypothesis and 
concluded that a nested random effect for the effect of the jth CpG site was valid in the 
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model fit (p-value=<0.001).  A plot of the standardized residuals versus the fitted values 
for the mixed ANOVA model is presented in Figure 3.7 below. 
Fitted values
St
a
n
da
rd
iz
e
d 
re
si
du
a
ls
-2
0
2
0.0 0.2 0.4 0.6 0.8
 
   Figure 3.7 Standardized residuals versus fitted  
   values in final mixed ANOVA model. 
 
Using the mixed ANOVA model (Eq. 3.5), the previously listed pairwise comparisons for 
testing differences in the factor level means of the adjacent mixing ratios were conducted.  
Here, 0:0 =− ⋅⋅⋅′⋅⋅⋅ rrH µµ versus 0: ≠− ⋅⋅⋅′⋅⋅⋅ rrAH µµ .  Testing was conducted at the 95% 
significance level and results for the five pairwise comparisons are summarized in Table 
3.3. 
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Pairwise 
Comparison 
Expected 
Differential 
Methylation 
Estimate Std. Error t-value p-value 
µ(100%F:0%M) vs. 
µ(50%F:50%M) 0.25 0.104 0.033 3.128 0.026 
µ(50%F:50%M) vs. 
µ(20%F:80%M) 0.15 0.170 0.033 5.116 0.004 
µ(20%F:80%M) vs. 
µ(10%F:90%M) 0.05 0.134 0.033 4.024 0.010 
µ(10%F:90%M) vs. 
µ(5%F:95%M) 0.025 0.088 0.033 2.641 0.046 
   µ(5%F:95%M) vs. 
µ(0%F:100%M) 0.025 0.086 0.033 2.595 0.049 
Table 3.3 Pairwise comparisons across adjacent mixing ratios. 
Notice first the discrepancies between the values of the expected differential methylation 
level and the estimate of differential methylation from the fitted mixed ANOVA model.  
The difference in these two columns is likely due to the high variation in proportion of 
methylation across CpG site.  Note from Figure 3.1, the boxplot of proportion methylation 
by percent of female genomic DNA in the hybridized sample, the amount of overlap 
among quantile boxes, especially between samples containing each 100% Female: 0% 
Male and 50% Female: 50% Male.  Nevertheless, at each pairwise comparison, the p-value 
is less than 0.05, and so we conclude that the Illumina technology can, in fact, detect 
differential methylation at levels less than 0.17.  Theoretically, this analysis demonstrates 
that evidence exists to support a hypothesis that the Illumina technology can detect 
differences in methylation at least as low as 0.025 since differential methylation was 
detected for two pairwise comparisons designed to query for this methylation level.  
However, given that the observed differential methylation levels were as low as 0.086, a 
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more conservative concluded estimate of the minimum detectable differential methylation 
would be closer to 0.086. 
 
3.3 Verification of fixed asymptote assumption 
 
 In the constructing the nonlinear model with nested random components in section 
3.2 above, it was assumed that as the percent of Female DNA in the sample approached 
100%, the asymptote of predicted methylation was fixed at 0.5.  This was motivated by the 
biological principle of methylation at CpG sites on the X-chromosome.  We now seek to 
determine if the given data support this assumption.  In doing so, we fit separate nonlinear 
models for each of the 17 CpG sites and used the predicted methylation level under the 
conditions of 100% Female DNA: 0% Male to predict site-specific asymptotes and 
associated confidence intervals.  The description of the model construction follows. 
 CpG site-specific nonlinear mixed models were constructed under each the Logistic 
regression framework previously described (Eq. 3.2) and the Asymptotic regression 
framework found in Pinheiro and Bates (2000) using a random effect for dilution order (1 
or 2).  These two models were chosen as appropriate candidate models because the shape 
of the nonlinear curve described appeared to adhere well to the shape of the dose-response 
curves exhibited in the mixture data set. 
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3.3(a) Nonlinear Mixed Model Formulation: Asymptotic Regression Model 
 
For the Asymptotic Regression model, an initial model (Equation 3.6) was fit 
including independent random effects for each the dilution order level (1 or 2).  Generally, 
the nonlinear mixed model employing one random effect is represented 
),,(~
17,...,1,2,1
),0(~
),(
2
Ψ0b
bBβA
N
jm
N
xfy
mj
mjmjmjmj
mj
==
+=
+=
ϕ
σε
εϕ
      (Eq. 3.6) 
where y summarizes the mean proportion of methylation as a function of x, mixing ratio.  
Here, β is a vector of fixed effects, with design matrix mjA .  The random effects, mjb , those 
corresponding to the mth dilution order for the jth CpG site, are independently distributed 
vectors with variance-covariance matrix Ψ and a corresponding design matrix, mjB .  
Using the framework of the Asymptotic regression model, this model is expressed  
),)exp(exp()(),( 3121 xxf mjmjmjmjmj ϕϕϕϕϕ −−+=               (Eq. 3.7) 
and the random coefficients are modeled 
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1ϕ represents the horizontal asymptote on the right side, 2ϕ represents the proportion 
methylated when the percent of Female genomic DNA present in the mixture is zero, and  
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3ϕ represents the natural logarithm of the rate constant and so quantifies the dose response 
relation. 
 
3.3(b) Nonlinear Mixed Model Formulation: Logistic Regression Model 
 
Again, an initial model (Equation 3.9) was fit including independent random effects 
for the dilution order level.  The same basic framework for the model stays the same in that 
for the mean proportion methylated, y, for the mth dilution order group and the jth CpG 
site is written as  
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                               (3.9) 
where ε is a normally distributed within-group error term.  The difference in the 
Asymptotic Regression model and the Logistic Regression model lies in ( ),, jmrjmrf xφ the 
link function.  Again, f is the real-valued, differentiable logistic function of a group 
specific parameter vector mjφ containing information on dilution order and a covariate 
vector jrx containing the levels of mixing ratios.  But now ( ),, rmjf xφ  is written as 
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                   (3.10) 
and the random coefficients are modeled 
38 
mjmjmj
mjmjmj
mjmjmj
mj
mj
mj
mj
b
b
b
333
222
111
3
2
1
,
+=
+=
+=










=
βϕ
βϕ
βϕ
ϕ
ϕ
ϕ
ϕ .                   (3.11) 
1ϕ represents the horizontal asymptote, 2ϕ represents the value of the percent of Female 
genomic DNA in the sample at the inflection point of the curve, and  3ϕ represents the 
scale parameter on the x-axis. 
 
3.3(c) Model Selection 
 
Now that the methodology underlying both the candidate models has been outlaid, 
both models were fit for each CpG site and model comparison was conducted according to 
the Akaike Information Criterion (AIC).  The AIC is a measure of the goodness of fit of an 
estimated statistical model and is commonly used as a tool for model selection.  A model 
with a lower AIC is considered better.  The AIC is computed, 
)ln(22 LAIC −= η         (3.12) 
where η is the number of parameters in the statistical model, and L is the maximized 
function of the likelihood for the estimated model.  Results of the AIC analysis are 
summarized in Table 3.4. 
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 AIC 
CpG 
site 
Asymptotic 
Regression 
Model 
Logistic 
Regression 
Model 
1 -214.24 -126.81 
2 -214.86 -152.14 
3 -190.65 -157.43 
4 -195.82 -124.20 
5 -177.35 -127.88 
6 -192.56 -144.77 
7 -198.72 -154.47 
8 -205.08 -131.58 
9 -203.98 -118.07 
10 -195.46 -114.94 
11 -201.70 -125.15 
12 -196.10 -109.88 
13 -168.16 -154.94 
14 -229.57 -210.85 
15 -189.13 -124.10 
16 -206.59 -208.94 
17 -203.94 -177.54 
   Table 3.4 AIC comparison by CpG site between Asymptotic 
   Regression and Logistic Regression models 
 
For each CpG site, the AIC demonstrates that the Asymptotic Regression model is more 
appropriate to our given dilution data.  The one possible exception to this is site 16 where 
the AIC of the Logistic Regression model is only slightly more negative than that of the 
Asymptotic Regression model.  However, since these values are so close, we conclude that 
the models are relatively equivalent in fit, and for consistency purposes, we choose to 
proceed with the Asymptotic Regression model for this site as well. 
In the search for the most well-suited yet parsimonious model, we next explored 
and modifications to the variance-covariance structures of our 17 Asymptotic Regression 
models.  Up to this point, we had assumed independent variance components.  Given that 
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plots of residuals did not show any particular trend such as with technical replicate order, 
we next dropped the constraint of independent variance components and considered an 
unstructured variance matrix.  However, in all cases, the original constraint of 
independence proved to be a better fit.  A final modification explored on our models, was 
to determine if each of the three random effects for the three modeling parameters were 
necessary.  This was assessed by fitting new Asymptotic Regression models for each CpG 
site where one of the random effects was dropped from the model.  The resulting reduced 
models were compared to the original full model by means of a Likelihood Ratio Test, 
where the test statistic is computed 

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1
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D         (3.13) 
Here, )( 0HL is the likelihood of the of the Asymptotic Regression model under the null 
hypothesis of a full model containing a random term for each of the three parameters in the 
model.  And, )( 0HL is the likelihood under the alternative hypothesis of a reduced model 
where either .0or,0,0 321 === jmjmjm bbb   The likelihood ratio test statistic was 
compared to a chi-squared distribution with 21 nn −  degrees of freedom, where 1n  and 2n  
are the degrees of freedom of the full and reduced models, respectively.
 
For each CpG site, it was found that jm2φ did not warrant a random component.  Likelihood 
ratios and p-values for this test are found in Table 3.2. 
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CpG site 
Likelihood 
of Full 
Model 
Likelihood of 
Reduced 
Model (no 
random term 
for mj2ϕ ) 
Likelihood 
Ratio 
P-value of 
Likelihood 
Ratio Test 
  1: EFNB1-645 114.12 114.12 6.04E-06 0.998 
  2: EFNB1-672 114.41 113.05 2.77E+00 0.096 
  3: ELK1-1163 102.32 102.32 3.15E-09 1.000 
  4: ELK1-1306 104.91 104.91 1.46E-06 0.990 
  5: ELK1-1495 95.67 95.67 2.13E-08 1.000 
  6: ELK1-877 103.28 101.87 2.83E+00 0.092 
  7: FMR1-1182 106.36 106.36 1.04E-09 1.000 
  8: FMR1-1440 109.54 109.54 4.66E-08 1.000 
  9: G6PD-1076 108.99 108.99 3.94E-06 0.998 
10: G6PD-1304 104.73 104.73 1.02E-08 1.000 
11: G6PD-834 107.85 107.85 2.11E-05 0.996 
12: GLA-1158 105.05 105.05 5.51E-07 0.999 
13: GLA-1294 91.08 91.08 2.45E-07 1.000 
14: GLA-1306 121.78 121.78 5.95E-07 0.999 
15: GLA-1388 101.56 101.56 6.54E-06 0.998 
16: GLA-881 110.30 110.30 6.33E-06 0.998 
17: GPC3-1182 108.97 108.97 4.75E+00 1.000 
Table 3.5 Results of Likelihood Ratio test to determine the significance of a 
random effect for mj2ϕ  parameter in Asymptotic Regression model. 
 
Owing to the large p-values for the Likelihood Ratio test at each CpG site, we failed to 
conclude that there was a difference between the full Asymptotic Regression Model 
containing a random effect for each parameter in the model and the reduced model, which 
lacks a random effect for jm2φ .  Therefore, we moved forward with the simpler reduced 
model.  More formally, this model can be written, 
),)exp(exp()(),( 3121 xxf mjmjmjmjmj ϕϕϕϕϕ −−+=        (3.14) 
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The appropriateness of this resulting model in summarizing the dilution data was verified 
both by plots of standardized residuals and plots of the fitted values overlaid upon 
observed values. 
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In examining the plots of the standardized residuals plotted as a function of the 
fitted values for the 17 CpG site-specific models, we observed that for each model, the 
residuals appear to be randomly and uniformly distributed about the horizontal zero line.  
This gives confidence of the appropriateness of the fit for our models.  A further check of 
model fit was accomplished by examining plots of model fitted values overlaid upon the 
observed values upon which the models were estimated (see Figure 3.5).  We saw that for 
each CpG site, the fitted curve of mean proportion methylated appeared to adhere very 
well to the shape of the observed data.  Therefore, we are confident in the fit of our 
Asymptotic Regression models, and we moved to construct hypothesis tests for the 
detection of differential methylation between mixing ratio levels at each CpG site.  
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3.3(d) Predicted CpG site specific response asymptotes 
  
 Upon the construction of the CpG site specific nonlinear mixed models, it was of 
interest to use the predicted proportion of methylation to estimate the asymptote as the 
percent of Female genomic DNA in the sample approaches 100%.  Therefore, using the 17 
CpG site specific models, point estimates of the predicted mean proportion of methylation 
were obtained where the percent of Female genomic DNA in the sample was 100%, and 
95% confidence intervals were calculated using the delta method to estimate the variance 
and applying a Bonferroni adjustment, i.e., 
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Point estimates and resulting 95% confidence intervals are summarized in Table 3.6 below. 
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CpG site 
Point 
Estimate 
Confidence 
Interval 
EFNB1-645 0.719 (0.673,0.765) 
EFNB1-672 0.644 (0.551,0.737) 
ELK1-1163 0.588 (0.544,0.631) 
ELK1-1306 0.545 (0.423,0.668) 
ELK1-1495 0.860 (0.836,0.884) 
ELK1-877 0.679 (0.636,0.723) 
FMR1-1182 0.551 (0.517,0.585) 
FMR1-1440 0.736 (0.677,0.794) 
G6PD-1076 0.638 (0.559,0.718) 
G6PD-1304 0.819 (0.796,0.842) 
G6PD-834 0.535 (0.404,0.667) 
GLA-1158 0.812 (0.778,0.845) 
GLA-1294 0.456 (0.108,0.802) 
GLA-1306 0.223 (-0.008,0.458) 
GLA-1388 0.747 (0.716,0.779) 
GLA-881 0.297 (0.073,0.521) 
GPC3-1182 0.500 (0.472,0.518) 
   Table 3.6 Point estimates and 95% confidence 
   intervals of predicted proportion methylated 
   for mixtures demonstrating 100% Female DNA 
  
It is evident from the above table that the asymptote of 0.5 was not obtained by every CpG 
site.  This is likely due to the fact that, similar to other high-throughput genomic platforms, 
probes have different hybridization affinities and therefore the theoretical 0.5 estimate was 
not attained by each CpG site.  However, as established in Chapter 3.1(c), an appropriate 
overall model fit was achieved and a significant dose-response relationship was indeed 
established. 
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3.4 Concluding remarks 
 
 In this chapter, we sought to explore our hypothesis that the Illumina technology 
can differentiate between levels of methylation less than 0.17.  It had been previously 
claimed that the Illumina technology could differentiate between levels of methylation by 
0.17, however, we hypothesized that the technology could indeed detect lesser levels of 
differential methylation.  To demonstrate the validity of our hypothesis, we used a dilution 
data set provided by the Illumina company, and we modeled the relationship between 
mixing ratio and proportion of methylation in X-chromosome linked genes.  This dilution 
data set of X-chromosome linked genes was key because it essentially provided us with a 
clinical data set in which the true methylation status was known.  By modeling the 
relationship between mixing ratio and proportion methylation according to nonlinear 
mixed models for each X-chromosome linked CpG site, we were able to accurately 
describe the nature of the relationship between the mixing ratio and proportion of 
methylation while concluding that a significant relationship exists between these two 
factors.  Furthermore, a mixed ANOVA model accounting for random variation due to 
dilution order, technical replicate order, and CpG site effect enabled hypothesis testing for 
differential mean methylation between adjacent mixing ratio groups.  In doing so, we 
showed that the Illumina technology can, in fact, discriminate between levels of 
differentiation at least as low as 0.086, rather than 0.17.  This is an especially interesting 
finding given the propensity of many to test differential methylation using a Filtered Two 
Sample t-test with a filter greater than or equal to 0.17, as summarized in Chapter 1.  
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Indeed, a filter of this magnitude likely reduces power for smaller but truly differential 
CpG sites that the technology is very capable of discriminating.  In Chapter 4, alternatives 
to a Two Sample t-test with and without a filter to analyze CpG site methylation data will 
be introduced.   
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CHAPTER 4 Proposed Two Group Inferential Methods For Testing Proportion Methylated 
 
 
4.1 Alternative Analysis Exploration 
 
Alternatives to the currently employed Two Sample t-test with and without a filter 
were sought, and an initial alternative analysis was motivated by the well known 
distributional property supposing that if ),(~ 1 κθGammaRij  and ),(~ 2 κθGammaGij then 
).,(~ 21 θθβ BetaGR
R
ijij
ij
ij +
=    Given that the formula for the proportion methylated 
resembles this property, a natural initial step in the analysis was to suppose that   the Red 
and Green channels each follow a Gamma distribution. This seems plausible as both Rij 
and Gij have a distributional range of ),[ ∞0 and because of the skewed shape of the 
distributions of the Red and Green channels present using the Hepatitis C Virus 
methylation dataset described in Chapter 2.1 (illustrated for a representative sample, 
beadarray 28, in Figure 4.1).  An additional artifact of the Red and Green channel data 
present in Figure 4.1 is that of dye bias.  The green dye is more efficient than the red, 
causing it to be incorporated faster and resulting in the bulk of the Green channel signal 
intensities being distributed at a much higher value than the Red channel signal intensities.  
Again in Figure 4.1 this artifact is demonstrated  for a representative sample, beadarray 
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number 28, where it can be seen that the intensities from the Green channel are much 
higher than the intensities from the Red Channel: 
 
Figure 4.1 Histogram of Green (top panel) and Red (bottom                
panel) channel intensities for a representative beadarray. 
 
For this reason, a constant scaling normalization method was applied.  Specifically, a 
unique scaling factor is  for each array was introduced to multiply the Green channel signal 
intensities, thus scaling down closer to the red values, i.e.,  
⋅⋅
⋅⋅
=
⋅⋅
i
i
G
R
is µ
µ
          (4.4) 
for .  Here, 
....
 and 
ii GR µµ are the arithmetic means of the Red and Green signal 
intensities across all CpG sites for a single array.  This array specific scaling factor was 
multiplied by the Green signal intensities, thus resulting in the Red and Green Channels 
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residing on a more similar range, as evidenced by the following histogram, again for 
beadarray 28. 
 
Figure 4.2 Histogram of Green uncorrected (top panel), Green      
corrected, and Red (bottom panel) channel intensities for a      
representative beadarray. Green corrected intensities were                     
post-constant-scale normalized. 
 
Upon computation of this scaled normalized data, β  estimates were calculated for each 
CpG site according to Equation 2.2.  Because each the Red and Green channels were 
hypothesized to be distributed as Gamma, then it follows that we assumed β  is distributed 
as Beta.  The Beta distribution is a family of continuous probability distributions 
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constrained on the interval  and defined by two positive shape parameters,  and .  
The density function of a variable z , that is distributed according to a beta distribution, 
, is 
.)1()()(
)(),;( qp zz
qp
qpqpzf −
ΓΓ
+Γ
=          (4.1) 
Because the Beta distribution is constrained on the interval , it is often a good 
distribution to model variables which are measured in proportions.  Further evidence in 
support of the hypothesis of the distribution of the proportion  methylation β  according to 
a Beta distribution is given that by nature of the computation of the proportion methylated 
estimates, β is a continuous random variable both centered on and restricted to the range 
[0,1].  Furthermore, for each CpG site in the HCV data set a Kolmogorov-Smirnov Test 
was employed to determine if evidence existed to refute this hypothesis. 
 
4.2 Kolmogorov-Smirnov Test 
 
 A Kolmogorov-Smirnov Test was conducted for each CpG site to assess whether 
evidence existed to refute the hypothesis that the proportion of methylation was distributed 
according to a beta distribution, i.e.   [ ]teveryfor),()(:0 tHtFH =  where )(tF  is the 
empirical distribution function for the 36 computed ratios at each CpG site 
( ),(~ jjij qpBetaβ under 0H ), calculated using the scaled data, and )(tH is the empirical 
distribution function for the Beta distribution function  (Hollander and Wolfe 1999).   
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Letting )72()1( ZZ <≤L denote the )3636()(72 +=+= hi ordered values for the combined 
sample of the ijj ββ ,...,1  and the hjj YY ,...,1 observations of the empirical distribution 
function for the Beta distribution, Hhj , the Kolmogorov-Smirnov test statistic is computed 
as 
{ }.)()( )()(
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. max shjsij
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j ZHZF −=Ω
=
         (4.2) 
For the empirical distribution function of the Beta distribution at the jth CpG site, the 
method of moments was used to estimate the parameters for the empirical distribution 
function of the  ),(
.... jj qpBeta distribution as a function of the data at each CpG site where: 
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Above, 
.. jz  is the sample mean and 
2
.. js  is the population variance of the ijβ ratios at each 
CpG site. 
This yielded promising results: in 1438 (93%) of the  ratio distributions computed 
for each CpG site, we failed to reject the null hypothesis, and so we do not have evidence 
to refute the claim that the distribution of the proportion of methylation at each CpG site 
follows a Beta distribution.  Thus it was decided to move forward with designing a 
hypothesis test that is based on a Beta distributed random variable to test for the 
equivalence of the two groups.  The hypothesis test based on a Beta distributed random 
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variable took two forms: that of a test based on the beta distribution and that of a large 
sample approximation.  A description of these two forms follows. 
 
4.3 Testing for Differentially Methylated CpG sites: Beta Distribution Motivated Two-
Sample Test 
 
4.3(a) Test Based on a Beta Distributed Random Variable 
 
 To design a test for the difference between two beta distributed random variables, 
assume that ),(~ 11 qpBetaX and ),(~ 22 qpBetaY are two given random variables.  It is 
of interest to test 0:0 =− YXH µµ  against the alternative .0: ≠− YXAH µµ   The null 
hypothesis can be equivalently expressed as .:0 YXH µµ =   In formulating the hypothesis 
test, it must be conducted under the conditions of the null hypothesis.  Therefore, given the 
observed data ),,,( 112111 1 jnjjj ββββ K=⋅  and ),,,( 222212 2 jnjjj ββββ K=⋅ at the jth CpG 
site, under the conditions of 0H , we form ),( 21 jjj ⋅⋅⋅⋅ = ββZ which is used to estimate pˆ  
and qˆ according to the method of moments estimators described in Equations 4.3 and 4.4, 
and as follows: 
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and 
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Here, 2
⋅⋅ js is the population variance of .⋅⋅ jZ Furthermore, note that  
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be the population variance of ).,(~
⋅⋅⋅⋅⋅⋅ jjj qpBetaZ  
These values can then be used to obtain a standardized quantile value, 
⋅⋅ jQ ,975.0 , from the 
beta distribution for a two sided 95%  confidence level (from 1-α/2 letting 05.0=α ) as 
follows: 
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1
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The critical value,
⋅⋅ jC ,975.0 , for testing the test statistic 21 jjjD ⋅⋅⋅⋅ −= µµ  at the jth CpG site 
would be computed as 
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        (4.8) 
and one would reject the null hypothesis of equal means between the two groups at the jth 
CpG site where 
⋅⋅⋅⋅
> jj CD ,975.0 . 
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Under the framework just described, it is assumed that the combined data between 
the two Beta distributed groups follows a Beta distribution, and it is this Beta distribution 
of the combined data that is used to compute a standardized quantile and, hence, a critical 
value to which a test statistic is compared.  Therefore, this Beta test specifically tests if the 
mean proportion methylated is equivalent between two groups at a specified CpG site.   
   
4.3(b) Likelihood Ratio Test 
 
As a large sample counterpart to the Beta test, an alternative test was designed 
under the likelihood ratio testing framework.  The likelihood ratio test was appropriate here 
since two nested distributions were present.  Under the likelihood ratio test, the same 
question of equivalence between groups is addressed in a slightly different manner.  Rather 
a two sample test for comparing the ratios for each CpG site between two groups, cirrhosis 
with and without concomitant HCC, reduced to testing if the ratio of the signal intensities 
adhered to identical Beta distributions at each site.  This was determined by testing if the 
Beta distribution parameters are the same for each group at each CpG site, i.e.,  
2121121210 /, qqorandppHqqqandpppH ≠≠======                (4.9)                          
The methodology of this large sample approximation test follows. 
To test the hypothesis of identically shaped Beta distributions at each CpG site 
( qqqandpppH ===== 21210 ), a likelihood ratio test was employed.  The first 
distribution, the distribution under the null hypothesis, assumed that both p and q 
parameters from the two groups were equal, and hence, the likelihood equation at the jth 
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CpG site under the null hypothesis is that of a Beta distribution with sample size n, given 
by 
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where the  are the computed  ratios and here, .  Now, the logarithm of the 
likelihood is 
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The second likelihood formed under the conditions of the alternative hypothesis, assumes 
that either or both p and q parameters from the two groups are not equal, and hence the 
likelihood equation of this second group is given by  
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where  and are the computed  ratios and sample sizes, respectively for the 
two groups in the jth CpG site , where .  For the purposes of the data here, the 
 are the  ratios from the HCC positive group ( ), and the are the  ratios 
from the HCC negative group ( ).  The logarithm of this likelihood is 
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 Consequently, the likelihood ratio test statistic for the jth CpG site , 
⋅⋅
Λ j  is 
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where 
⋅⋅ jpˆ and ⋅⋅ jqˆ are the maximum likelihood estimates computed under the null 
hypothesis and 2211 ˆand,ˆ,ˆ,ˆ jjjj qpqp ⋅⋅⋅⋅  are those computed under the alternative hypothesis.  
Hence, the likelihood ratio test can be written under  as: Reject   if Cj >Λ ⋅⋅  where C 
is the   percentile point of a Chi Square distribution with k degrees of 
freedom and the p-value is computed as )(1
⋅⋅
Λ−= jj Fp ν .  Here, ν  is the difference in the 
number of parameters between the logarithms of the likelihood under the alternative and 
null hypotheses (ν =4-2=2), and νF  is the cumulative distribution function of the 
χ2 distribution.  For the purposes of this analysis, tests were conducted at an  
significance level.   
 It should be noted that in the computation of the test statistic of the likelihood ratio 
test, an iterative algorithm was employed to compute the maximum likelihood estimates.  
A closed form expression for the computation of the maximum likelihood estimated under 
a beta distribution does not exist, so the Nelder Mead simplex was used. 
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4.3(c) Nelder Mead Simplex 
 
 The Nelder Mead algorithm is a direct search method which operates on the 
assumption of a simplex.  More specifically, where n parameters are to be estimated, a 
simplex  in nℜ  is formed by the convex hull of the n+1 vertices nnxx ℜ∈,...,0 .  The 
corresponding objective function, )(xf  is then evaluated at the vertices of the simplex,  
,,...,1,0for  ),( njxf j = and it moves in the direction of improved response.  At each step, 
the transformation of the simplex is determined by computing the vertices, together with 
their function values, and by comparison of these function values with those at the vertices 
of the existing simplex.  This process is terminated when the working simplex becomes 
sufficiently small as judged by pre-determined threshold value.   
 Now, for a random variable y such that bya ≤≤ , the family of beta distributions 
includes all probability density functions of the form  
1
11
)(
)()(
),(
1)(
−+
−−
−
−−
= qp
qp
ab
ybay
qpB
yp              (Eq. 4.15) 
where p>0 and q>0. Johnson & Kotz (1970) describe method of moments estimators for 
the four parameters in Equation 4.15. Additionally, they describe an iterative method for 
approximating maximum likelihood estimates of p and q when a and b are known. 
Krishnamoorthy (2006) suggested that the moment estimates be used as initial values in 
the iterative procedure for obtaining maximum likelihood estimates. Additionally, if one of 
the values (p or q) are known, the equations simplify (Johnson & Kotz, 1970). For 
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example, if q is known to be 1, the distribution actually becomes the standard power 
function. Because when performing hundreds of hypothesis tests for a high-throughput 
methylation dataset, it would not be practical to know a or b or make assumptions about 
either p or q, when maximizing the likelihood we used the standard form of the probability 
density function, 
11 )1(),(
1)( −− −= qp xx
qpB
xp                   (Eq. 4.16) 
in which ( ) ( )abayx −−= which allowed us to solve for p and q.  In this manner, the 
maximum likelihood estimates for the above described likelihood ratio test were 
determined, where the objective function was the maximum likelihood equation of the 
standard form of the probability density function. 
 Since the methodology which underlies both our Beta test and our proposed 
likelihood ratio based test has been fully developed, a third alternative analysis method is 
described. 
 
4.4 Testing for Differentially Methylated CpG sites: Bivariate Normal Distribution 
Motivated Test 
 
As another exploratory measure, it was hypothesized that each the Red and Green 
channels were distributed Normal.  This hypothesis, similar to the previous hypothesis of 
the Gamma distribution, is a common assumption made for log2 transformed channel data 
(Brody et al., 2002). One could argue that in principle, the normal distribution is not an 
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appropriate fit for the Red and Green Channel intensities, values that were constrained on 
[ )∞,0 by nature.  However, given that the channel intensities were centered about a value 
that was much greater than zero and that by artifact of the background phenomenon, the 
intensities are clustered such that they never truly get to zero, it was considered appropriate 
to continue with this line of study.  Again, to see if evidence exists to refute this 
hypothesis, Kolmogorov Smirnov tests were performed for the Red and the scaled Green 
channel signal intensities at each CpG site in the HCV data set.  Thus the null hypothesis 
[ ]teveryfor),()(:0 tHtFH =  was tested where F(t) is the empirical distribution function 
for each the Red and Green channels , calculated using the aforementioned scaled data, and 
where ),(~ 2
jj RRj NR ⋅⋅⋅ σµ and ),(~ 2 jj GGj NG ⋅⋅⋅ σµ under the null hypothesis.  H(t) is the 
empirical distribution function for the Normal distribution function.  The sample mean and 
sample variance for each CpG site were used to estimate the parameters for the empirical 
distribution function of the  ),( 2jjN σµ distribution as a function of the data.  Here, we 
failed to reject the null hypothesis in 1,421 (92%) CpG sites in the red channel and 1,527 
(99%) CpG sites in the green channel out of a total 1,547 CpG sites per channel.  
Therefore, it was concluded that we did not have evidence to refute our assumption of 
Normality.  It was furthermore known that the correlation between the Red and Green 
channels was approximately -0.62, so it was concluded that the Red and Green channels 
were distributed ),,,,Normal(Bivariate 22 ρσσµµ GRGR . 
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Again for testing purposes, the ratio )( GRR +=β was of particular interest.  
Given that Red and Green Channels were distributed Bivariate ),,,,Normal( 22 ρσσµµ GRGR , 
it follows then that the ratio )( GRR +=β has a complex distributional form.   
  For this reason, bootstrap methods underlay the hypothesis testing designed to 
compare the ratios for each CpG site between the two groups.  The bootstrap method is 
especially useful because it enables one to design a hypothesis test on a set of values by 
estimating all pertinent values from an approximate distribution, namely the empirical 
distribution of the observed data.  This proves valuable in situations such as the one 
present, where the underlying distribution made the formulation of a hypothesis test 
difficult.   
The test formulation was as follows: first a test statistic was computed as a function 
of the observed data.  Here, the mean was used as the location parameter, and the statistic 
used for testing was the difference in the mean β  ratio between the two groups, i.e., 
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This test statistic was computed for each CpG site, letting the 1n  samples originating from 
patients presenting cirrhosis without HCC be called Group 1 and letting the remaining 2n  
samples originating from patients presenting cirrhosis with HCC be called Group 2.  Next 
let the empirical distribution function of Group 1 be denoted F and of Group 2, G.  Under 
the null hypothesis, any of the 21 nn + observations could have come from either F or G, i.e. 
 which implies that .  This hypothesis was tested by 
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computing the empirical distribution function of the test statistic by combining the 1n  
observations from F and the 2n  observations from G to form a single set of values of 
size 21 nn + .  A sample of size 1n  was drawn with replacement from the combined set of 
21 nn +  values to represent the observations from F, and the latter 2n  observations 
represent those from F.  The statistic *ˆθ  was computed using these artificially created 
samples. For each CpG site, this process of sampling and computing the test statistic was 
repeated 2,500 times, thereby creating an empirical distribution function of the bootstrap 
test statistic.  A two-sided 100(1-α)% level bootstrap hypothesis test was constructed for 
each CpG site by comparing ∗j.ˆθ  to the )%2/-100(1  theandupper  )%2/(100 αα lower 
percentiles, Bj.θ  computed from the empirical distribution of the observed data.  The p-
value was calculated, 
{ }** ˆor ˆ# jBjjBjjp ⋅⋅⋅⋅ −<>= θθθθ .       (4.16) 
This chapter has described methodology for three proposed alternatives to the 
widely employed Two Sample t-test and the Filtered Two Sample t-test.  These three 
alternatives were in the form of a test based on a Beta distributed random variable, a 
Likelihood ratio based test, and a Bootstrap-based test.  In the next chapter, the properties 
of all five tests will be compared and contrasted using an extensive simulation study.   
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CHAPTER 5 Simulation Study 
 
In this chapter we describe a comparison of the three proposed inferential methods 
with the commonly used Two-Sample t-test and the Filtered Two Sample t-test performed 
using simulated data. Specifically, for each simulation scenario we examined either the 
Type I or Type II error rates.  A simulated data set was imperative so that knowledge as to 
a certain CpG site’s true methylation status (differentially methylated between two groups, 
yes or no) was certain.  We chose to design our simulation study to preserve as many of the 
characteristics inherent to our application dataset as possible.  For this reason, data were 
generated in two manners, the first of which generated proportion methylated data 
according to a Beta distribution, and the second of which generated Red and Green channel 
data according to a Bivariate Normal distribution with correlation coefficient equal to -0.6 
upon which  β  proportion methylated data were computed.  The Type I and Type II error 
rates were calculated and compared for each inferential method under both simulation 
scenarios.  Under each the Beta distribution and the Bivariate Normal distribution scenario, 
data were generated for 3,152 CpG sites where there were 20 samples in Group 1 and 16 
samples in Group 2.  This sample size was chosen through an analysis in nQuery.  All 
significance tests were conducted at the 05.0=α significance level; therefore, because we 
wished to estimate a Type I error rate which we expected to be 0.05 and accurate to the 
hundredths decimal (+/- 0.01), the number of samples needed for a two-sided 99.0% 
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confidence interval for a single proportion using the large sample normal approximation 
extending 0.01 from the observed proportion for an expected proportion of 0.05 is 3,152. 
For a more complete analysis, the number of samples per group was varied to 
further explore the behavior of the Type I and Type II error rates due to sample size.  
Methodology for testing the Type I and Type II error rates follows. 
 
5.1 Testing Type I error rates 
 
 Type I error is the error of rejecting a null hypothesis when it indeed is true.  
Comparing the Type 1 error rates of the two proposed tests along with the Two Sample t-
tests involved calculating the number of times a certain test found a particular CpG site 
differentially methylated between two classes of outcomes when the truth was that the 
CpG site, in fact, was not differentially methylated.  Therefore, it was of interest to 
generate a data set for two groups having no difference in proportion methylated.  For a 
given inferential method, the Type I error was then calculated as the proportion of CpG 
sites declared significantly differentially methylated between two treatment groups.   
In an effort to ensure the generation of realistic data, values from the test data were 
used as a starting point.   The CpG site with Illumina code 3923 was used to model non-
significantly differentially methylated data.  Note that while the Two Sample t-test found 
CpG site 3923 non-significantly differentiated (p-value= 0.763), any difference in beta 
values between the two outcome groups present at this CpG site would become null by 
means of the data simulation method now explained. 
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5.1(a) Type 1 error data simulation methods and results: Beta distribution 
 
 To study the Type I error rate, beta distributed data were generated using the same 
shape and scale, p and q, parameters for both outcome groups.  Thus, using all proportion 
methylated observations across the two outcome groups of the CpG site with Illumina code 
3923, the sample mean and variance were calculated.  These moments were then used to 
compute the method of moments estimators for p and q as outlined in Equations 4.6 and 
4.7.  Using these estimators, pˆ and qˆ , beta distributed data were generated for 3,152 CpG 
sites for both a Group 1 random beta variable )ˆ,ˆ(~ qpBetaX  containing 20 observations 
and a Group 2 random variable )ˆ,ˆ(~ qpBetaY  containing 16.  In this manner, it was 
ensured that no true statistically significant difference existed for each CpG site between 
the two groups of generated data. 
 The simulated data set was analyzed under the assumptions of each of the five 
testing measures.  For the beta test, as outlined in Chapter 4, and the Type I error rate was 
calculated as 
{ } 152,3/#
,975.0 ⋅⋅>− jjj QyxwheresitesCpG ,                   (5.1) 
and under the remaining tests, the Type I error rate was calculated as  
{ } 152,3/05.0# <valuepwhosesitesCpG .                    (5.2) 
Results are presented in Table 5.1. 
Note that data generated according to the beta distribution are single valued on the range 
( )1,0 . Because the bootstrap test relies on sampling data from the individual Red and Green 
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channels, it cannot be performed on data that have been generated according to a beta 
distribution, and hence results of the Type I error behavior of the Bootstrap test under the 
assumption of Beta distributed data is not available. 
 Type I Error Rate  
Number of 
Samples 
per Group  
Two 
Sample 
t-test  
Two Sample  
t-test  
p value <0.05 
and  
|∆β| > 0.17   
Beta test Likelihood 
ratio test 
20,16  0.048 0 0.0416 0.048 
Table 5.1 Type I Error rate comparison where data has been computed  
under the assumption of a Beta distribution.  
 
Since testing was conducted at the  significance level, a Type I error rate 
close to 0.05 was considered most desirable.  Using this criterion, it was evident that the 
Two Sample t-test, the Beta distribution test and the Likelihood Ratio test each performed 
well.  Meanwhile, the Type I error rate of the filtered Two Sample t-test was too low.   
To gain a better understanding of the behavior of the Type I error under the four 
available testing conditions, data were again generated in the aforementioned manner while 
varying the number of samples per group.  Results are presented below in Table 5.2: 
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 Type I Error Rate  
Number of 
Samples 
per Group  
Two 
Sample 
t-test  
Two Sample  
T test  
p-value <0.05 
and |∆β| > 0.17   
Beta test Likelihood 
ratio test 
20,16  0.048 0 0.0416 0.048 
40,40  0.055 0 0.0495 0.063 
80,80  0.054 0 0.0425 0.059 
45,50  0.057 0 0.0498 0.056 
15,15  0.046 0 0.0374 0.043 
Table 5.2 Type I Error rate comparison across varying sample sizes where data 
have been computed under the assumption of a Beta distribution. 
 
Across a wide range of sample sizes, the Two Sample t-test, the Beta distribution 
test, and the Likelihood ratio based test perform very well and very comparably. Note that 
the filtered Two Sample t-test does not accurately quantify the Type I error rate.  As 
expected, the Type I Error Rate was furthest from the nominal 0.05 level for all tests when 
the sample sizes were reduced to 15 and 15 in each group. 
 
5.1(b) Type 1 error data simulation methods and results: Bivariate Normal distribution 
 
 As an alternative to the assumption that the proportion methylated variable follows 
a Beta distribution, it was discussed in Chapter 4.4 that there is evidence to support a claim 
that the Red and Green channels follow a Bivariate Normal distribution.  Thus, a thorough 
examination of the Type I error rate behavior for these five statistical measures involves a 
comparison of the error rates when each test has been performed using data simulated 
under the assumption of Bivariate Normality.  Once again, the CpG site in our test data set 
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with Illumina code 3923 was used to model the data.  For this CpG site, the means and 
variances of each the red and green channels were calculated across all samples, regardless 
of classification group.  This resulted in one mean and standard deviation for the red 
channel data and one mean and standard deviation for the green channel data.  
Furthermore, as previously stated, the chip-wide mean correlation between the Red and 
Green channels was approximately -0.6, so this value, together with the computed  mean 
and variance parameters from CpG site 3923 were used as the parameters of the bivariate 
normal distribution that generated our test set data.  Upon the generation of the 36 samples 
for each of the 3,152 CpG sites, any negative values were changed to zero to better 
simulate the beta variable data.  Kolmogorov Smirnov tests were performed to ensure that 
evidence did not exist to claim that the resulting data did not preserve the Bivariate Normal 
distribution, and in all cases, this proved true. 
Type I error rates were computed and are presented in Table 5.3. 
 Type I Error Rate  
Number of 
Samples 
per Group  
Two 
Sample 
t-test  
Two Sample t-
test p value 
<0.05 and |∆β| 
> 0.17   
Beta test Likelihood 
ratio test 
Bootstrap 
test 
20,16 0.044 0 0.0416 0.048 
 
    0.048 
 
Table 5.3 Type I Error rate comparison where data has been computed under the 
assumption of a Bivariate Normal distribution. 
 
Once again, the Two Sample t-test, the Beta test and the Likelihood ratio test all 
three perform reasonably well under the assumption that the data are distributed Bivariate 
Normal.  Furthermore, neither the Filtered Two Sample t-test nor the Bootstrap test 
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accurately quantify the Type I error here.  With the exception of the Likelihood ratio based 
test, this is a trend that continues as sample size is varied, as illustrated in Table 5.4 below.  
The Likelihood ratio based test, rather, has an inflated estimate of the Type I error rate as 
sample size increases, demonstrating that similar to the Filtered Two Sample t-test, it is not 
an appropriate decision measure. 
 It is interesting to note that regardless of whether the data are assumed to follow a 
Beta distribution or a Bivariate Normal Distribution, the Type I error behavior of each the 
Two-Sample t-test and the Beta test is both quite comparable and accurate. 
 Type I Error Rate  
Number of 
Samples 
per Group  
Two 
Sample 
t-test  
Two Sample  
t-test  
p value <0.05 
and |∆β| > 0.17   
Beta test Likelihood 
ratio test 
Bootstrap 
test 
20,16  0.044 0 0.0416 0.048 0.048 
40,40  0.042 0 0.0495 0.075 0.042 
80,80  0.059 0 0.0425 0.076 0.058 
45,50  0.047 0 0.0498 0.070 0.045 
15,15  0.040 0 0.0374 0.040 0.043 
Table 5.4 Type I Error rate comparison across varying sample sizes where data has           
been computed under the assumption of a Bivariate Normal distribution. 
 
 
5.2 Testing Type II Error Rates 
 
In addition to comparing the Type I error rates, a complete analysis of the five 
proposed tests also involved the comparison of their Type II error rates.  Type II error is 
the error of failing to reject a null hypothesis when it is not true.  The computation of the 
Type II error resulted from calculating the number of times a certain test found no 
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difference in the methylation status of particular CpG site between two classes of outcomes 
when the truth was that the sites were indeed differentially methylated.  Therefore, it was 
of interest to generate a data set that for two outcome groups, a difference in methylation 
status existed for every CpG site.  The Type II error was then calculated as the proportion 
of CpG sites that a certain test found non-significantly differentially methylated between 
two treatment groups.  All significance tests were performed at the  significance 
level. 
 Again, to ensure the generation of realistic data, values from the test data were used 
as a starting point.   In Bibikova, et al. (2006b), it was estimated that the Illumina 
technology can discriminate levels of methylation ( -values) that differ by 0.17 or more.  
So to generate data, the means and variances of a CpG site that demonstrated significant 
differential methylation were used as a starting point for generating data.  Because we were 
searching for a site with measurable methylation levels, a certain CpG site was considered 
differentially methylated if the mean proportion methylated in each of the treatment groups 
was at 0.2 or greater and if the difference in the mean proportion methylated between the 
two groups was 0.17 or more.  When tested by the currently accepted method of the two-
sample t-test, the CpG site with Illumina code 4092 had a difference in beta values 
between the two groups of 0.172 with a corresponding p-value of 0.005.  Furthermore, this 
site demonstrated a mean methylation of 0.46 and 0.29 in the first and second outcome 
groups, respectively.  Thus, this site was considered differentially methylated and was used 
initially to model data for simulations exploring the behavior of the Type II error.  Again, 
the Type II error behavior of each test was explored under the assumption that data were 
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distributed according to each the Beta distribution and the Bivariate Normal distribution.  
Data generation and results under these two scenarios are as follows. 
 
5.2(a) Type II error data simulation methods and results: Beta distribution 
 
 To study the Type II error rate, data from the two outcome groups were generated 
using different beta distributions.  To generate data from differing beta distributions, the 
method of moments estimators were calculated for each of the treatment groups of CpG 
site 4092 resulting in 1pˆ  and 1qˆ for the first treatment group and 2pˆ  and 2qˆ for the second 
treatment group.  These estimators were used to generate two random beta variables, 
)ˆ,ˆ(~ 11 qpBetaΑ  and )ˆ,ˆ(~ 22 qpBetaΒ each of length 1,000.  One thousand was chosen 
here as a large number to give stable estimates.  The standardized quantile, 975.0Q was 
computed according to Equation 4.10 as a function of this combined generated data.  Next, 
two new beta random variables, )ˆ,ˆ(~ 11 qpBetaX and )ˆ,ˆ(~ 22 qpBetaY were generated of 
length 20 and 16, respectively, for the 3,152 CpG sites to achieve the desired accuracy.  In 
this manner, it was ensured that a difference in the mean proportion methylated between X 
and Y for the jth CpG site was equal to approximately 0.17, as presented in the test data 
CpG site 4092. 
 The simulated data set was analyzed under the assumptions of each of the five 
testing measures.  For the beta test, as outlined in Chapter 3, and the Type II error rate was 
calculated as 
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     (5.3) 
and under the remaining tests, the Type II error rate was calculated as  
{ } 152,3/05.0# >valuepwhosesitesCpG .        (5.4) 
Results are presented in Table 5.5. 
Note again that data generated according to the beta distribution are single valued 
on the range ( )1,0 . Because the bootstrap test relies on sampling data from the individual 
Red and Green channels, it cannot be performed on data that have been generated 
according to a beta distribution, and hence results of the Type II error behavior of the 
Bootstrap test under the assumption of Beta distributed data is not available. 
Furthermore, it is important to note that the Type II error rates for the Filtered Two 
Sample t-test are not included in subsequent Type II error rate tables (Tables 5.5-5.12).  In 
the identification of a uniformly most powerful test, power should be compared among 
tests at a fixed alpha-level, and  the Filtered Two Sample t-test cannot attain a Type I error 
of 0.05 due to the imposed threshold.  Because the (Unfiltered) Two Sample t-test, the 
Beta test, the Likelihood ratio-based test, and the Bootstrap-based test (where applicable) 
each demonstrated a roughly equivalent Type I error rate about 050.=α  across various 
sample sizes, the Type II error rates of these tests are reported in subsequent tables with the 
Type II error rate of the Filtered Two Sample t-test following in the text for informational 
purposes. 
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 Type II Error Rate 
Test 
Set 
∆β 
Observed 
∆β 
Illumina 
Code X  Y  
Test Set 
p-value (t 
test) 
Two 
Sample 
t-test  
Beta 
Test 
Likelihood 
ratio test 
0.17 0.17 946 0.46 0.29 0.005 0.177 0.181 0.055 
Table 5.5 Type II Error rate comparison where data has been computed under the 
assumption of a Beta distribution. 
 
In Table 5.5, the Test Set β∆  column lists the difference in mean proportion 
methylated between the two outcome groups for which we sought to generate data.  The 
Observed β∆ column lists the actual β∆ present in our generated data.  Meanwhile, the 
columns denoted Illumina Code, X , Y , and Test Set p-value (t-test) describe the reference 
Illumina code of the CpG site used to generate our data, the mean proportion methylated 
present in our test data for the first and second outcome groups, and the p-value of this 
CpG site when a Two Sample t-test is performed to test for differential methylation, 
respectively.  The aforementioned columns are listed to demonstrate that our data were 
successfully generated using a CpG site containing both positive methylation and 
significantly differentiated methylation, according to the currently accepted testing 
method.  The following three columns show the Type II error rates of the three applicable 
proposed tests under the assumption that the data were generated according to a Beta 
distribution.  When assessing Type II error, a smaller rate is better, where approximately 
0.20 approaches the upper limit of a Type II error rate for a well-suited test.  Here, we see 
that each the Two Sample t-test, the Beta Test, and the Likelihood ratio based test each 
perform well.  The Type II error rate for the Filtered Two Sample t-test under the 
assumption of a sample size of 20 in outcome group 1 and 16 in outcome group 2 is 0.491.  
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Therefore, while we cannot directly compare this error rate to those of the other three 
applicable tests under the assumption of Beta distributed data, we can conclude that the 
Filtered Two Sample t-test is a highly conservative testing measure that in possessing a 
small Type I error rate, likely trades for it a Type II error rate that is too high. This 
translates to a loss in power.  This is a trend that is more fully illustrated as we vary both 
the level of differential methylation (Table 5.6) and the sample size (Tables 5.7-5.8) 
Table 5.6 details how the Type II error rate changes with varying levels of β∆ .  
We observe that a similar trend for the Type II error rate continues across β∆ .  Namely, 
the Two Sample t-test, the Beta test and the Likelihood ratio based test each perform well 
concerning the preservation of an acceptable error rate.  The Type II error rates of the 
Filtered Two Sample t-test for differential methylation levels are as follows: Type II Error 
rate( 20.0=∆β )=0.345, Type II Error rate( 2358 siteCpG  ,10.0=∆β )=1.0, Type II Error 
rate( 2208 siteCpG  ,10.0=∆β )=0.949, and Type II Error rate( 05.0=∆β )=1.0.  These rates 
are clearly consistently high and even become severely inflated, as hypothesized, when the 
observed β∆ dips below the threshold. 
 An additional artifact of interest in Table 5.6 is the difference in Type II Error rates 
observed for each the Two Sample t-test, the Beta test and the Likelihood ratio based test 
between the two sites presenting a test set β∆ =0.10.  Note that while each CpG site 2358 
and 2208 were used to successfully generated data with β∆ =0.10, the Type II error for the 
three aforementioned tests is much higher when CpG site 2208 had been used to generate 
data, rather than when CpG site 2358.  Two reasons have been identified to explain this 
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phenomenon.  First, we noted that according to the currently accepted testing method, the 
Two Sample t-test, site 2358 has a much smaller p-value than site 2208.  Second, it can be 
computed that the variances of the two outcome groups present in site 2358 is much 
smaller than the variances present in the two outcome groups present in site 2208.  This is 
verified by noting that as estimated by the method of moments parameters for the Beta 
distribution in Equations 4.6 and 4.7. 22.10ˆand,09.4ˆ,24.2ˆ,89.1ˆ 2211 ==== qpqp .  So, 
when computing the variances of each outcome group for these two Beta-distributed sites 
according to the equation, 
)1()()var( 2 +++= qpqp
pq
z ,          (5.5) 
it was determined that for site 2358, 005.0)r(aˆvand003.0)r(aˆv 21 == zz , while for site 
2208, .014.0)r(aˆvand024.0)r(aˆv 21 == zz   Thus, due to these two reasons, we can 
conclude that while sites 2358 and 2208 both generated data to test for a β∆ =0.10, the 
data of CpG site 2358 both demonstrated a more significant difference between the two 
treatment groups and possessed less variation in the data, resulting in more precisely 
significantly differentiated generated data on which to conduct hypothesis testing.  
Therefore, it is understood that CpG site 2358 generates data that produces a more 
acceptable Type II Error rate than CpG site 2208. 
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 Type II Error Rate 
Test 
Set 
∆β 
Observed 
∆β 
Illumina 
Code X  Y  
Test Set 
p-value 
(t test) 
Two 
Sample 
t-test  
Beta 
Test 
Likelihood 
ratio test 
0.17 0.17 4092 0.46 0.29 0.005 0.177 0.181 0.055 
0.20 0.20 4297 0.52 0.32 0.008 0.239 0.200 0.043 
0.10 0.10 2358 0.47 0.38 <0.001 0.007 0.003 0.004 
0.10 0.10 2208 0.47 0.37 0.039 0.454 0.447 0.455 
-0.05 -0.05 4038 0.76 0.81 0.009 0.231 0.148 0.219 
Table 5.6 Type II Error rate comparison across varying levels of differential proportion 
methylated where data has been generated with 20 samples in outcome group 1 and 16 
samples in outcome group 2 according to a Beta distribution. 
 
The next step in the analysis was to explore the behavior of the Type II error rate across 
varying levels of differential proportion methylated for each 40 samples in outcome groups 
1 and 2 and 80 samples in outcome groups 1 and 2.  Results are presented in Tables 5.7 
and 5.8, respectively. 
     
 Type II Error Rate 
Test 
Set 
∆β 
Observed 
∆β 
Illumina 
Code X  Y  
Test Set 
p-value (t 
test) 
Two 
Sample 
t-test  
Beta 
Test 
Likelihood 
ratio test 
0.17 0.17 4092 0.46 0.29 0.005 0.009 0.012 <0.001 
0.20 0.20 4297 0.52 0.32 0.008 0.011 0.008 <0.001 
0.10 0.10 2358 0.47 0.38 <0.001 <0.001 <0.001 <0.001 
0.10 0.10 2208 0.47 0.37 0.039 0.121 0.120 0.104 
-0.05 -0.05 4038 0.76 0.81 0.009 0.019 0.009 0.019 
Table 5.7 Type II Error rate comparison across varying levels of differential proportion 
methylated where data has been generated with 40 samples each in outcome groups 1 and 
2 according to a Beta distribution. 
 
When data have been generated according to the Beta distribution with 40 samples 
in each of the treatment groups, the same trends seen previously with smaller sample sizes 
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continued and became even more defined.  We see that as sample size increased, the Type 
II error rates of each the Two Sample t-test, the Beta distribution test, and the Likelihood 
ratio based test decreased, as to be expected.  We also note that the increased sample size 
helped to overcome the increased error rate for the more marginally significant and highly 
dispersed data generated by CpG site 2208 among the three currently well-performing 
tests.  The Type II error rates under the assumption of 40 samples in each outcome group 
are as follows: Type II Error rate( 17.0=∆β )=0.494,Type II Error rate( 20.0=∆β )=0.264, 
Type II Error rate( 2358 siteCpG  ,10.0=∆β )=1.0, Type II Error rate 
( 2208 siteCpG  ,10.0=∆β )=0.991, and Type II Error rate( 05.0=∆β )=1.0. Because of the 
unbending threshold imposed upon the Filtered Two Sample t-test, the Type II error rate of 
this test still remained severely inflated for levels of β∆  at or below 0.17.  As seen below, 
these trends become further defined as sample size increases to 80 samples in each 
outcome group.  Therefore, when solely observing the Type II error rate across both 
varying levels of differential methylation and sample size, the Two Sample t-test, the Beta 
distribution test, and the Likelihood ratio based test each perform well. 
 
 
 
 
 
 
80 
     
 Type II Error Rate 
Test 
Set 
∆β 
Observed 
∆β 
Illumina 
Code X  Y  
Test Set 
p-value (t 
test) 
Two 
Sample 
t-test  
Beta 
Test 
Likelihood 
ratio test 
0.17 0.17 4092 0.46 0.29 0.005 <0.001 0.012 <0.001 
0.20 0.20 4297 0.52 0.32 0.008 <0.001 0.008 <0.001 
0.10 0.10 2358 0.47 0.38 <0.001 <0.001 <0.001 <0.001 
0.10 0.10 2208 0.47 0.37 0.039 0.006 0.120 0.003 
-0.05 -0.05 4038 0.76 0.81 0.009 <0.001 0.009 <0.001 
Table 5.8 Type II Error rate comparison across varying levels of differential proportion 
methylated where data has been generated with 80 samples each in outcome groups 1 and 
2 according to a Beta distribution. 
 
We now turn to examine the behavior of the Type II error under both varying levels 
of differential methylation and sample size for the proposed tests where data have been 
generated according to the Bivariate Normal distribution. 
 
5.2(b) Type II error data simulation methods and results: Bivariate Normal distribution 
 
As in the examination of Type I error, the Type II error behavior of the five 
proposed tests was explored under the assumption that it was generated both under a Beta 
distribution and a Bivariate Normal distribution.  Data generation under the Bivariate 
Normal distribution was as follows.  Again, initially using test data CpG site 4092 to 
model realistic data with an approximate mean proportion methylated difference of 0.17 
between the two outcome groups, the mean and variance of each the Red and Green 
channels for the Group 1 were found.  Together with a correlation coefficient of , 
these values were used to generate bivariate normal random variables that became the Red 
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and Green channels for the first group of the simulated data.  This process was repeated by 
calculating the mean and variance of each the Red and Green channels for Group 2 in 
selected the CpG site of the test data set.  The generated bivariate normal random variables 
using these values became the Red and Green channels for the second group of the 
simulated data.  Like when testing the Type I error rate, the generated data set was filtered 
so that any negative values were changed to zero, per the formula for the calculation of 
( )))0,max()0,(max()0,max(, GRR +=ββ .  This process was performed 3,152 times, 
meaning that all CpG sites were generated to be differentially methylated between the two 
groups.  Then, with this fully prepared data set, the significance testing again commenced.  
Results of this analysis are presented below. 
 
      Type II Error Rate 
Test 
Set 
∆β 
Obs. 
 ∆β 
Illum. 
Code X  Y  
Test Set 
p-value 
(t test) 
Two 
Sample 
t-test  
Beta 
Test 
Likelihood 
ratio test 
Bootstrap 
Test 
0.17 0.15 946 0.46 0.29 0.005 0.192 0.251 0.135 0.213 
Table 5.9 Type II Error Rate comparison at minimum methylation discrimination level 
where data has been generated according to the Bivariate Normal distribution with 20 
samples in outcome group 1 and 16 samples in outcome group 2. 
 
To reiterate, in Table 5.9, the Test Set β∆  column lists the difference in mean 
proportion methylated between the two outcome groups for which we sought to generate 
data.  The Observed β∆ column lists the actual β∆ present in our generated data.  
Meanwhile, the columns denoted Illumina Code, X , Y , and Test Set p-value (t-test) 
describe the reference Illumina code of the CpG site used to generate our data, the mean 
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proportion methylated present in our test data for the first and second outcome groups, and 
the p-value of this CpG site when a two sample t-test is performed to test for differential 
methylation, respectively.  The following four columns illustrate the Type II error rate for 
the four proposed tests when data have been generated under the assumptions of the given 
CpG site.  Because data generated under the Bivariate Normal distribution in a sense 
creates two channel data, the Type II error of the Bootstrap test can now be assessed, as it 
relies on this information. 
 Table 5.9 already demonstrates similar results to those seen when data were 
generated according to the Beta distribution--each test preserved appropriate Type II error 
rates. The Type II error rate of the Filtered Two Sample t-test when testing a differential 
methylation of 0.17 is 0.616.   
The effect of the magnitude of the difference in methylation levels on Type II error 
rate was next explored.  The process of generating data and running the five tests was 
repeated where different significantly differentiated CpG sites from the test data were 
chosen to generate the data.  These CpG sites from the test data were chosen to achieve 
varying levels in the  variable, as the CpG site with Illumina code 4092 was chosen to 
achieve a .  Results are presented in Table 5.10 below. 
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      Type II Error Rate 
Test 
Set 
∆β 
Obs. 
 ∆β 
Illum. 
Code X  Y  
Test Set 
p-value 
(t test) 
Two 
Sample 
t-test  
Beta 
Test 
Likelihood 
ratio test 
Bootstrap 
Test 
0.17 0.15 4092 0.46 0.29 0.005 0.192 0.251 0.135 0.213 
0.20 0.17 4297 0.52 0.32 0.008 0.176 0.208 0.171 0.156 
0.10 0.09 2358 0.47 0.38 <0.001 0.250 0.229 0.266 0.228 
0.10 0.08 2208 0.47 0.37 0.039 0.539 0.576 0.441 0.563 
-0.05 -0.04 4038 0.76 0.81 0.009 0.701 0.601 0.646 0.690 
Table 5.10 Type II Error rate comparison across varying levels of differential proportion 
methylated where data has been generated with 20 samples in outcome group 1 and 16 
samples in outcome group 2 according to a Bivariate Normal distribution. 
 
Here,  each of the four tests included in Table 5.10 perform relatively well in respect to the 
Type II error rate across most varying levels of differential proportion methylated.  
However, for small β∆ (i.e., β∆ =0.05), these tests all exhibit a high Type II error. 
Alternatively, the Type II error rates of the Filtered Two Sample t-test are as follows: Type 
II Error rate( 17.0=∆β )=0.616,Type II Error rate( 20.0=∆β )=0.642, Type II Error 
rate( 2358 siteCpG  ,10.0=∆β )=0.994, Type II Error rate( 2208 siteCpG  ,10.0=∆β )= 
0.986, and Type II Error rate( 05.0=∆β )=1.0, which are, again, inflated, especially for 
17.0<∆β , the imposed threshold level.  Again, as observed in Chapter 5.2(a), the Type II 
error rates of all tests inflates when the data used to generate the data are both more 
marginally significant and more variable.  This is seen when comparing the Type II error 
rates for data generated using the more highly significant and less variable CpG site 2358 
to the less significant and more variable CpG site 2208 which are both used to test for a 
difference in proportion methylated of 0.10. 
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The next step in the analysis was to explore the behavior of the Type II error rate 
across varying levels of differential proportion methylated for each 40 samples in outcome 
groups 1 and 2 and 80 samples in outcome groups 1 and 2.  Results are presented in Tables 
5.11 and 5.12, respectively. 
      Type II Error Rate 
Test 
Set 
∆β 
Obs. 
 ∆β 
Illum. 
Code X  Y  
Test Set 
p-value 
(t test) 
Two 
Sample 
t-test  
Beta 
Test 
Likelihood 
ratio test 
Bootstrap 
Test 
0.17 0.15 4092 0.46 0.29 0.005 0.014 0.024 0.004 0.013 
0.20 0.17 4297 0.52 0.32 0.008 0.007 0.010 0.016 0.006 
0.10 0.09 2358 0.47 0.38 <0.001 0.023 0.015 0.028 0.023 
0.10 0.08 2208 0.47 0.37 0.039 0.222 0.258 0.110 0.249 
-0.05 -0.04 4038 0.76 0.81 0.009 0.418 0.314 0.347 0.411 
Table 5.11 Type II Error rate comparison across varying levels of differential proportion 
methylated where data has been generated with 40 samples in each outcome group 1 and 
group 2 according to a Bivariate Normal distribution. 
 
 
 
 
      Type II Error Rate 
Test 
Set 
∆β 
Obs. 
 ∆β 
Illum. 
Code X  Y  
Test Set 
p-value 
(t test) 
Two 
Sample 
t-test  
Beta 
Test 
Likelihood 
ratio test 
Bootstrap 
Test 
0.17 0.15 4092 0.46 0.29 0.005 <0.001 <0.001 <0.001 0.001 
0.20 0.17 4297 0.52 0.32 0.008 <0.001 <0.001 <0.001 <0.001 
0.10 0.09 2358 0.47 0.38 <0.001 <0.001 <0.001 <0.001 <0.001 
0.10 0.08 2208 0.47 0.37 0.039 0.030 0.041 0.006 0.044 
-0.05 -0.04 4038 0.76 0.81 0.009 0.132 0.089 0.064 0.130 
Table 5.12 Type II Error rate comparison across varying levels of differential proportion 
methylated where data has been generated with 80 samples in each outcome group 1 and 
group 2 according to a Bivariate Normal distribution. 
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Tables 5.11 and 5.12 illustrate that as sample size increases, the Type II error rate 
of each the Two Sample t-test, the Beta test, the Likelihood ratio based test, and the 
Bootstrap based test decreases.  Even for testing a very small absolute difference in 
proportion methylated of 0.05 does the Type II error rate become acceptably small when 
sample size increases to 80 samples per outcome group.  In fact, when there are 40 samples 
per outcome group, the Beta test, in particular, demonstrates a Type II error rate of 0.314, 
which could be considered an acceptable error rate under certain testing scenarios.  The 
Type II error rates of the Filtered Two Sample t-test when there are 40 samples in each 
outcome groups 1 and 2 are as follows: Type II Error rate( 17.0=∆β )=0.671,Type II Error 
rate( 20.0=∆β )=0.725, Type II Error rate( 2358 siteCpG  ,10.0=∆β )=1.0, Type II Error 
rate( 2208 siteCpG  ,10.0=∆β )=0.999, and Type II Error rate( 05.0=∆β )=1.0.  
Furthermore, the Type II error rates of the Filtered Two Sample t-test when there are 80 
samples in each outcome groups 1 and 2 are as follows: Type II Error 
rate( 17.0=∆β )=0.746,Type II Error rate( 20.0=∆β )=0.803, Type II Error 
rate( 2358 siteCpG  ,10.0=∆β )=1.0, Type II Error rate( 2208 siteCpG  ,10.0=∆β )=1.0, and 
Type II Error rate( 05.0=∆β )=1.0. 
 
5.3 Application of the Beta Test to Hepatitis C Virus data set 
 
As demonstrated by both appropriate Type I and Type II error rates, the Beta test is 
a well-suited statistical measure for detecting differential methylation between two 
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outcome groups.  As previously stated, methodologies for the development of alternative 
testing procedures were motivated by a Hepatitis C Virus data set. (Archer et al., 2010)  
The full dataset consists of methylation data from 1,547 CpG sites for analysis for each of 
36 patients who present either HCV cirrhosis without concomitant Hepatocellular 
Carcinoma (HCC) (N=16) or HCV cirrhosis with concomitant HCC (N=20).  While results 
have been published applying a Filtered Two Sample t-test to this data, a re-analysis was 
conducted applying the Beta test here developed.  At the 05.0=α level, it was determined 
that 277 CpG sites were significantly differentially methylated, as compared with the 205 
sites differentially methylated using a standard Two Sample t-test.  As to be expected, 
there was much overlap between sites found significantly differentially methylated under 
the two testing scenarios.  A table of these 277 CpG sites found differentially methylated is 
found in Appendix A. 
 
5.4 Conclusions: Determination of a well-defined statistical testing measure 
 
 In choosing an appropriate statistical testing measure for a certain class of data, it is 
important to weigh both the Type I and Type II error rates.  Here, we sought an appropriate 
testing measure for the identification of differential CpG site methylation between two 
groups of samples—a typical testing scenario concerning data collected with the Illumina 
GoldenGate technology.  Currently, both the Two Sample t-test and, increasingly, the 
Filtered Two Sample t-test are widely used to analyze differential methylation patterns in 
this class of data.  After concern that both the distributional assumption of normality 
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underlying the Two Sample t-test might not be appropriate for testing on a proportion 
methylated variable and that the Filtered Two Sample t-test could reduce power for sites 
exhibiting truly differential methylation that was below the filter level, alternative testing 
measures were explored.  These three alternative testing measures took the form of a test 
based on the Beta distribution and on two large sample tests, a likelihood ratio based test 
and a bootstrap based test.  It had been hypothesized that the proportion methylated 
variable, β , upon which hypothesis testing was conducted, followed a Beta distribution, 
and it had also been hypothesized that the Red and Green two channel data followed a 
Bivariate Normal distribution.  Therefore, data were generated under each of these 
distributions, and the Type I and Type II error rates were computed for each test when 
applied to these simulated data sets.   
For data generated under each of the distributions, both the Two Sample t-test and 
the Beta distribution test accurately quantify Type I error rates across small to large sample 
sizes.  The Boostrap based test also accurately quantified the Type I error rate under the 
distribution assumption of Bivariate normality, but by nature of the test construction, the 
Type I error rates could not be applied to the single valued data generated here under a 
Beta distribution.  Quite notably however, the Filtered Two Sample t-test demonstrates a 
Type I error rate that is too low, and so it does not accurately quantify the Type I error rate.  
Additionally, the Likelihood ratio based test exhibited a Type I error rate that was slightly 
inflated under the assumption of Bivariate Normal data.  Concerning the Type II error 
rates, the Two Sample t-test, the Beta test and the Likelihood Ratio based test preserved an 
appropriate error, especially for large sample sizes, under both distributional assumptions.  
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The Bootstrap based test, performed well with respect to the Type II error rate, as well, 
under the testable assumption of Bivariate Normality.  Owing to both its differential Type I 
error rate when compared to the four alternative testing measures and its inability for fixing 
this error, the Filtered Two Sample t-test could not be directly compared.  Nevertheless, it 
was evident that the imposition of a filter likely decreases power for truly differential sites 
that exhibit β∆ less than the filtering level.   
Because the Two Sample t-test and the Beta test demonstrate both appropriate Type 
I and Type II error rates, these two testing measures are decided to be the most preferable 
tests for CpG site methylation data.  While the Bootstrap based test demonstrated both 
appropriate Type I and Type II error rates under the assumption of Bivariate Normal data, 
the Two Sample t-test and the Beta test have the distinct advantage that they can be 
performed on data presented as either two channel array data or computed proportion 
methylated data.  Because the Bootstrap based test relies on sampling data from each the 
Red and Green channels, it cannot be applied to data that has already been summarized as 
proportion methylated data, as is frequently the case.   
Concerning the Two Sample t-test and the Beta test, it cannot be claimed whether 
one of these two tests is superior to the other.  Rather, the Type I and Type II error rates of 
both of these tests under each distributional assumption are quite comparable.  A clinician 
might prefer to use the Two Sample t-test because it is a well known and straightforward 
testing measure that is already in use.  However, despite its accuracy, it can still be claimed 
that the fundamental distributional assumption of data arising from the entire real number 
line is violated.  It is for this reason, on the other hand, that the statistician might prefer to 
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use the Beta distribution test because it is more statistically rigorous in its distributional 
assumptions.   
Two final points merit noting.  First, one should note how poorly the Filtered Two 
Sample t-test performed.  As hypothesized, the application of a filter severely reduces 
power for CpG sites demonstrating smaller but truly differential levels of proportion 
methylation.  Therefore, the application of a Filtered Two Sample t test cannot be 
recommended for the analysis of CpG site methylation data.  Second, one should note that 
especially for larger sample sizes, the Two Sample t-test and the Beta distribution test 
perform well across levels of differential methylation—even those levels of methylation 
less than 0.17.  This gives evidence in support of a hypothesis that the Illumina technology 
can, in fact, detect differential methylation at levels less than 17.0=∆β .  How small of a 
difference in methylation that the Illumina technology can detect was addressed in Chapter 
4.  
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CHAPTER 6 Conclusions and Recommendations 
 
 Abnormal DNA methylation has emerged as an important area of study for 
understanding many clinical pathologies.  As with any developing clinical theories, sound 
statistical methods must be devised to analyze the new types of emerging data to ensure 
accurate conclusions.  In this thesis, the methods for identifying a change in methylation 
pattern were studied and modifications to these methods were proposed.  Specifically, a 
study of abnormal DNA methylation as it relates in the progression from HCV-cirrhosis to 
HCC was employed as an impetus for our analysis.  For this study, data were collected 
according to the GoldenGate Methylation BeadArray Cancer Panel I platform developed 
by Illumina for cancer-focused methylation analysis.  This technology presents data in the 
form of two channel array data containing expression values for the methylation target 
sequence (Red) as well as expression values for the unmethylated target sequence (Green).  
Data are summarized in the form of a proportion methylated variable for each CpG site, 
and current analysis methods for the identification of differential methylation between two 
outcome groups at each CpG site include the performance of either a Two-Sample t-test or 
a Filtered Two-Sample t-test on the proportion methylated variable. 
 Each the Two Sample t-test and the Filtered Two Sample t-test elicit concerns over 
their statistical assumptions and thus the validity of their conclusions.  The Two Sample t-
test assumes that the data upon which it is being performed arise from a distribution 
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encompassing the entire real number line, which violates the fact that the proportion 
methylated variable is, in fact, a proportion on the range of 0 to 1.  The Filtered Two 
Sample t-test imposes the additional constraint that a CpG site can be concluded 
differentially methylated between two outcome groups if the difference in the proportion 
methylated variables between the two groups is greater than some threshold.  Any CpG 
sites that are truly differentially methylated but possess a difference in methylation that is 
less than the threshold would then present no statistical power.  Therefore, the validity of 
the Filtered Two Sample t-test rests upon the accuracy of the imposed threshold.  It was in 
response to these concerns that the aims of this thesis materialized.  First, we sought 
statistically to demonstrate any deficiencies in the two existing testing methods while 
proposing appropriate alternative testing methods.  Second, we sought to establish an 
accurate minimum level of discernable differential methylation for the Illumina 
technology, both for reference value and for statistical use if a filter was to be imposed 
upon a statistical test, as is increasingly commonly seen in literature. 
 In accomplishing our first aim, we proposed a test based on a Beta distributed 
random variable.  Our motivation behind the Beta test was based on the assumption that 
the Red and Green channels followed a Gamma distribution and hence the ratio would be 
beta distributed. It is important to note that this distributional property supposes that the 
two Gamma distributed random variables were independent of each other.  As expected 
from the lack of independence between the methylated and unmethylated states of a given 
CpG site, this was not the case with the given data, but rather the mean correlation of the 
Red and Green channels across all 36 chips was -0.62 (standard error = 0.03). 
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Nevertheless, by means of a simulation study comparing the Type I and Type II error rates 
of this proposed test to that of the Two Sample t-test, we concluded that both tests, in fact, 
performed equally well.  Alternatively, due to such differing Type I error rates, the Type II 
error rates of the Filtered Two Sample t-test could not be directly compared to those of the 
remaining tests.  However, we gained evidence in support of our hypothesis that the 
Filtered Two-Sample t-test is not a viable testing alternative in that it appears to inflate 
Type I error while diminishing Type II error, especially for the CpG sites mentioned—
those with smaller but truly differential methylation that the filter allows.  As a result of 
these findings, it is recommended that either the Two Sample t-test or the test based on a 
Beta distributed random variable be employed in future studies.  In fact, both of these 
testing measures perform as well as any appropriately designed statistical test, so it is not 
recommended that any type of filter needs to be applied.  As far as deciding between these 
two tests which testing measure to use, it is assumed that a clinician might find the Two 
Sample t-test preferable to use because of its simplicity and familiarity in implementation.  
On the other hand, it could be claimed that a statistician would prefer the use of the test 
based on a Beta distributed random variable, since it is statistically sound in its 
assumptions.  For, as well as the Two Sample t-test performs, it still can be argued that it 
violates a basic distributional assumption of the proportion methylated variable. 
 Our findings into the poor performance of the Filtered t-test further supported the 
second aim—to establish an accurate minimum level of discernable differential 
methylation.  Again, two alternative testing measures have been well established in the 
Two Sample t-test and the test based on a Beta distributed random variable to accurately 
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differentiate methylation patterns between two outcome groups, and so there is no need to 
apply any type of filter when simply looking for differentially methylated CpG sites.  
Nevertheless, if a minimum level of differentiation is to be employed, an accurate value 
must be established.  While a previous estimate of 0.17 had been established based on a 
dilution study of female genomic DNA into male genomic DNA, a closer look into the 
analysis of the study revealed that not all known characteristics of the data had been 
properly accounted for, and so it was concluded that by re-analyzing the data, a more 
appropriate minimum discernable level could be established.  By means of a mixed effects 
Logistic regression model, it was sought to model methylation levels as a function of the 
dilution ratio of Female to Male DNA while accounting for random differences among 
dilution order, technical replicate order, and CpG site. This nonlinear mixed effects model 
accounted for the true shape of the relationship between the percent of Female genomic 
DNA in a sample and the proportion of methylation while establishing the significance of 
this relation.  This analysis was followed by the formulation of a mixed ANOVA model, 
accounting for the same variables and random differences, for the purpose of statistical 
comparisons of adjacent mixing ratios.  In so doing, it was determined that the Illumina 
technology was able to differentiate between levels of methylation that differed by as little 
as 0.086 (comparing 5% Female: 0% Male versus 0% Female: 100% Male).  Clearly, the 
Illumina technology can discern levels of methylation with more accuracy than anticipated, 
and so the use of filters on the order of 0.17 or greater that are seen in literature are missing 
much valuable information that is ready to be used. 
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 In conclusion, one seeking to identify CpG sites which are differentially methylated 
between two outcome groups should employ either a Two Sample t-test or a test based on 
a Beta distribution.  Furthermore, it has been concluded that the Illumina technology can 
differentiate methylation levels that differ at least as low as 0.086.  Therefore, although it is 
not recommended in a traditional testing scenario, if a filter is to be applied to the Two 
Sample t-test procedure, it should be on the order of 0.086.   
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APPENDIX A 
 
Table of CpG sites found significant using test based on the Beta Distribution 
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Symbol Illumina ID 
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for 
Cirrhosis 
Group, 1β  
Mean 
Proportion 
Methylated 
for HCC 
Group, 
2β  β∆  Beta Test 
Two 
Sample t-
test 
Filtered 
Two 
Sample t-
test 
AATK AATK_P709_R_01 0.021 0.031 0.010 1 1 0 
ABCB4 ABCB4_E429_F_01 0.904 0.881 -0.023 1 0 0 
ABCB4 ABCB4_P51_F_01 0.587 0.670 0.083 1 1 0 
ABL1 ABL1_P53_F_01 0.033 0.046 0.014 1 1 0 
AFF3 AFF3_P808_F_01 0.156 0.236 0.079 1 1 0 
AKT1 AKT1_P310_R_01 0.946 0.968 0.022 1 1 0 
ALK ALK_P28_F_01 0.826 0.776 -0.050 1 0 0 
ALPL ALPL_P278_F_01 0.377 0.500 0.123 1 0 0 
APP APP_E8_F_01 0.975 0.963 -0.013 1 0 0 
ARAF ARAF_E38_F_01 0.953 0.966 0.012 1 0 0 
ARHGDIB ARHGDIB_P148_R_01 0.994 0.982 -0.012 1 1 0 
ASCL1 ASCL1_E24_F_01 0.999 0.995 -0.003 1 0 0 
ATP10A ATP10A_P147_F_01 0.486 0.599 0.113 1 1 0 
AXL AXL_E61_F_01 0.927 0.910 -0.017 1 1 0 
BCAM BCAM_E100_R_01 0.085 0.229 0.144 1 1 0 
BCL2L2 BCL2L2_E172_F_01 0.939 0.915 -0.024 1 0 0 
BCL2L2 BCL2L2_P280_F_01 0.054 0.046 -0.008 1 1 0 
BCR BCR_P422_F_01 1.000 0.998 -0.002 1 0 0 
BMP3 BMP3_E147_F_01 0.009 0.020 0.011 1 1 0 
BMP3 BMP3_P56_R_01 0.033 0.057 0.024 1 1 0 
CAPG CAPG_E228_F_01 0.344 0.287 -0.057 1 1 0 
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CASP6 CASP6_P230_R_01 0.932 0.891 -0.042 1 1 0 
CAV2 CAV2_E33_R_01 0.110 0.284 0.174 1 1 1 
CCKAR CCKAR_E79_F_01 0.041 0.092 0.050 1 1 0 
CD81 CD81_P211_F_01 0.988 0.937 -0.051 1 0 0 
CD9 CD9_E14_R_01 0.979 0.972 -0.007 1 0 0 
CDH1 CDH1_P45_F_01 0.628 0.550 -0.077 1 1 0 
CDH13 CDH13_E102_F_01 0.994 0.979 -0.015 1 0 0 
CDH17 CDH17_P532_F_01 0.409 0.356 -0.053 1 1 0 
CDKN1A CDKN1A_E101_F_01 0.048 0.119 0.071 1 1 0 
CDKN1B CDKN1B_P1161_F_01 0.972 0.958 -0.014 1 0 0 
CDKN2B CDKN2B_E220_F_01 0.999 1.000 0.000 1 0 0 
CEBPA CEBPA_P706_F_01 0.019 0.030 0.011 1 1 0 
CHD2 CHD2_P667_F_01 0.990 0.997 0.006 1 0 0 
CLDN4 CLDN4_P1120_R_01 0.008 0.033 0.026 1 1 0 
COL1A2 COL1A2_E299_F_01 0.935 0.899 -0.035 1 0 0 
COL6A1 COL6A1_P425_F_01 0.973 0.979 0.007 1 0 0 
COMT COMT_E401_F_01 0.974 0.963 -0.011 1 0 0 
CPNE1 CPNE1_P138_F_01 0.017 0.024 0.007 1 1 0 
CREBBP CREBBP_P712_R_01 0.714 0.756 0.041 1 1 0 
CRIP1 CRIP1_P274_F_01 0.600 0.544 -0.056 1 1 0 
CSF1 CSF1_P339_F_01 0.314 0.443 0.129 1 1 0 
CSF1R CSF1R_P73_F_01 0.165 0.277 0.111 1 1 0 
CSF2 CSF2_E248_R_01 0.944 0.954 0.010 1 0 0 
CSF2 CSF2_P605_F_01 0.987 0.981 -0.007 1 1 0 
CSF3R CSF3R_P8_F_01 0.938 0.924 -0.014 1 0 0 
CSK CSK_P740_R_01 0.046 0.083 0.036 1 1 0 
CTAG2 CTAG2_P1426_F_01 0.882 0.860 -0.022 1 1 0 
CTSH CTSH_P238_F_01 0.003 0.009 0.006 1 1 0 
DAB2 DAB2_P35_F_01 0.993 0.998 0.005 1 0 0 
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DAB2IP DAB2IP_E18_R_01 0.995 0.992 -0.003 1 0 0 
DAPK1 DAPK1_P345_R_01 0.974 0.981 0.007 1 0 0 
DBC1 DBC1_E204_F_01 0.997 0.992 -0.006 1 1 0 
DCC DCC_E53_R_01 0.751 0.720 -0.031 1 0 0 
DCC DCC_P471_R_01 0.965 0.949 -0.016 1 1 0 
DKC1 DKC1_E101_F_01 0.975 0.958 -0.017 1 0 0 
DLG3 DLG3_P62_R_01 0.798 0.737 -0.062 1 1 0 
DNAJC15 DNAJC15_E26_R_01 0.006 0.014 0.008 1 1 0 
DNASE1L1 DNASE1L1_P39_R_01 0.626 0.553 -0.073 1 1 0 
DST DST_E31_F_01 0.989 0.930 -0.060 1 0 0 
DST DST_P262_R_01 1.000 0.997 -0.003 1 1 0 
EDNRB EDNRB_P148_R_01 0.037 0.072 0.034 1 1 0 
EFNA1 EFNA1_P591_R_01 0.840 0.874 0.034 1 1 0 
EFNB1 EFNB1_E69_F_01 0.276 0.421 0.145 1 1 0 
EFNB3 EFNB3_P442_R_01 1.000 1.000 0.000 1 0 0 
EGF EGF_P413_F_01 0.958 0.949 -0.009 1 0 0 
ELK1 ELK1_E156_F_01 0.108 0.146 0.038 1 1 0 
ELK3 ELK3_P514_F_01 0.955 0.937 -0.018 1 0 0 
EMR3 EMR3_E61_F_01 0.073 0.120 0.047 1 1 0 
ENC1 ENC1_P484_R_01 0.880 0.904 0.024 1 1 0 
EPHA3 EPHA3_E156_R_01 0.897 0.810 -0.087 1 1 0 
EPHA5 EPHA5_E158_R_01 0.821 0.780 -0.040 1 0 0 
EPHA8 EPHA8_P256_F_01 0.371 0.468 0.097 1 1 0 
EPHB4 EPHB4_P313_R_01 0.807 0.754 -0.053 1 1 0 
EPHX1 EPHX1_P22_F_01 0.216 0.358 0.142 1 1 0 
ESR1 ER_seq_a1_S60_F_01 0.959 0.923 -0.037 1 1 0 
ERBB3 ERBB3_E331_F_01 0.982 0.971 -0.011 1 0 0 
ERG ERG_E28_F_01 0.999 0.998 -0.001 1 0 0 
ERN1 ERN1_P809_R_01 0.689 0.625 -0.064 1 1 0 
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F2R F2R_P839_F_01 0.378 0.474 0.096 1 1 0 
FABP3 FABP3_P598_F_01 0.680 0.751 0.072 1 1 0 
FAT FAT_P279_R_01 0.119 0.167 0.048 1 1 0 
FES FES_P223_R_01 0.961 0.934 -0.026 1 1 0 
FGF2 FGF2_P229_F_01 0.079 0.118 0.039 1 1 0 
FGF6 FGF6_E294_F_01 0.702 0.775 0.073 1 1 0 
FGFR1 FGFR1_P204_F_01 0.873 0.844 -0.030 1 0 0 
FGFR2 FGFR2_P266_R_01 0.290 0.533 0.243 1 1 1 
FHIT FHIT_P93_R_01 0.908 0.852 -0.056 1 1 0 
FLI1 FLI1_P620_R_01 0.936 0.984 0.047 1 0 0 
FMR1 FMR1_P484_R_01 0.178 0.208 0.030 1 1 0 
FZD7 FZD7_E296_F_01 0.018 0.028 0.010 1 1 0 
FZD9 FZD9_P15_R_01 1.000 0.999 -0.001 1 0 0 
GABRA5 GABRA5_P862_R_01 0.841 0.800 -0.041 1 1 0 
GABRG3 GABRG3_P75_F_01 0.137 0.100 -0.036 1 1 0 
GAS1 GAS1_P754_R_01 0.042 0.078 0.036 1 1 0 
GAS7 GAS7_P622_R_01 0.989 0.982 -0.007 1 0 0 
GFI1 GFI1_P45_R_01 0.999 0.995 -0.003 1 1 0 
GLI2 GLI2_E90_F_01 0.973 0.961 -0.012 1 0 0 
GLI3 GLI3_P453_R_01 0.997 0.999 0.002 1 0 0 
GNG7 GNG7_E310_R_01 0.967 0.946 -0.021 1 1 0 
GPR116 GPR116_E328_R_01 0.178 0.137 -0.041 1 1 0 
GSTM2 GSTM2_P453_R_01 0.092 0.123 0.031 1 1 0 
GSTP1 GSTP1_P74_F_01 0.803 0.832 0.029 1 0 0 
HBII-13 HBII-13_P991_R_01 0.010 0.025 0.015 1 1 0 
HBII-52 HBII-52_P659_F_01 0.850 0.872 0.022 1 0 0 
HCK HCK_P46_R_01 0.637 0.572 -0.066 1 1 0 
HDAC6 HDAC6_P153_F_01 0.289 0.247 -0.042 1 0 0 
HDAC9 HDAC9_E38_F_01 0.995 0.984 -0.010 1 0 0 
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HGF HGF_E102_R_01 0.990 0.985 -0.006 1 0 0 
HIC2 HIC2_P498_F_01 0.979 0.956 -0.024 1 1 0 
HLA-DOB HLA-DOB_E432_R_01 0.046 0.092 0.046 1 1 0 
HOXA9 HOXA9_P1141_R_01 0.744 0.812 0.069 1 1 0 
HOXB2 HOXB2_P488_R_01 0.094 0.128 0.034 1 1 0 
HPN HPN_P823_F_01 0.999 1.000 0.001 1 0 0 
HPSE HPSE_P93_F_01 0.999 0.995 -0.004 1 0 0 
HTR1B HTR1B_P222_F_01 0.876 0.849 -0.027 1 0 0 
HTR2A HTR2A_P853_F_01 0.110 0.148 0.038 1 1 0 
IAPP IAPP_E280_F_01 0.986 0.966 -0.019 1 1 0 
ICAM1 ICAM1_P119_R_01 0.455 0.593 0.139 1 1 0 
IFNG IFNG_P459_R_01 0.973 0.988 0.015 1 0 0 
IFNGR2 IFNGR2_E164_F_01 0.364 0.522 0.157 1 1 0 
IGF1R IGF1R_E186_R_01 0.589 0.509 -0.080 1 1 0 
IGF2R IGF2R_P396_R_01 0.391 0.485 0.094 1 1 0 
IGFBP1 IGFBP1_E48_R_01 0.367 0.451 0.084 1 1 0 
IGFBP6 IGFBP6_P328_R_01 0.052 0.085 0.033 1 1 0 
IGSF4C IGSF4C_P533_R_01 0.552 0.470 -0.082 1 1 0 
IHH IHH_P246_R_01 0.387 0.343 -0.044 1 1 0 
IL13 IL13_E75_R_01 0.168 0.351 0.183 1 1 1 
IL16 IL16_P226_F_01 0.252 0.335 0.083 1 1 0 
IL18BP IL18BP_E285_F_01 0.410 0.465 0.055 1 1 0 
IL4 IL4_P262_R_01 0.945 0.958 0.013 1 1 0 
IL6 IL6_E168_F_01 0.439 0.411 -0.027 1 1 0 
IL6 IL6_P213_R_01 0.994 0.988 -0.006 1 0 0 
IMPACT IMPACT_P186_F_01 0.801 0.766 -0.035 1 1 0 
IMPACT IMPACT_P234_R_01 0.999 0.995 -0.004 1 0 0 
IRAK1 IRAK1_P312_F_01 0.039 0.044 0.005 1 1 0 
IRAK1 IRAK1_P455_R_01 0.105 0.080 -0.025 1 1 0 
IRF5 IRF5_E101_F_01 0.940 0.956 0.015 1 1 0 
104 
     
0
0
210
Hreject
tofail0Hreject1
0:
==
=−=∆ βββH
 
Gene 
Symbol Illumina ID 
Mean 
Proportion 
Methylated 
for 
Cirrhosis 
Group, 1β  
Mean 
Proportion 
Methylated 
for HCC 
Group, 
2β  β∆  Beta Test 
Two 
Sample t-
test 
Filtered 
Two 
Sample t-
test 
        
IRF7 IRF7_E236_R_01 0.680 0.729 0.049 1 1 0 
ITGA6 ITGA6_P298_R_01 0.133 0.195 0.062 1 1 0 
ITGB1 ITGB1_P451_F_01 0.819 0.784 -0.036 1 0 0 
KCNK4 KCNK4_P171_R_01 0.999 0.998 -0.001 1 0 0 
KCNQ1 KCNQ1_E349_R_01 1.000 0.999 -0.001 1 0 0 
KRAS KRAS_P651_F_01 0.128 0.169 0.041 1 1 0 
LAMB1 LAMB1_E144_R_01 0.195 0.243 0.048 1 1 0 
LAMC1 LAMC1_E466_R_01 0.286 0.406 0.119 1 1 0 
LAMC1 LAMC1_P808_F_01 0.412 0.459 0.047 1 0 0 
LCN2 LCN2_P86_R_01 0.952 0.937 -0.014 1 0 0 
LEFTY2 LEFTY2_P561_F_01 0.093 0.130 0.038 1 1 0 
LIG4 LIG4_P194_F_01 0.992 0.903 -0.088 1 0 0 
LOX LOX_P71_F_01 0.448 0.515 0.067 1 1 0 
MAF MAF_P826_R_01 0.062 0.141 0.078 1 1 0 
MAP3K1 MAP3K1_E81_F_01 0.283 0.391 0.108 1 1 0 
MAP3K1 MAP3K1_P7_F_01 0.004 0.011 0.007 1 1 0 
MAP3K9 MAP3K9_E17_R_01 0.767 0.706 -0.061 1 0 0 
MAPK12 MAPK12_P416_F_01 0.211 0.258 0.047 1 1 0 
MAPK14 MAPK14_P327_R_01 0.998 0.997 -0.002 1 0 0 
MAS1 MAS1_P469_R_01 0.989 0.981 -0.008 1 0 0 
MAS1 MAS1_P657_R_01 0.966 0.953 -0.014 1 1 0 
MCF2 MCF2_P445_F_01 0.954 0.942 -0.012 1 0 0 
ABCB1 MDR1_seq_42_S300_R_01 0.996 0.997 0.001 1 0 0 
MFAP4 MFAP4_P10_R_01 0.013 0.023 0.010 1 1 0 
MKRN3 MKRN3_P108_F_01 0.985 0.978 -0.007 1 0 0 
MLH3 MLH3_E72_F_01 0.218 0.275 0.057 1 1 0 
MLLT4 MLLT4_P1400_F_01 0.130 0.188 0.058 1 1 0 
MME MME_E29_F_01 0.800 0.757 -0.043 1 0 0 
MMP1 MMP1_P397_R_01 0.739 0.779 0.040 1 0 0 
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MMP9 MMP9_E88_R_01 0.992 0.985 -0.007 1 0 0 
MMP9 MMP9_P237_R_01 0.814 0.764 -0.050 1 1 0 
MPO MPO_E302_R_01 0.038 0.062 0.024 1 1 0 
MST1R MST1R_P87_R_01 0.110 0.090 -0.021 1 1 0 
MT1A MT1A_E13_R_01 0.791 0.832 0.042 1 0 0 
MYBL2 MYBL2_P354_F_01 0.286 0.457 0.172 1 1 1 
MYCL1 MYCL1_P502_R_01 0.946 0.964 0.018 1 1 0 
MYCN MYCN_P464_R_01 0.393 0.582 0.188 1 1 1 
MYLK MYLK_E132_R_01 0.551 0.800 0.249 1 1 1 
NAT2 NAT2_P11_F_01 0.999 1.000 0.001 1 0 0 
NCL NCL_P1102_F_01 0.998 0.996 -0.002 1 0 0 
NES NES_P239_R_01 0.017 0.023 0.006 1 1 0 
NOTCH2 NOTCH2_P312_R_01 0.753 0.709 -0.044 1 0 0 
NOTCH3 NOTCH3_P198_R_01 0.050 0.068 0.018 1 1 0 
NPR2 NPR2_P1093_F_01 0.079 0.066 -0.014 1 1 0 
NPR2 NPR2_P618_F_01 0.034 0.078 0.044 1 1 0 
NRG1 NRG1_P558_R_01 0.986 0.976 -0.010 1 0 0 
NTRK1 NTRK1_E74_F_01 0.015 0.020 0.005 1 1 0 
NTRK2 NTRK2_P395_R_01 0.943 0.908 -0.035 1 1 0 
OSM OSM_P34_F_01 0.997 0.979 -0.018 1 0 0 
PAX6 PAX6_E129_F_01 0.911 0.868 -0.043 1 1 0 
PAX6 PAX6_P1121_F_01 0.315 0.220 -0.095 1 1 0 
PCTK1 PCTK1_E77_R_01 0.900 0.853 -0.047 1 1 0 
PDE1B PDE1B_E141_F_01 0.488 0.444 -0.044 1 0 0 
PDGFB PDGFB_P719_F_01 0.994 0.979 -0.014 1 1 0 
PECAM1 PECAM1_E32_R_01 0.317 0.515 0.199 1 1 1 
PEG3 PEG3_E496_F_01 0.901 0.919 0.018 1 1 0 
PENK PENK_E26_F_01 0.816 0.864 0.048 1 1 0 
PENK PENK_P447_R_01 1.000 1.000 0.000 1 0 0 
PGF PGF_E33_F_01 0.940 0.958 0.018 1 0 0 
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PGF PGF_P320_F_01 0.058 0.092 0.034 1 1 0 
PGR PGR_E183_R_01 0.925 0.900 -0.024 1 1 0 
PLAGL1 PLAGL1_P236_R_01 0.993 0.986 -0.007 1 0 0 
PLAGL1 PLAGL1_P334_F_01 0.862 0.879 0.017 1 1 0 
PLAUR PLAUR_P82_F_01 0.266 0.301 0.034 1 1 0 
POMC POMC_E254_F_01 0.991 0.984 -0.006 1 0 0 
PSCA PSCA_P135_F_01 0.908 0.882 -0.026 1 0 0 
PSIP1 PSIP1_P163_R_01 0.964 0.930 -0.034 1 1 0 
PTCH2 PTCH2_P568_R_01 0.879 0.836 -0.043 1 1 0 
PTGS2 PTGS2_P308_F_01 0.998 0.996 -0.002 1 0 0 
PTHLH PTHLH_P15_R_01 0.966 0.934 -0.032 1 1 0 
PTK2B PTK2B_P673_R_01 0.898 0.879 -0.020 1 1 0 
PTPN6 PTPN6_E171_R_01 0.998 0.997 -0.001 1 0 0 
PTPN6 PTPN6_P282_R_01 0.044 0.074 0.030 1 1 0 
PTPNS1 PTPNS1_P301_R_01 0.039 0.050 0.011 1 1 0 
PTPRG PTPRG_E40_R_01 0.962 0.947 -0.014 1 0 0 
PTPRG PTPRG_P476_F_01 0.942 0.859 -0.083 1 0 0 
PTPRH PTPRH_P255_F_01 0.999 1.000 0.001 1 0 0 
PYCARD PYCARD_P150_F_01 0.822 0.864 0.041 1 0 0 
RAD50 RAD50_P191_F_01 0.810 0.766 -0.044 1 1 0 
RAN RAN_P581_R_01 0.959 0.919 -0.040 1 1 0 
RET RET_seq_53_S374_F_01 0.227 0.342 0.115 1 1 0 
RYK RYK_P493_F_01 0.978 0.945 -0.034 1 1 0 
S100A2 S100A2_E36_R_01 0.171 0.238 0.067 1 1 0 
S100A4 S100A4_P194_R_01 0.996 0.998 0.002 1 0 0 
SCGB3A1 SCGB3A1_P103_R_01 0.909 0.932 0.023 1 0 0 
SEMA3B SEMA3B_P110_R_01 0.006 0.016 0.010 1 1 0 
5-Sep SEPT5_P464_R_01 0.117 0.159 0.042 1 1 0 
SERPINE1 SERPINE1_E189_R_01 0.039 0.080 0.041 1 1 0 
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SFN SFN_P248_F_01 0.992 0.982 -0.010 1 1 0 
SFTPB SFTPB_P689_R_01 0.890 0.847 -0.043 1 0 0 
SGCE SGCE_E149_F_01 0.163 0.185 0.022 1 1 0 
SGCE SGCE_P250_R_01 0.013 0.023 0.010 1 1 0 
SH3BP2 SH3BP2_P771_R_01 0.080 0.110 0.030 1 1 0 
SHB SHB_P473_R_01 0.209 0.274 0.065 1 1 0 
SIN3B SIN3B_P607_F_01 0.999 0.999 0.000 1 0 0 
SLIT2 SLIT2_E111_R_01 0.950 0.963 0.012 1 1 0 
SMO SMO_E57_F_01 0.908 0.930 0.023 1 1 0 
SNRPN SNRPN_E14_F_01 0.999 0.999 0.000 1 0 0 
SNURF SNURF_P2_R_01 0.650 0.599 -0.051 1 0 0 
SPARC SPARC_P195_F_01 0.980 0.968 -0.012 1 0 0 
SPDEF SPDEF_P6_R_01 0.696 0.749 0.053 1 0 0 
SPI1 SPI1_P48_F_01 1.000 0.999 0.000 1 0 0 
SPP1 SPP1_E140_R_01 0.998 0.996 -0.002 1 0 0 
SPP1 SPP1_P647_F_01 0.851 0.791 -0.060 1 0 0 
SRC SRC_E100_R_01 0.602 0.530 -0.072 1 0 0 
STAT5A STAT5A_P704_R_01 0.950 0.933 -0.017 1 0 0 
TAL1 TAL1_P817_F_01 0.160 0.130 -0.030 1 1 0 
TDG TDG_E129_F_01 0.996 0.992 -0.004 1 0 0 
TFDP1 TFDP1_P543_R_01 0.916 0.935 0.019 1 0 0 
TFF2 TFF2_P178_F_01 0.997 0.999 0.002 1 0 0 
TFRC TFRC_P414_R_01 0.942 0.920 -0.022 1 0 0 
TIMP1 TIMP1_E254_R_01 0.964 0.943 -0.021 1 0 0 
TIMP3 TIMP3_P1114_R_01 0.782 0.839 0.057 1 1 0 
TJP2 TJP2_P518_F_01 0.505 0.649 0.144 1 1 0 
TMEFF1 TMEFF1_E180_R_01 0.009 0.019 0.009 1 1 0 
TMEFF1 TMEFF1_P234_F_01 0.030 0.090 0.059 1 1 0 
TMEFF2 TMEFF2_P152_R_01 0.152 0.193 0.041 1 1 0 
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TNFRSF10B TNFRSF10B_E198_R_01 0.108 0.087 -0.021 1 1 0 
TNFRSF1B TNFRSF1B_E5_F_01 0.200 0.232 0.032 1 1 0 
TNFSF10 TNFSF10_P2_R_01 0.855 0.831 -0.024 1 1 0 
TP73 TP73_P496_F_01 0.988 0.992 0.005 1 0 0 
TSC2 TSC2_E140_F_01 0.753 0.685 -0.068 1 0 0 
TSG101 TSG101_P257_R_01 0.831 0.902 0.072 1 1 0 
UGT1A1 UGT1A1_P564_R_01 1.000 1.000 0.000 1 0 0 
UGT1A7 UGT1A7_P751_R_01 1.000 0.994 -0.006 1 0 0 
VAMP8 VAMP8_P241_F_01 0.966 0.932 -0.034 1 1 0 
VAV2 VAV2_E58_F_01 0.982 0.969 -0.013 1 1 0 
VIM VIM_P811_R_01 0.001 0.008 0.007 1 1 0 
WNT1 WNT1_E157_F_01 0.683 0.732 0.049 1 0 0 
YES1 YES1_P600_F_01 0.994 0.979 -0.015 1 1 0 
ZAP70 ZAP70_P220_R_01 0.993 0.980 -0.013 1 1 0 
ZIM3 ZIM3_E203_F_01 0.338 0.283 -0.055 1 1 0 
ZNF264 ZNF264_P397_F_01 0.460 0.396 -0.065 1 1 0 
ZNFN1A1 ZNFN1A1_E102_F_01 0.609 0.658 0.049 1 0 0 
CC 8 (3433) PCR16_HK3_1321_F 1.000 0.999 -0.001 1 0 0 
Negative Neg7_PPIH_9972_R 0.158 0.311 0.153 1 1 0 
Negative Neg15_HK3_8743_R 0.029 0.049 0.021 1 1 0 
Negative Neg16_PPIF_4992_R 0.942 0.895 -0.047 1 1 0 
Negative Neg48_PPIG_45960_R 0.999 0.997 -0.002 1 0 0 
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APPENDIX B 
 
Source Code for the construction of the nonlinear mixed model in Chapter 3 
#########################################################################
#### #  This file constructs the most appropriate hierarchical model and    ############# 
#####    establishes a dose response relation.                                            #############                                                 
######################################################################### 
 
 
setwd("C://Documents and Settings//Laptop User//Desktop//Research") 
xchrom.new<-read.csv('XchromBeta.new.csv') 
 
library(nlme) 
names(xchrom.new) 
#[1] "index"     "site"      "TargetID"  "meth"      "dose"      "sample"    "trep"      
"SampleRep" "trep2"   
attach(xchrom.new) 
site<-as.factor(site);dose<-as.factor(dose);sample<-as.factor(sample) 
plot(meth~dose,xlab="Percent of female genomic DNA in sample",ylab="Proportion 
Methylated") 
 
CpGdata<-xchrom.new 
#dilution<-groupedData(meth~dose|sample,data=CpGdata) 
dilution<-groupedData(meth~dose|sample/Rep/site,data=xchrom.new) 
plot(dilution,display=1,collapse=1,ylab="Proportion Methylated",xlab="Percent of female 
genomic DNA in sample") 
 
#Simple Logistic Model 
model1<-nlme(meth~.5/(1+exp(-(dose-mid)/scal)),data=dilution,start=c(5,5),fixed =  mid 
+ scal ~ 1,random=list(sample=pdDiag(mid+scal~1),Rep= pdDiag(mid+scal~1),site= 
pdDiag(mid+scal~1)))  
model1a<-update(model1, weights=varExp(form=~dose|site))  #Variance model in which 
the site variance increases exponentially with age 
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model1b<-update(model1a, random=list(sample=pdDiag(mid+scal~1),Rep= 
pdDiag(mid+scal~1),site= pdDiag(scal~1))) 
model1c<-update(model1a, random=list(sample=pdDiag(mid+scal~1),Rep= 
pdDiag(mid+scal~1))) 
#> anova(model1a,model1c) 
#        Model df       AIC       BIC   logLik   Test  L.Ratio p-value 
#model1a     1 26 -1222.222 -1100.454 637.1108                         
#model1c     2 24 -1231.735 -1119.334 639.8674 1 vs 2 5.513169  0.0635 
 
p3.est<-summary(model1a)$tTable[2,] 
#       Value    Std.Error           DF      t-value      p-value  
#8.398883e+00 1.394291e+00 5.940000e+02 6.023765e+00 2.988831e-09 
 
dimnames(p3.est)[[2]]<-dimnames(summary(model1a)$tTable)[[2]] 
lower.ci<-p3.est[1]-2*p3.est[2] 
upper.ci<-p3.est[1]+2*p3.est[2] 
p3.est2<-cbind(p3.est,lower.ci,upper.ci) 
p3.est2[1,] 
#   p3.est  lower.ci  upper.ci  
 #8.398883  5.610301 11.187466 
 
fitted.mean<-numeric() 
fitted.mean[1]<-mean(fitted(model1a)[CpGdata$dose=="100"]) 
fitted.mean[2]<-mean(fitted(model1a)[CpGdata$dose=="50"]) 
fitted.mean[3]<-mean(fitted(model1a)[CpGdata$dose=="20"]) 
fitted.mean[4]<-mean(fitted(model1a)[CpGdata$dose=="10"]) 
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fitted.mean[5]<-mean(fitted(model1a)[CpGdata$dose=="5"]) 
fitted.mean[6]<-mean(fitted(model1a)[CpGdata$dose=="0"]) 
dose.mean<-c(100,50,20,10,5,0) 
plot(fitted.mean~dose.mean,type='l',ylab="Proportion Methylated",xlab="Percent of 
female genomic DNA in sample",ylim=c(0,1),main=" ") 
points(CpGdata$meth~CpGdata$dose) 
 
# Nonlinear method for testing significance of dose-response 
dilution<-groupedData(meth~dose|sample/Rep/site,data=CpGdata) 
p3.est[i,]<-summary(model2b)$tTable[3,] 
} 
dimnames(p3.est)[[2]]<-dimnames(summary(model1a)$tTable)[[2]] 
lower.ci<-p3.est[,1]-2*p3.est[,2] 
upper.ci<-p3.est[,1]+2*p3.est[,2] 
p3.est2<-cbind(p3.est,lower.ci,upper.ci) 
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APPENDIX C 
 
Source code for the establishment of a minimum level of detectable differential level of 
methylation 
#########################################################################
#####  This file computes the correlation matrix among the 17 CpG sites and ########## 
#####   fits a mixed ANOVA model including nested effects.  Pairwise    ##############              
#####   comparisons are calculated for the determination the minimum  level  ########## 
#####   of  detectable differential methylation                                            ############## 
######################################################################### 
 
setwd("C://Documents and Settings//Laptop User//Desktop//Research") 
xchrom.new<-read.csv('XchromBeta.new.csv') 
xchrom.cor<-read.csv('XchromBeta.csv') 
 
#Correlation matrix 
xchrom.cor<-read.csv('XchromBeta.csv',row.names=1) 
correlation<-round(cor(t(xchrom.cor)),3) 
dimnames(correlation)[[1]]<-rownames(xchrom.cor) 
dimnames(correlation)[[2]]<-rownames(xchrom.cor) 
write.table(correlation,"Correlation.csv",sep=",") 
library(nlme) 
 
names(xchrom.new) 
#[1] "index"     "site"      "TargetID"  "meth"      "dose"      "sample"    "trep"      
"SampleRep" "trep2"   
attach(xchrom.new) 
site<-as.factor(site);dose<-as.factor(dose);sample<-as.factor(sample) 
plot(meth~dose,xlab="Percent of female genomic DNA in sample",ylab="Proportion 
Methylated") 
 
##Fit one anova model for all CpG sites using dose as fixed effect and site nested within 
sample as random effects 
# Since model is function of categorical variable (dose), regression and anova same here 
xchrom.new<-read.csv('XchromBeta.new.csv') 
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xchrom.new$site<-as.factor(xchrom.new$site) 
xchrom.new$dose<-as.factor(xchrom.new$dose) 
xchrom.new$sample<-as.factor(xchrom.new$sample) 
xchrom.new$Rep<-as.factor(xchrom.new$Rep) 
attach(xchrom.new) 
plot(meth~dose,xlab="Percent of female genomic DNA in sample",ylab="Proportion 
Methylated") 
detach() 
library(nlme) 
overall<-lme(meth~dose,random=~1|sample/Rep/site,data=xchrom.new) 
overall.reduced<-lme(meth~dose,random=~1|sample/Rep,data=xchrom.new) 
anova(overall,overall.reduced) 
overall.reduced2<-lme(meth~dose,random=~1|sample,data=xchrom.new) 
anova(overall.reduced,overall.reduced2) 
anova(overall) 
plot(overall) 
##Linear Contrasts for pairwise comparisons 
library(gmodels) 
contrast.0.5<-c(-1,1,0,0,0,0) 
contrast.5.10<-c(0,-1,1,0,0,0) 
contrast.10.20<-c(0,0,-1,1,0,0) 
contrast.20.50<-c(0,0,0,-1,1,0) 
contrast.50.100<-c(0,0,0,0,-1,1) 
fit<-lme(meth~dose,random=~1|sample/Rep/site,data=xchrom.new) 
all.contrasts<-
rbind(contrast.0.5,contrast.5.10,contrast.10.20,contrast.20.50,contrast.50.100) 
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pairwise.result<-fit.contrast(model=fit, varname="dose", all.contrasts) 
#Since pvalues<0.05, each contrast significant, so we reject H0:equal mean methylation in 
two groups  
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APPENDIX D 
 
Source code for Chapter 3.3 CpG site specific hierarchical models 
#########################################################################
##### This file constructs hierarchical models per CpG site              ############# 
##### It creates diagnostic plots for these models and computes point      #############  
#####  estimates at dose=100 and corresponding confidence intervals    ############# 
######################################################################### 
 
 
 
setwd("C://Documents and Settings//Laptop User//Desktop//Research") 
xchrom.new<-read.csv('XchromBeta.new.csv') 
 
library(nlme) 
names(xchrom.new) 
#[1] "index"     "site"      "TargetID"  "meth"      "dose"      "sample"    "trep"      
"SampleRep" "trep2"   
attach(xchrom.new) 
site<-as.factor(site);dose<-as.factor(dose);sample<-as.factor(sample) 
plot(meth~dose,xlab="Percent of female genomic DNA in sample",ylab="Proportion 
Methylated") 
 
#Change site depending on for which CpG site the model is being formulated 
CpGdata<-xchrom.new[site==17,] 
dilution<-groupedData(meth~dose|sample,data=CpGdata) 
#Simple Logistic Model 
model1<-nlme(meth~Asym/(1+exp(-(dose-mid)/scal)),data=dilution,start=c(.8,5,5),fixed = 
Asym + mid + scal ~ 1,random=list(sample=pdDiag(Asym+mid+scal~1)))  
model1a<-nlme(meth~Asym/(1+exp(-(dose-mid)/scal)),data=dilution,start=c(.72,5,5),fixed 
= Asym + mid + scal ~ 1,random=list(sample=~Asym+mid+scal~1)) 
#Asymptotic Regression Model 
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model2<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,-
3),fixed = p1 + p2 + p3~ 1,random=list(sample=pdDiag(p1+p2+p3~1)))  
anova(model1,model2) 
model2a<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,-
3),fixed = p1 + p2 + p3~ 1,random=list(sample=pdDiag(p1+p2~1))) 
model2b<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,-
3),fixed = p1 + p2 + p3~ 1,random=list(sample=pdDiag(p1+p3~1))) 
model2c<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,-
3),fixed = p1 + p2 + p3~ 1,random=list(sample=pdDiag(p2+p3~1))) 
model2d<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,-
3),fixed = p1 + p2 + p3~ 1,random=list(sample=pdDiag(p1~1))) 
model3<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,-
3),fixed = p1 + p2 + p3~ 1,random=list(sample=~p2+p3~1)) 
anova(model2,model2a,model2b,model2c,model2d) 
#calculating predicted value and confidence interval at dose=100 for each CpG site 
out<-summary(model2b) 
### Extract Point estimate ### 
mean(predict(model2b,newdata=dilution[dilution$dose==100,])) 
 
### Extract the estimates ### 
a<-model2b$coefficients$fixed[1] 
b<-model2b$coefficients$fixed[2] 
c<-model2b$coefficients$fixed[3] 
 
### Construct Jacobian (at x=100) #### 
da<- 1-exp(-100*exp(c)) 
db<- exp(-100*exp(c)) 
dc<- b*exp(-100*exp(c))*(-100*exp(c))+a*exp(-100*exp(c))*(100*exp(c)) 
vec<-matrix(c(da,db,dc),ncol=3) 
 
### Estimate CI with Bonferroni adjustment ### 
### Using the delta method to estimate variance JV(t)J^T where J is Jacobian, V(t) is 
variance-covariance matrix, ^T is transpose. 
### and use in constructing the CI with a Bonferroni adjustment 
mean(predict(model2b,newdata=dilution[dilution$dose==100,])) - qnorm(1-
0.05/17)*sqrt(vec%*%out$varFix%*%t(vec)) 
117 
mean(predict(model2b,newdata=dilution[dilution$dose==100,])) + qnorm(1-
0.05/17)*sqrt(vec%*%out$varFix%*%t(vec)) 
 
################# 
## Residual Plots ## 
################# 
 
par(mfrow=c(4,5)) 
 ident<-rep(0,2) 
other<-c(-.5,1.5) 
 
# Residuals vs fitted values 
#Change main depending on CpG site 
#plot(resid(model2b)~fitted(model2b),xlab="Fitted Values",ylab="Standardized 
Residuals",main="CpG Site 1: EFNB1-645",ylim=c(-.08,.08),xlim=c(0,1)) 
# lines(ident~other) 
 
# Fitted mean methylation vs dose 
fitted.mean<-numeric() 
fitted.mean[1]<-mean(fitted(model2b)[CpGdata$dose=="100"]) 
fitted.mean[2]<-mean(fitted(model2b)[CpGdata$dose=="50"]) 
fitted.mean[3]<-mean(fitted(model2b)[CpGdata$dose=="20"]) 
fitted.mean[4]<-mean(fitted(model2b)[CpGdata$dose=="10"]) 
fitted.mean[5]<-mean(fitted(model2b)[CpGdata$dose=="5"]) 
fitted.mean[6]<-mean(fitted(model2b)[CpGdata$dose=="0"]) 
dose.mean<-c(100,50,20,10,5,0) 
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plot(fitted.mean~dose.mean,type='l',ylab="Proportion Methylated",xlab="Percent of 
female genomic DNA in sample",ylim=c(0,1),main="CpG Site 1: EFNB1-645") 
points(CpGdata$meth~CpGdata$dose) 
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APPENDIX E 
 
Source code for Chapter 5 data simulations for the computation of Type I error under the 
assumption of Beta distributed data 
#########################################################################
##### This file tests type I error according to the ttest, the filtered        ############# 
##### ttest, the LRT, the bootstrap test and the beta test under the       #############  
#####  condition that the data has been generated according to the    ############# 
##### Beta distribution.                                                                               ############# 
######################################################################### 
 
library(beadarray) 
setwd("D:/") 
 
## Read in data with no normalization or background correction 
targets <- read.csv("phenotype.csv", header=T) 
liver<-
readIllumina(arrayNames=targets$FileName,useImages=FALSE,singleChannel=FALSE,ta
rgets=targets,backgroundMethod="none") 
 
 
## Bead Summary Data 
R<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="R") 
G<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="G") 
dim(R) #there are 1624 beadtypes in the Red Channel 
dim(G) #there are 1624 beadtypes in the Green Channel 
 
##Merging Red Channel Data with associated gene information 
codeR<-featureNames(R) 
M<-exprs(R) 
RedData<-data.frame(M,codeR) 
dim(RedData) 
OMA<-read.csv("GS0007005-OMA.csv",header=TRUE) 
RedOMA<-
merge(RedData,OMA,by.x="codeR",by.y="IllumiCode.name",all.x=FALSE,all.y=TRUE) 
dim(RedOMA)   
#There are 1547 beadtypes in the red channel summaries that also have gene annotation 
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info 
 
##Merging Green Channel Data with associated gene information 
codeG<-featureNames(G) 
U<-exprs(G) 
GreenData<-data.frame(U,codeG) 
dim(GreenData) 
GreenOMA<-
merge(GreenData,OMA,by.x="codeG",by.y="IllumiCode.name",all.x=FALSE,all.y=TRU
E) 
dim(GreenOMA)   
#There are 1547 beadtypes in the green channel summaries that also have gene annotation 
info 
 
#There are 22 negative control beads 
 
#Red Channel 
#create dataframe of negative control beads 
indR<-grep("Negative",RedOMA$Gene_Symbol) 
negR<-RedOMA[indR,] 
#create vector of length 36, where each entry is the sample mean of the neg control 
beadtype in a particular array 
RedMean<-numeric() 
for (i in 1:36) { 
 RedMean[i]<-mean(negR[,i+1]) 
 i<-i+1 
} 
 
#Frequency histogram of the means 
hist(RedMean,main=paste(" "),xlab=paste("mean of Red (Methylated) 
Channel"),col="red") 
 
#Green Channel 
#create dataframe of negative control beads 
indG<-grep("Negative",GreenOMA$Gene_Symbol) 
negG<-GreenOMA[indG,] 
#create vector of length 36, where each entry is the sample mean of the  
#negative control beadtype in a particular array 
GreenMean<-numeric() 
for (i in 1:36) { 
 GreenMean[i]<-mean(negG[,i+1]) 
 i<-i+1 
} 
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#Frequency histogram of the means 
x11() 
hist(GreenMean,main=paste(" "),xlab=paste("mean of Green (Unmethylated) 
Channel"),col="green") 
 
###Compute beta variable 
 
# initialize beta data frame to store values 
beta<-data.frame() 
# isolating average intensity for each beadtype for R and G channels 
RedAvg<-RedOMA[,2:37] 
GreenAvg<-GreenOMA[,2:37] 
#compute beta 
a<-0 
for (i in 1:36) { 
  j<-1 
  for (j in 1:1547) { 
    diff1<-RedAvg[j,i]-RedMean[i] 
    diff2<-GreenAvg[j,i]-GreenMean[i] 
    num<-max(diff1,0) 
    den<-num+max(diff2,0) 
    n<-num/den 
    a<-ifelse(n=="NaN",a+1,a) 
    beta[j,i]<-n 
    j<-j+1 
    } 
  i<-i+1 
} 
# This produces NaN values where beta=0/(0+0) 
 
##Apply Scaling factor 
RedMean<-apply(RedOMA[,2:37],2,mean) 
GreenMean<-apply(GreenOMA[,2:37],2,mean) 
scale2<-numeric() 
for (i in 1:36) { 
scale2[i]<-RedMean[i]/GreenMean[i]   ### KJA changes MRed to RedMean[i] 
} 
 
CorrectedGreenOMA2<-matrix(nrow=1547,ncol=36) 
for (i in 1:36){ 
CorrectedGreenOMA2[,i]<-scale2[i]*GreenOMA[,i+1] 
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} 
 
### Two sample t-test to determine differentially methylated sites 
 
library(multtest) 
#Compute t-test test statistic 
liver.results<-mt.teststat(beta,targets$Diagnosis) 
#Compute adjusted degrees of freedom for unequal sample size 
rawp0.liver<-2*(1-pnorm(abs(liver.results))) 
df.func<-function(beta,class=targets$Diagnosis) { 
var1<-var(beta[class=="Cirrhosis HCC"]) 
var2<-var(beta[class=="Cirrhosis non-HCC"]) 
n1<-length(beta[class=="Cirrhosis HCC"]) 
n2<-length(beta[class=="Cirrhosis non-HCC"]) 
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1)) 
df 
} 
degrees.f<-apply(beta,1,df.func) 
##p values for t distn 
rawp0.liver<-2*(1-pt(abs(liver.results),degrees.f))  
code<-data.frame(GreenOMA$codeG) 
class<-targets$Diagnosis 
deltabeta<-numeric() 
for (i in 1:1547){ 
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))-
mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"])) 
} 
data<-cbind(code,deltabeta,rawp0.liver) 
code<-data.frame(GreenOMA$codeG) 
class<-targets$Diagnosis 
deltabeta<-numeric() 
for (i in 1:1547){ 
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))-
mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"])) 
} 
data<-cbind(code,deltabeta,rawp0.liver) 
 
################# 
### Generating Data Null case data:Non-differentially methylated 
#################  
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set.seed(123) 
test<-as.character(deltabeta) 
site<-1493 
sig.beta<-beta[site,] 
beta.positive<-as.numeric(sig.beta) 
mu.beta<-mean(beta.positive) 
s2.beta<-var(beta.positive) 
a<-mu.beta*(mu.beta*(1-mu.beta)/s2.beta-1) 
p<-(1-mu.beta)*(mu.beta*(1-mu.beta)/s2.beta-1) 
 
n1<-20 
n2<-16 
set.seed(234) 
for (i in 1:3152){ 
beta.new[i,1:20]<-rbeta(n1,a,p) 
beta.new[i,21:36]<-rbeta(n2,a,p) 
 
 
#################### 
#### T Test########### 
#################### 
library(multtest) 
#Compute t-test test statistic 
##0 is HCC pos group; 1 is HCC neg group 
#Change these values depending on tested sample size 
indicator<-rep(0:1,c(20,16)) 
#indicator<-rep(0:1,c(15,15)) 
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liver.results<-mt.teststat(beta.new,indicator) 
 
#Compute adjusted degrees of freedom for unequal sample size 
rawp0.liver<-2*(1-pnorm(abs(liver.results))) 
df.func<-function(beta.new,class=indicator) { 
var1<-var(beta.new[class==0]) 
var2<-var(beta.new[class==1]) 
n1<-length(beta.new[class==0]) 
n2<-length(beta.new[class==1]) 
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1)) 
df 
} 
degrees.f<-apply(beta.new,1,df.func) 
p0.liver<-2*(1-pt(abs(liver.results),degrees.f)) ##p values for t distn 
 
sig.level<-0.05 
type1<-numeric() 
not.sig.ttest<-p0.liver[1:3152] 
for (i in 1:3152){ 
type1[i]<-ifelse(not.sig.ttest[i]<sig.level,1,0) 
} 
type1error.ttest<-sum(type1)/3152 
 
################## 
#####Bibikova###### 
################## 
type1.bib<-numeric() 
for (i in 1:3152){ 
delta.beta<-mean(beta.new[i,1:20])-mean(beta.new[i,21:36]) 
type1.bib[i]<-ifelse(not.sig.ttest[i]<sig.level & delta.beta>0.17,1,0) 
} 
type1error.bib<-sum(type1.bib)/3152 
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#################### 
#### LR Test######### 
#################### 
# derivative using R 
null.expression<-expression(n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-1)* 
log(input)+(q-1)*log(1-input)) 
dx.null<-deriv(null.expression,c('p','q')) 
# grr is the gradient for the null likelihood 
grr<-function(par,input) { 
 p<-par[1] 
 q<-par[2] 
 n<-length(input) 
 c(n*(digamma(p+q)/gamma(p+q)-digamma(p)/gamma(p))+sum(log(input)), 
 n*(digamma(p+q)/gamma(p+q)-digamma(q)/gamma(q))+sum(log(1-input)) 
 ) 
} 
# grr1 is the gradient for the alt likelihood 
grr1<-function(par,input1,input2) { 
 p1<-par[1] 
 q1<-par[2] 
 n1<-length(input1) 
 p2<-par[3] 
 q2<-par[4] 
 n2<-length(input2) 
 c(n1*(digamma(p1+q1)/gamma(p1+q1)-digamma(p1)/gamma(p1))+sum(log(input1)), 
 n1*(digamma(p1+q1)/gamma(p1+q1)-digamma(q1)/gamma(q1))+sum(log(1-input1)), 
n2*(digamma(p2+q2)/gamma(p2+q2)-digamma(p2)/gamma(p2))+sum(log(input2)), 
 n2*(digamma(p2+q2)/gamma(p2+q2)-digamma(q2)/gamma(q2))+sum(log(1-input2)) 
 ) 
} 
 
# This is the null function to be minimized 
null.function<-function(par,input) { 
 p<-par[1] 
 q<-par[2] 
 n<-length(input) 
 null.like<- n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-
1)*sum(log(input))+(q-1)*sum(log(1-input)) 
 -null.like 
 } 
# Alternative function 
alt.function<-function(par,input1,input2) { 
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 p1<-par[1] 
 q1<-par[2] 
 n1<-length(input1) 
 p2<-par[3] 
 q2<-par[4] 
 n2<-length(input2) 
 log.like<- n1*(log(gamma(p1+q1))-log(gamma(p1))-log(gamma(q1)))+(p1-
1)*sum(log(input1))+(q1-1)*sum(log(1-input1)) + n2*(log(gamma(p2+q2))-
log(gamma(p2))-log(gamma(q2)))+(p2-1)*sum(log(input2))+(q2-1)*sum(log(1-input2)) 
 -log.like 
 } 
 
null<-numeric() 
alt<-numeric() 
for (i in 1:3152){ 
 null[i]<-optim(par=c(.5,.5),fn=null.function,gr=grr,input=beta.new[i,],method='Nelder-
Mead')$value 
#Change indices depending on sample size 
 alt[i]<-
optim(par=rep(.5,4),fn=alt.function,input1=beta.new[i,1:20],input2=beta.new[i,21:36],met
hod='Nelder-Mead')$value 
} 
like.test<--2*(alt-null) 
pvals.like<-pchisq(like.test,df=2,lower.tail=FALSE) 
#Type 1: say not equal when are equal 
type1.like<-numeric() 
not.sig.like<-pvals.like[1:3152] 
for (i in 1:3152){ 
type1.like[i]<-ifelse(not.sig.like[i]<sig.level,1,0) 
} 
type1error.like<-sum(type1.like)/3152 
 
#################### 
#### Bstrap########### 
#################### 
Red<-red.nonsig 
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Green<-green.nonsig 
#Change limits depending on  sample size 
Red.pos<-Red[,1:20] 
Red.neg<-Red[,21:36] 
Green.pos<-Green[,1:20] 
Green.neg<-Green[,21:36] 
teststat<-numeric() 
for (i in 1:3152){ 
teststat[i]<-mean((Red.pos[i,])/(Red.pos[i,]+Green.pos[i,]))-
mean((Red.neg[i,])/(Red.neg[i,]+Green.neg[i,])) 
} 
 
# Number of bootstrap samples 
B<-2500 
 
# Compute bootstrap test statistic 
b.teststat<-matrix(ncol=B,nrow=3152) 
 
for (b in 1:B) { 
bsample<-sample(1:36,replace=TRUE) 
red<-Red[,bsample] 
green<-Green[,bsample] 
#Change limits depending on sample size 
Red.positive<-red[,1:20] 
Green.positive<-green[,1:20] 
Red.negative<-red[,21:36] 
Green.negative<-green[,21:36] 
for (i in 1:3152){ 
b.teststat[i,b]<-mean((Red.positive[i,])/(Red.positive[i,]+Green.positive[i,]))-
mean((Red.negative[i,])/(Red.negative[i,]+Green.negative[i,])) 
} 
} 
 
b.teststat.sort<-matrix(ncol=B,nrow=3152) 
for (i in 1:3152){ 
b.teststat.sort[i,]<-sort(b.teststat[i,]) 
} 
 
result<-numeric() 
for (i in 1:3152){ 
result[i]<-ifelse(teststat[i]<b.teststat.sort[i,25]|teststat[i]>b.teststat.sort[i,975],1,0) 
} 
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#Achieved significance level 
asl<-numeric() 
for (i in 1:3152){ 
asl[i]<-sum(ifelse(b.teststat[i,]>abs(teststat[i]) | b.teststat[i,]< -abs(teststat[i]),1,0))/B 
} 
sig.level<-0.05 
 
#Type 1: say not equal when are equal 
type1.bstrap<-numeric() 
not.sig.bstrap<-asl[1:3152] 
for (i in 1:3152){ 
type1.bstrap[i]<-ifelse(not.sig.bstrap[i]<sig.level,1,0) 
} 
type1error.bstrap<-sum(type1.bstrap)/3152 
 
##################### 
#### Beta Test ######### 
##################### 
set.seed(123) 
test<-as.character(deltabeta) 
site<-1493 
sig.beta<-beta[site,] 
beta.positive<-as.numeric(sig.beta) 
mu.beta<-mean(beta.positive) 
s2.beta<-var(beta.positive) 
a<-mu.beta*(mu.beta*(1-mu.beta)/s2.beta-1) 
p<-(1-mu.beta)*(mu.beta*(1-mu.beta)/s2.beta-1) 
 
mean <- a/(a + p) 
variance <- function(a, b) a * b/((a + b + 1) * (a + b)^2) 
Q <- (qbeta(0.975, a, p) - mean)/sqrt(variance(a, p)) 
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set.seed(123) 
reject <- numeric() 
#Change n1 and n2 depending on sample size 
n1 <- 20 
n2 <- 16 
for (i in 1:10000) { 
x <- rbeta(n1, a, p) 
y <- rbeta(n2, a, p) 
Critical <- 0 + Q * sqrt(variance(a, p)/n1 + variance(a,p)/n2) 
reject[i] <- ifelse(abs(mean(x) - mean(y)) > Critical, 1,0) 
} 
#Type I error according to Beta Test 
type1error.beta<-sum(reject)/10000 
 
type1error.ttest 
type1error.bib 
type1error.like 
type1error.bstrap 
type1error.beta 
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APPENDIX F 
 
Source code for Chapter 5 data simulations for the computation of Type I error under the 
assumption of Bivariate Normal distributed data 
#########################################################################
##### This file tests type I error according to the ttest, the filtered        ############# 
##### ttest, the LRT, the bootstrap test and the beta test under the       #############  
#####  condition that the data has been generated according to the    ############# 
##### Bivariate Normal distribution.                                                     ############# 
######################################################################### 
 
library(beadarray) 
setwd("D:/") 
 
## Read in data with no normalization or background correction 
targets <- read.csv("phenotype.csv", header=T) 
liver<-
readIllumina(arrayNames=targets$FileName,useImages=FALSE,singleChannel=FALSE,ta
rgets=targets,backgroundMethod="none") 
 
 
## Bead Summary Data 
R<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="R") 
G<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="G") 
dim(R) #there are 1624 beadtypes in the Red Channel 
dim(G) #there are 1624 beadtypes in the Green Channel 
 
##Merging Red Channel Data with associated gene information 
codeR<-featureNames(R) 
M<-exprs(R) 
RedData<-data.frame(M,codeR) 
dim(RedData) 
OMA<-read.csv("GS0007005-OMA.csv",header=TRUE) 
RedOMA<-
merge(RedData,OMA,by.x="codeR",by.y="IllumiCode.name",all.x=FALSE,all.y=TRUE) 
dim(RedOMA)   
#There are 1547 beadtypes in the red channel summaries that also have gene annotation 
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info 
 
##Merging Green Channel Data with associated gene information 
codeG<-featureNames(G) 
U<-exprs(G) 
GreenData<-data.frame(U,codeG) 
dim(GreenData) 
GreenOMA<-
merge(GreenData,OMA,by.x="codeG",by.y="IllumiCode.name",all.x=FALSE,all.y=TRU
E) 
dim(GreenOMA)   
#There are 1547 beadtypes in the green channel summaries that also have gene annotation 
info 
 
#There are 22 negative control beads 
 
#Red Channel 
#create dataframe of negative control beads 
indR<-grep("Negative",RedOMA$Gene_Symbol) 
negR<-RedOMA[indR,] 
#create vector of length 36, where each entry is the sample mean of the neg control 
beadtype in a particular array 
RedMean<-numeric() 
for (i in 1:36) { 
 RedMean[i]<-mean(negR[,i+1]) 
 i<-i+1 
} 
 
#Frequency histogram of the means 
hist(RedMean,main=paste(" "),xlab=paste("mean of Red (Methylated) 
Channel"),col="red") 
 
#Green Channel 
#create dataframe of negative control beads 
indG<-grep("Negative",GreenOMA$Gene_Symbol) 
negG<-GreenOMA[indG,] 
#create vector of length 36, where each entry is the sample mean of the  
#negative control beadtype in a particular array 
GreenMean<-numeric() 
for (i in 1:36) { 
 GreenMean[i]<-mean(negG[,i+1]) 
 i<-i+1 
} 
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#Frequency histogram of the means 
x11() 
hist(GreenMean,main=paste(" "),xlab=paste("mean of Green (Unmethylated) 
Channel"),col="green") 
 
###Compute beta variable 
 
# initialize beta data frame to store values 
beta<-data.frame() 
# isolating average intensity for each beadtype for R and G channels 
RedAvg<-RedOMA[,2:37] 
GreenAvg<-GreenOMA[,2:37] 
#compute beta 
a<-0 
for (i in 1:36) { 
  j<-1 
  for (j in 1:1547) { 
    diff1<-RedAvg[j,i]-RedMean[i] 
    diff2<-GreenAvg[j,i]-GreenMean[i] 
    num<-max(diff1,0) 
    den<-num+max(diff2,0) 
    n<-num/den 
    a<-ifelse(n=="NaN",a+1,a) 
    beta[j,i]<-n 
    j<-j+1 
    } 
  i<-i+1 
} 
# This produces NaN values where beta=0/(0+0) 
 
##Apply Scaling factor 
RedMean<-apply(RedOMA[,2:37],2,mean) 
GreenMean<-apply(GreenOMA[,2:37],2,mean) 
scale2<-numeric() 
for (i in 1:36) { 
scale2[i]<-RedMean[i]/GreenMean[i]   ### KJA changes MRed to RedMean[i] 
} 
 
CorrectedGreenOMA2<-matrix(nrow=1547,ncol=36) 
for (i in 1:36){ 
CorrectedGreenOMA2[,i]<-scale2[i]*GreenOMA[,i+1] 
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} 
 
### Two sample t-test to determine differentially methylated sites 
 
library(multtest) 
#Compute t-test test statistic 
liver.results<-mt.teststat(beta,targets$Diagnosis) 
#Compute adjusted degrees of freedom for unequal sample size 
rawp0.liver<-2*(1-pnorm(abs(liver.results))) 
df.func<-function(beta,class=targets$Diagnosis) { 
var1<-var(beta[class=="Cirrhosis HCC"]) 
var2<-var(beta[class=="Cirrhosis non-HCC"]) 
n1<-length(beta[class=="Cirrhosis HCC"]) 
n2<-length(beta[class=="Cirrhosis non-HCC"]) 
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1)) 
df 
} 
degrees.f<-apply(beta,1,df.func) 
##p values for t distn 
rawp0.liver<-2*(1-pt(abs(liver.results),degrees.f))  
code<-data.frame(GreenOMA$codeG) 
class<-targets$Diagnosis 
deltabeta<-numeric() 
for (i in 1:1547){ 
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))-
mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"])) 
} 
data<-cbind(code,deltabeta,rawp0.liver) 
code<-data.frame(GreenOMA$codeG) 
class<-targets$Diagnosis 
deltabeta<-numeric() 
for (i in 1:1547){ 
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))-
mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"])) 
} 
data<-cbind(code,deltabeta,rawp0.liver) 
 
################# 
### Generating Data Null case data:Non-differentially methylated 
#################  
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set.seed(123) 
site<-703 
 
library(MASS) 
## Differentially expressed CpG sites 
nreps<-3152 
#Change ncol depending on desired sample size 
red.nonsig<-matrix(nrow=nreps,ncol=36) 
green.nonsig<-matrix(nrow=nreps,ncol=36) 
nonsig.green<-CorrectedGreenOMA2[site,]  
green<-as.numeric(nonsig.green) 
mu.green.nonsig<-mean(green) 
s2.green.nonsig<-var(green) 
nonsig.red<-RedOMA[site,2:37] 
red<-as.numeric(nonsig.red) 
mu.red.nonsig<-mean(red) 
s2.red.nonsig<-var(red) 
covar<-(-0.6)*sqrt(s2.green.nonsig)*sqrt(s2.red.nonsig) 
for (i in 1:nreps){ 
#Change length depending on desired sample size 
nonsig<-
mvrnorm(36,mu=c(mu.red.nonsig,mu.green.nonsig),Sigma=matrix(c(s2.red.nonsig,covar,c
ovar,s2.green.nonsig),nrow=2)) 
red.nonsig[i,]<-nonsig[,1] 
green.nonsig[i,]<-nonsig[,2] 
} 
beta.new<-red.nonsig/(red.nonsig+green.nonsig) 
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#################### 
#### T Test########### 
#################### 
library(multtest) 
#Compute t-test test statistic 
##0 is HCC pos group; 1 is HCC neg group 
#Change these values depending on tested sample size 
indicator<-rep(0:1,c(20,16)) 
#indicator<-rep(0:1,c(15,15)) 
liver.results<-mt.teststat(beta.new,indicator) 
 
#Compute adjusted degrees of freedom for unequal sample size 
rawp0.liver<-2*(1-pnorm(abs(liver.results))) 
df.func<-function(beta.new,class=indicator) { 
var1<-var(beta.new[class==0]) 
var2<-var(beta.new[class==1]) 
n1<-length(beta.new[class==0]) 
n2<-length(beta.new[class==1]) 
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1)) 
df 
} 
degrees.f<-apply(beta.new,1,df.func) 
p0.liver<-2*(1-pt(abs(liver.results),degrees.f)) ##p values for t distn 
 
sig.level<-0.05 
type1<-numeric() 
not.sig.ttest<-p0.liver[1:3152] 
for (i in 1:3152){ 
type1[i]<-ifelse(not.sig.ttest[i]<sig.level,1,0) 
} 
type1error.ttest<-sum(type1)/3152 
 
################## 
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#####Bibikova###### 
################## 
 
type1.bib<-numeric() 
for (i in 1:3152){ 
delta.beta<-mean(beta.new[i,1:20])-mean(beta.new[i,21:36]) 
type1.bib[i]<-ifelse(not.sig.ttest[i]<sig.level & delta.beta>0.17,1,0) 
} 
type1error.bib<-sum(type1.bib)/3152 
 
#################### 
#### LR Test######### 
#################### 
 
# the derivative using R 
null.expression<-expression(n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-1)* 
log(input)+(q-1)*log(1-input)) 
dx.null<-deriv(null.expression,c('p','q')) 
# grr is the gradient for the null likelihood 
grr<-function(par,input) { 
 p<-par[1] 
 q<-par[2] 
 n<-length(input) 
 c(n*(digamma(p+q)/gamma(p+q)-digamma(p)/gamma(p))+sum(log(input)), 
 n*(digamma(p+q)/gamma(p+q)-digamma(q)/gamma(q))+sum(log(1-input)) 
 ) 
} 
# grr1 is the gradient for the alt likelihood 
grr1<-function(par,input1,input2) { 
 p1<-par[1] 
 q1<-par[2] 
 n1<-length(input1) 
 p2<-par[3] 
 q2<-par[4] 
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 n2<-length(input2) 
 c(n1*(digamma(p1+q1)/gamma(p1+q1)-digamma(p1)/gamma(p1))+sum(log(input1)), 
 n1*(digamma(p1+q1)/gamma(p1+q1)-digamma(q1)/gamma(q1))+sum(log(1-input1)), 
n2*(digamma(p2+q2)/gamma(p2+q2)-digamma(p2)/gamma(p2))+sum(log(input2)), 
 n2*(digamma(p2+q2)/gamma(p2+q2)-digamma(q2)/gamma(q2))+sum(log(1-input2)) 
 ) 
} 
 
# This is the null function to be minimized 
null.function<-function(par,input) { 
 p<-par[1] 
 q<-par[2] 
 n<-length(input) 
 null.like<- n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-
1)*sum(log(input))+(q-1)*sum(log(1-input)) 
 -null.like 
 } 
# Alternative function 
alt.function<-function(par,input1,input2) { 
 p1<-par[1] 
 q1<-par[2] 
 n1<-length(input1) 
 p2<-par[3] 
 q2<-par[4] 
 n2<-length(input2) 
 log.like<- n1*(log(gamma(p1+q1))-log(gamma(p1))-log(gamma(q1)))+(p1-
1)*sum(log(input1))+(q1-1)*sum(log(1-input1)) + n2*(log(gamma(p2+q2))-
log(gamma(p2))-log(gamma(q2)))+(p2-1)*sum(log(input2))+(q2-1)*sum(log(1-input2)) 
 -log.like 
 } 
 
null<-numeric() 
alt<-numeric() 
for (i in 1:3152){ 
 null[i]<-optim(par=c(.5,.5),fn=null.function,gr=grr,input=beta.new[i,],method='Nelder-
Mead')$value 
#Change limits depending on sample size 
 alt[i]<-
optim(par=rep(.5,4),fn=alt.function,input1=beta.new[i,1:20],input2=beta.new[i,21:36],met
hod='Nelder-Mead')$value 
} 
like.test<--2*(alt-null) 
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pvals.like<-pchisq(like.test,df=2,lower.tail=FALSE) 
#Type 1: say not equal when are equal 
type1.like<-numeric() 
not.sig.like<-pvals.like[1:3152] 
for (i in 1:3152){ 
type1.like[i]<-ifelse(not.sig.like[i]<sig.level,1,0) 
} 
type1error.like<-sum(type1.like)/3152 
 
#################### 
#### Bstrap########### 
#################### 
Red<-red.nonsig 
Green<-green.nonsig 
#Change indices depending on sample size 
Red.pos<-Red[,1:20] 
Red.neg<-Red[,21:36] 
Green.pos<-Green[,1:20] 
Green.neg<-Green[,21:36] 
teststat<-numeric() 
for (i in 1:3152){ 
teststat[i]<-mean((Red.pos[i,])/(Red.pos[i,]+Green.pos[i,]))-
mean((Red.neg[i,])/(Red.neg[i,]+Green.neg[i,])) 
} 
 
# Number of bootstrap samples 
B<-2500 
 
# Compute bootstrap test statistic 
b.teststat<-matrix(ncol=B,nrow=3152) 
 
for (b in 1:B) { 
bsample<-sample(1:36,replace=TRUE) 
red<-Red[,bsample] 
green<-Green[,bsample] 
#Change indices depending on Sample size 
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Red.positive<-red[,1:20] 
Green.positive<-green[,1:20] 
Red.negative<-red[,21:36] 
Green.negative<-green[,21:36] 
for (i in 1:3152){ 
b.teststat[i,b]<-mean((Red.positive[i,])/(Red.positive[i,]+Green.positive[i,]))-
mean((Red.negative[i,])/(Red.negative[i,]+Green.negative[i,])) 
} 
 
} 
 
b.teststat.sort<-matrix(ncol=B,nrow=3152) 
for (i in 1:3152){ 
b.teststat.sort[i,]<-sort(b.teststat[i,]) 
} 
 
result<-numeric() 
for (i in 1:3152){ 
result[i]<-ifelse(teststat[i]<b.teststat.sort[i,25]|teststat[i]>b.teststat.sort[i,975],1,0) 
} 
 
#Achieved significance level 
asl<-numeric() 
for (i in 1:3152){ 
asl[i]<-sum(ifelse(b.teststat[i,]>abs(teststat[i]) | b.teststat[i,]< -abs(teststat[i]),1,0))/B 
} 
sig.level<-0.05 
 
#Type 1: say not equal when are equal 
type1.bstrap<-numeric() 
not.sig.bstrap<-asl[1:3152] 
for (i in 1:3152){ 
type1.bstrap[i]<-ifelse(not.sig.bstrap[i]<sig.level,1,0) 
} 
type1error.bstrap<-sum(type1.bstrap)/3152 
 
################################# 
###### Beta Test ################### 
################################## 
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set.seed(123) 
site<-1493 
 
library(MASS) 
nonsig.green<-CorrectedGreenOMA2[site,]##  
green<-as.numeric(nonsig.green) 
mu.green.nonsig<-mean(green) 
s2.green.nonsig<-var(green) 
nonsig.red<-RedOMA[site,2:37] 
red<-as.numeric(nonsig.red) 
mu.red.nonsig<-mean(red) 
s2.red.nonsig<-var(red) 
covar<-(-0.6)*sqrt(s2.green.nonsig)*sqrt(s2.red.nonsig) 
nonsig<-
mvrnorm(1000,mu=c(mu.red.nonsig,mu.green.nonsig),Sigma=matrix(c(s2.red.nonsig,cova
r,covar,s2.green.nonsig),nrow=2)) 
red.nonsig<-nonsig[,1] 
green.nonsig<-nonsig[,2] 
beta<-red.nonsig/(red.nonsig+green.nonsig) 
mu.beta<-mean(beta) 
s2.beta<-var(beta) 
a<-mu.beta*(mu.beta*(1-mu.beta)/s2.beta-1) 
p<-(1-mu.beta)*(mu.beta*(1-mu.beta)/s2.beta-1) 
 
mean <- a/(a + p) 
variance <- function(a, b) a * b/((a + b + 1) * (a + b)^2) 
Q <- (qbeta(0.975, a, p) - mean)/sqrt(variance(a, p)) 
 
set.seed(123) 
141 
reject <- numeric() 
# Change n1 and n2 depending on sample size 
n1 <- 20 
n2 <- 16 
for (i in 1:10000) { 
x <- rbeta(n1, a, p) 
y <- rbeta(n2, a, p) 
Critical <- 0 + Q * sqrt(variance(a, p)/n1 + variance(a,p)/n2) 
reject[i] <- ifelse(abs(mean(x) - mean(y)) > Critical, 1,0) 
} 
type1error.beta<-sum(reject)/10000 
 
type1error.ttest 
type1error.bib 
type1error.like 
type1error.bstrap 
type1error.beta 
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APPENDIX G 
 
Source code for Chapter 5 data simulations for the computation of Type II error under the 
assumption of Beta distributed data 
#########################################################################
##### This file tests type II error according to the ttest, the filtered        ############# 
##### ttest, the LRT, the bootstrap test and the beta test under the       #############  
#####  condition that the data has been generated according to the    ############# 
##### Beta distribution.  Concludes with the application of the Beta  ############# 
##### test to HCV data set.                                                     ############# 
######################################################################### 
library(beadarray) 
setwd("D:/") 
 
## Read in data with no normalization or background correction 
targets <- read.csv("phenotype.csv", header=T) 
liver<-
readIllumina(arrayNames=targets$FileName,useImages=FALSE,singleChannel=FALSE,ta
rgets=targets,backgroundMethod="none") 
 
 
## Bead Summary Data 
R<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="R") 
G<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="G") 
dim(R) #there are 1624 beadtypes in the Red Channel 
dim(G) #there are 1624 beadtypes in the Green Channel 
 
##Merging Red Channel Data with associated gene information 
codeR<-featureNames(R) 
M<-exprs(R) 
RedData<-data.frame(M,codeR) 
dim(RedData) 
OMA<-read.csv("GS0007005-OMA.csv",header=TRUE) 
RedOMA<-
merge(RedData,OMA,by.x="codeR",by.y="IllumiCode.name",all.x=FALSE,all.y=TRUE) 
dim(RedOMA)  #There are 1547 beadtypes in the red channel summaries that also have 
gene annotation info 
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##Merging Green Channel Data with associated gene information 
codeG<-featureNames(G) 
U<-exprs(G) 
GreenData<-data.frame(U,codeG) 
dim(GreenData) 
#OMA<-read.csv("GS0007005-OMA.csv",header=TRUE) 
GreenOMA<-
merge(GreenData,OMA,by.x="codeG",by.y="IllumiCode.name",all.x=FALSE,all.y=TRU
E) 
dim(GreenOMA)  #There are 1547 beadtypes in the green channel summaries that also 
have gene annotation info 
 
#There are 22 negative control beads 
 
#Red Channel 
#create dataframe of negative control beads 
indR<-grep("Negative",RedOMA$Gene_Symbol) 
negR<-RedOMA[indR,] 
#create vector of length 36, where each entry is the sample mean of the negative control 
beadtype in a particular array 
RedMean<-numeric() 
for (i in 1:36) { 
 RedMean[i]<-mean(negR[,i+1]) 
 i<-i+1 
} 
 
#Frequency histogram of the means 
hist(RedMean,main=paste(" "),xlab=paste("mean of Red (Methylated) 
Channel"),col="red") 
 
#Green Channel 
#create dataframe of negative control beads 
indG<-grep("Negative",GreenOMA$Gene_Symbol) 
negG<-GreenOMA[indG,] 
#create vector of length 36, where each entry is the sample mean of the negative control 
beadtype in a particular array 
GreenMean<-numeric() 
for (i in 1:36) { 
 GreenMean[i]<-mean(negG[,i+1]) 
 i<-i+1 
} 
#Frequency histogram of the means 
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x11() 
hist(GreenMean,main=paste(" "),xlab=paste("mean of Green (Unmethylated) 
Channel"),col="green") 
 
#Compute beta 
 
# initialize beta data frame to store values 
beta<-data.frame() 
# isolating average intensity for each beadtype for R and G channels 
RedAvg<-RedOMA[,2:37] 
GreenAvg<-GreenOMA[,2:37] 
#compute beta 
a<-0 
for (i in 1:36) { 
  j<-1 
  for (j in 1:1547) { 
    diff1<-RedAvg[j,i]-RedMean[i] 
    diff2<-GreenAvg[j,i]-GreenMean[i] 
    num<-max(diff1,0) 
    den<-num+max(diff2,0) 
    n<-num/den 
    a<-ifelse(n=="NaN",a+1,a) 
    beta[j,i]<-n 
    j<-j+1 
    } 
  i<-i+1 
} 
# This produces NaN values where beta=0/(0+0) 
# Set NaN values to 0 ?? 
 
 
 
################# 
##Scale 
RedMean<-apply(RedOMA[,2:37],2,mean) 
 
GreenMean<-apply(GreenOMA[,2:37],2,mean) 
scale2<-numeric() 
for (i in 1:36) { 
scale2[i]<-RedMean[i]/GreenMean[i]   ### KJA changes MRed to RedMean[i] 
} 
 
CorrectedGreenOMA2<-matrix(nrow=1547,ncol=36) 
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for (i in 1:36){ 
CorrectedGreenOMA2[,i]<-scale2[i]*GreenOMA[,i+1] 
} 
 
################# 
### Two sample t-test to determine differentially methylated sites 
#################### 
 
library(multtest) 
#Compute t-test test statistic 
liver.results<-mt.teststat(beta,targets$Diagnosis) 
#Compute adjusted degrees of freedom for unequal sample size 
rawp0.liver<-2*(1-pnorm(abs(liver.results))) 
df.func<-function(beta,class=targets$Diagnosis) { 
var1<-var(beta[class=="Cirrhosis HCC"]) 
var2<-var(beta[class=="Cirrhosis non-HCC"]) 
n1<-length(beta[class=="Cirrhosis HCC"]) 
n2<-length(beta[class=="Cirrhosis non-HCC"]) 
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1)) 
df 
} 
degrees.f<-apply(beta,1,df.func) 
rawp0.liver<-2*(1-pt(abs(liver.results),degrees.f)) ##p values for t distn 
 
code<-data.frame(GreenOMA$codeG) 
class<-targets$Diagnosis 
deltabeta<-numeric() 
for (i in 1:1547){ 
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))-
mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"])) 
} 
data<-cbind(code,deltabeta,rawp0.liver) 
code<-data.frame(GreenOMA$codeG) 
class<-targets$Diagnosis 
deltabeta<-numeric() 
for (i in 1:1547){ 
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))-
mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"])) 
} 
data<-cbind(code,deltabeta,rawp0.liver) 
 
#To identify sites with specific deltabetas 
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#Compute delta beta 
delbeta<-numeric() 
mu.HCCpos<-numeric() 
mu.HCCneg<-numeric() 
abs.delbeta<-numeric() 
for (i in 1:1547){ 
mu.HCCpos[i]<-mean(as.numeric(beta[i,targets$Diagnosis=="Cirrhosis HCC"])) 
mu.HCCneg[i]<-mean(as.numeric(beta[i,targets$Diagnosis=="Cirrhosis non-HCC"])) 
delbeta[i]<-mu.HCCpos[i]-mu.HCCneg[i] 
abs.delbeta[i]<-abs(delbeta[i]) 
} 
 
index<-1:1547 
new.data<-cbind(index,mu.HCCpos,mu.HCCneg,delbeta,abs.delbeta,rawp0.liver) 
#sites of interest are those where both means>0.2 
ind<-numeric() 
ind.a<-numeric() 
for (i in 1:1547){ 
ind[i]<-ifelse(mu.HCCpos[i]>0.2 & mu.HCCneg[i]>0.2,1,0)} 
of.interest<-new.data[ind==1,] 
#sort by increasing values of absolute value of delta beta 
of.interest<-of.interest[order(of.interest[,5]),] 
 
#843 sites where both means >0.2 
#for testing about 0.17 
ind2<-numeric() 
for (i in 1:843){ 
ind2[i]<-ifelse(.15<of.interest[i,5] & of.interest[i,5]<.18,1,0)} 
sub2<-of.interest[ind2==1,] 
#site 946 
 
#for testing about .2 
ind3<-numeric() 
for (i in 1:843){ 
ind3[i]<-ifelse(.18<of.interest[i,5],1,0)} 
sub3<-of.interest[ind3==1,] 
#site 1051 
 
#for testing about .1 
ind4<-numeric() 
for (i in 1:843){ 
ind4[i]<-ifelse(.08<of.interest[i,5] && of.interest[i,5]<.12,1,0)} 
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sub4<-of.interest[ind4==1,] 
# site 441 
 
#for testing about .5 
ind5<-numeric() 
for (i in 1:843){ 
ind5[i]<-ifelse(.049<of.interest[i,5] && of.interest[i,5]<.055,1,0)} 
sub5<-of.interest[ind5==1,] 
#site 920 
 
################## 
#Generate beta data### 
################### 
##Type II error 
##Generate significantly differentially expressed data 
nreps<-3152 
 
set.seed(123) 
test<-as.character(deltabeta) 
site<-946 
sig.beta<-beta[site,] 
beta.positive<-as.numeric(sig.beta[targets$Diagnosis=="Cirrhosis HCC"]) 
mu.beta.positive<-mean(beta.positive) 
s2.beta.positive<-var(beta.positive) 
a.positive<-mu.beta.positive*(mu.beta.positive*(1-mu.beta.positive)/s2.beta.positive-1) 
p.positive<-(1-mu.beta.positive)*(mu.beta.positive*(1-mu.beta.positive)/s2.beta.positive-
1) 
beta.negative<-as.numeric(sig.beta[targets$Diagnosis=="Cirrhosis non-HCC"]) 
mu.beta.negative<-mean(beta.negative) 
s2.beta.negative<-var(beta.negative) 
a.negative<-mu.beta.negative*(mu.beta.negative*(1-mu.beta.negative)/s2.beta.negative-1) 
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p.negative<-(1-mu.beta.negative)*(mu.beta.negative*(1-
mu.beta.negative)/s2.beta.negative-1) 
#Change ncol depending on sample size 
beta.new<-matrix(nrow=nreps,ncol=36) 
set.seed(123) 
for (i in 1:nreps){ 
#change length of data depending on sample size 
beta.new[i,1:20]<-rbeta(20,a.positive,p.positive) 
beta.new[i,21:36]<-rbeta(16,a.negative,p.negative) 
} 
 
#################### 
#### T Test########### 
#################### 
library(multtest) 
#Compute t-test test statistic 
##0 is HCC pos group; 1 is HCC neg group 
#Change these numbers depending on sample size 
indicator<-rep(0:1,c(20,16)) 
#indicator<-rep(0:1,c(80,80)) 
liver.results<-mt.teststat(beta.new,indicator) 
 
 
 
#Compute adjusted degrees of freedom for unequal sample size 
rawp0.liver<-2*(1-pnorm(abs(liver.results))) 
df.func<-function(beta.new,class=indicator) { 
var1<-var(beta.new[class==0]) 
var2<-var(beta.new[class==1]) 
n1<-length(beta.new[class==0]) 
n2<-length(beta.new[class==1]) 
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1)) 
df 
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} 
degrees.f<-apply(beta.new,1,df.func) 
p0.liver<-2*(1-pt(abs(liver.results),degrees.f)) ##p values for t distn 
 
sig.level<-0.05 
type2<-numeric() 
not.sig.ttest<-p0.liver 
type2<-numeric() 
for (i in 1:nreps){ 
type2[i]<-ifelse(p0.liver[i]>sig.level,1,0) 
} 
type2error.ttest<-sum(type2)/nreps 
 
################## 
#####Bibikova###### 
####Filtered ttest##### 
################## 
type2.bib<-numeric() 
for (i in 1:nreps){ 
#Change indices depending on sample size 
delta.beta<-abs(mean(beta.new[i,1:20])-mean(beta.new[i,21:36])) 
type2.bib[i]<-ifelse(not.sig.ttest[i]>sig.level | delta.beta<0.17,1,0) 
} 
type2error.bib<-sum(type2.bib)/nreps 
 
#################### 
#### LR Test######### 
#################### 
# derivative using R 
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null.expression<-expression(n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-1)* 
log(input)+(q-1)*log(1-input)) 
dx.null<-deriv(null.expression,c('p','q')) 
# grr is the gradient for the null likelihood 
grr<-function(par,input) { 
 p<-par[1] 
 q<-par[2] 
 n<-length(input) 
 c(n*(gamma(p+q)*digamma(p+q)/gamma(p+q)-
gamma(p)*digamma(p)/gamma(p))+sum(log(input)), 
 n*(gamma(p+q)*digamma(p+q)/gamma(p+q)-
gamma(q)*digamma(q)/gamma(q))+sum(log(1-input)) 
 ) 
} 
# null function to be minimized 
null.function<-function(par,input) { 
 p<-par[1] 
 q<-par[2] 
 n<-length(input) 
 null.like<- n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-
1)*sum(log(input))+(q-1)*sum(log(1-input)) 
 -null.like 
 } 
# Alternative function 
alt.function<-function(par,input1,input2) { 
 p1<-par[1] 
 q1<-par[2] 
 n1<-length(input1) 
 p2<-par[3] 
 q2<-par[4] 
 n2<-length(input2) 
 log.like<- n1*(log(gamma(p1+q1))-log(gamma(p1))-log(gamma(q1)))+(p1-
1)*sum(log(input1))+(q1-1)*sum(log(1-input1)) + n2*(log(gamma(p2+q2))-
log(gamma(p2))-log(gamma(q2)))+(p2-1)*sum(log(input2))+(q2-1)*sum(log(1-input2)) 
 -log.like 
 } 
null<-numeric() 
alt<-numeric() 
for (i in 1:nreps){ 
 null[i]<-optim(par=c(.5,.5),fn=null.function,gr=grr,input=beta.new[i,],method='Nelder-
Mead')$value 
151 
 alt[i]<-
optim(par=rep(.5,4),fn=alt.function,input1=beta.new[i,1:20],input2=beta.new[i,21:36],met
hod='Nelder-Mead')$value 
} 
like.test<--2*(alt-null) 
 
pvals.like<-pchisq(like.test,df=2,lower.tail=FALSE) 
 
#Type 2: say equal when not equal 
sig.like<-pvals.like 
type2.like<-numeric() 
for (i in 1:nreps){ 
type2.like[i]<-ifelse(sig.like[i]>sig.level,1,0) 
} 
type2error.like<-sum(type2.like)/nreps 
 
#################### 
#### Bstrap########### 
#################### 
Red<-red.data.new 
Green<-green.data.new 
#Change indices depending on sample size 
Red.pos<-Red[,1:20] 
Red.neg<-Red[,21:36] 
Green.pos<-Green[,1:20] 
Green.neg<-Green[,21:36] 
teststat<-numeric() 
for (i in 1:nreps){ 
teststat[i]<-mean((Red.pos[i,])/(Red.pos[i,]+Green.pos[i,]))-
mean((Red.neg[i,])/(Red.neg[i,]+Green.neg[i,])) 
} 
 
# Number of bootstrap samples 
B<-2500 
 
b.teststat<-matrix(ncol=B,nrow=nreps) 
set.seed(123) 
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for (b in 1:B) { 
bsample<-sample(1:36,replace=TRUE) 
red<-Red[,bsample] 
green<-Green[,bsample] 
Red.positive<-red[,1:20] 
Green.positive<-green[,1:20] 
Red.negative<-red[,21:36] 
Green.negative<-green[,21:36] 
for (i in 1:nreps){ 
b.teststat[i,b]<-mean((Red.positive[i,])/(Red.positive[i,]+Green.positive[i,]))-
mean((Red.negative[i,])/(Red.negative[i,]+Green.negative[i,])) 
} 
 
} 
 
b.teststat.sort<-matrix(ncol=B,nrow=nreps) 
for (i in 1:nreps){ 
b.teststat.sort[i,]<-sort(b.teststat[i,]) 
} 
 
result<-numeric() 
for (i in 1:nreps){ 
result[i]<-ifelse(teststat[i]<b.teststat.sort[i,25]|teststat[i]>b.teststat.sort[i,975],1,0) 
} 
 
 
asl<-numeric() 
for (i in 1:nreps){ 
asl[i]<-sum(ifelse(b.teststat[i,]>abs(teststat[i]) | b.teststat[i,]< -abs(teststat[i]),1,0))/B 
} 
sig.level<-0.05 
 
#Type 2: say equal when not equal 
sig.bstrap<-asl 
type2.bstrap<-numeric() 
for (i in 1:nreps){ 
type2.bstrap[i]<-ifelse(sig.bstrap[i]>sig.level,1,0) 
} 
type2error.bstrap<-sum(type2.bstrap)/nreps 
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############################ 
######## Beta Test ############ 
############################ 
 
variance <- function(a, b) a * b/((a + b + 1) * (a + b)^2) 
mean.beta <- function(x,y) { 
 #xbar <- (length(x)*mean(x)+length(y)*mean(y))/(length(x)+length(y)) 
xbar<-mean(c(x,y)) 
#v <- 
(length(x)*(var(x)+(mean(x))^2)+length(y)*(var(y)+(mean(y))^2))/(length(x++length(y))-
xbar^2 
v<-var(c(x,y))*(length(c(x,y))-1)/length(c(x,y)) 
a <- xbar * (xbar * (1 - xbar)/v - 1) 
b <- (1 - xbar) * (xbar * (1 - xbar)/v - 1) 
var <- variance(a, b) 
list(xbar = xbar, alpha = a, beta = b, var = var) 
} 
 
set.seed(123) 
x.pos<-rbeta(3152,a.positive,p.positive) 
set.seed(123) 
x.neg<-rbeta(3152,a.negative,p.negative) 
 
combined <- mean.beta(x.pos, x.neg) 
Q <- (qbeta(0.975, combined$alpha, combined$beta) - combined$alpha/(combined$alpha 
+ combined$beta))/sqrt(variance(combined$alpha, combined$beta)) 
set.seed(123) 
power <- numeric() 
n1 <- 20 
n2 <- 16 
set.seed(123) 
for (i in 1:3152) { 
x <- rbeta(n1, a.positive, p.positive) 
y <- rbeta(n2, a.negative, p.negative) 
Critical <- 0 + Q * sqrt(variance(a.positive, p.positive)/n1 + 
variance(a.negative,p.negative)/n2) 
power[i] <- ifelse(abs(mean(x) - mean(y)) > Critical, 1, 0) 
} 
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type2error.beta<-1-sum(power)/3152 
 
type2error.ttest 
type2error.bib 
type2error.beta 
type2error.like 
type2error.bstrap 
 
 
 
############################ 
######## Applying Beta test to Archer data############ 
############################ 
 
variance <- function(a, b) a * b/((a + b + 1) * (a + b)^2) 
mean.beta <- function(x,y) { 
 #xbar <- (length(x)*mean(x)+length(y)*mean(y))/(length(x)+length(y)) 
xbar<-mean(c(x,y)) 
#v <- 
(length(x)*(var(x)+(mean(x))^2)+length(y)*(var(y)+(mean(y))^2))/(length(x++length(y))-
xbar^2 
v<-var(c(x,y))*(length(c(x,y))-1)/length(c(x,y)) 
a <- xbar * (xbar * (1 - xbar)/v - 1) 
b <- (1 - xbar) * (xbar * (1 - xbar)/v - 1) 
var <- variance(a, b) 
list(xbar = xbar, alpha = a, beta = b, var = var) 
} 
 
Q<-numeric() 
for (i in 1:1547){ 
x.pos<-as.numeric(beta[i,targets$Diagnosis=="Cirrhosis HCC"]) 
x.neg<-as.numeric(beta[i,targets$Diagnosis=="Cirrhosis non-HCC"]) 
 
combined <- mean.beta(x.pos, x.neg) 
Q [i]<- (qbeta(0.975, combined$alpha, combined$beta) - 
combined$alpha/(combined$alpha + combined$beta))/sqrt(variance(combined$alpha, 
combined$beta)) 
} 
 
Critical<-numeric() 
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a.positive<-numeric() 
p.positive<-numeric() 
a.negative<-numeric() 
p.negative<-numeric() 
reject<-numeric() 
index<-numeric() 
beta.pval<-numeric() 
for (i in 1:1547) { 
x <- as.numeric(beta[i,targets$Diagnosis=="Cirrhosis HCC"]) 
y <- as.numeric(beta[i,targets$Diagnosis=="Cirrhosis non-HCC"]) 
v.x<-var(x)*(length(x)-1)/length(x) 
v.y<-var(y)*(length(y)-1)/length(y) 
a.positive[i]<- mean(x)* (mean(x) * (1 - mean(x))/v.x - 1) 
p.positive [i]<- (1 - mean(x)) * (mean(x) * (1 - mean(x))/v.x - 1) 
a.negative[i]<-mean(y) * (mean(y) * (1 - mean(y))/v.y - 1) 
p.negative [i]<- (1 -mean(y)) * (mean(y) * (1 -mean(y))/v.y - 1) 
Critical[i]<- 0 + Q[i] * sqrt(variance(a.positive[i], p.positive[i])/length(x) + 
variance(a.negative[i],p.negative[i])/length(y)) 
reject[i]<-ifelse(abs(mean(x)-mean(y))>Critical[i],1,0) 
} 
sum(reject,na.rm=TRUE) #277 significant sites for two sided test at 0.05 significance level 
versus 227 with ttest 
 
ttest.sig<-ifelse(rawp0.liver<0.05,1,0) #205 significant 
 
filt.sig<-ifelse(rawp0.liver>0.05|deltabeta<0.17,0,1) #7 significant 
index<-1:1547 
compare<-cbind(index,ttest.sig,reject)  #see that for the most part, the two tests find the 
same CpG sites significantly differentially methylated 
 
results<-
cbind(as.numeric(mu.HCCpos),as.numeric(mu.HCCneg),as.numeric(delbeta),as.numeric(r
eject),as.numeric(ttest.sig),as.numeric(filt.sig),as.vector(OMA$Gene_Symbol),as.vector(O
MA$Ilmn_ID)) 
keep<-results[results[,4]==1,] 
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APPENDIX H 
 
Source code for Chapter 5 data simulations for the computation of Type II error under the 
assumption of Bivariate Normal distributed data 
#########################################################################
##### This file tests type II error according to the ttest, the filtered        ############# 
##### ttest, the LRT, the bootstrap test and the beta test under the       #############  
#####  condition that the data has been generated according to the    ############# 
##### Bivariate Normal distribution.                                                     ############# 
######################################################################### 
 
library(beadarray) 
setwd("D:/") 
 
## Read in data with no normalization or background correction 
targets <- read.csv("phenotype.csv", header=T) 
liver<-
readIllumina(arrayNames=targets$FileName,useImages=FALSE,singleChannel=FALSE,ta
rgets=targets,backgroundMethod="none") 
 
 
## Bead Summary Data 
R<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="R") 
G<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="G") 
dim(R) #there are 1624 beadtypes in the Red Channel 
dim(G) #there are 1624 beadtypes in the Green Channel 
 
##Merging Red Channel Data with associated gene information 
codeR<-featureNames(R) 
M<-exprs(R) 
RedData<-data.frame(M,codeR) 
dim(RedData) 
OMA<-read.csv("GS0007005-OMA.csv",header=TRUE) 
RedOMA<-
merge(RedData,OMA,by.x="codeR",by.y="IllumiCode.name",all.x=FALSE,all.y=TRUE) 
dim(RedOMA)   
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#There are 1547 beadtypes in the red channel summaries that also have gene annotation 
info 
 
##Merging Green Channel Data with associated gene information 
codeG<-featureNames(G) 
U<-exprs(G) 
GreenData<-data.frame(U,codeG) 
dim(GreenData) 
GreenOMA<-
merge(GreenData,OMA,by.x="codeG",by.y="IllumiCode.name",all.x=FALSE,all.y=TRU
E) 
dim(GreenOMA)   
#There are 1547 beadtypes in the green channel summaries that also have gene annotation 
info 
 
#There are 22 negative control beads 
 
#Red Channel 
#create dataframe of negative control beads 
indR<-grep("Negative",RedOMA$Gene_Symbol) 
negR<-RedOMA[indR,] 
#create vector of length 36, where each entry is the sample mean of the neg control 
beadtype in a particular array 
RedMean<-numeric() 
for (i in 1:36) { 
 RedMean[i]<-mean(negR[,i+1]) 
 i<-i+1 
} 
 
#Frequency histogram of the means 
hist(RedMean,main=paste(" "),xlab=paste("mean of Red (Methylated) 
Channel"),col="red") 
 
#Green Channel 
#create dataframe of negative control beads 
indG<-grep("Negative",GreenOMA$Gene_Symbol) 
negG<-GreenOMA[indG,] 
#create vector of length 36, where each entry is the sample mean of the  
#negative control beadtype in a particular array 
GreenMean<-numeric() 
for (i in 1:36) { 
 GreenMean[i]<-mean(negG[,i+1]) 
 i<-i+1 
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} 
#Frequency histogram of the means 
x11() 
hist(GreenMean,main=paste(" "),xlab=paste("mean of Green (Unmethylated) 
Channel"),col="green") 
 
###Compute beta variable 
 
# initialize beta data frame to store values 
beta<-data.frame() 
# isolating average intensity for each beadtype for R and G channels 
RedAvg<-RedOMA[,2:37] 
GreenAvg<-GreenOMA[,2:37] 
#compute beta 
a<-0 
for (i in 1:36) { 
  j<-1 
  for (j in 1:1547) { 
    diff1<-RedAvg[j,i]-RedMean[i] 
    diff2<-GreenAvg[j,i]-GreenMean[i] 
    num<-max(diff1,0) 
    den<-num+max(diff2,0) 
    n<-num/den 
    a<-ifelse(n=="NaN",a+1,a) 
    beta[j,i]<-n 
    j<-j+1 
    } 
  i<-i+1 
} 
# This produces NaN values where beta=0/(0+0) 
 
##Apply Scaling factor 
RedMean<-apply(RedOMA[,2:37],2,mean) 
GreenMean<-apply(GreenOMA[,2:37],2,mean) 
scale2<-numeric() 
for (i in 1:36) { 
scale2[i]<-RedMean[i]/GreenMean[i]   ### KJA changes MRed to RedMean[i] 
} 
 
CorrectedGreenOMA2<-matrix(nrow=1547,ncol=36) 
for (i in 1:36){ 
CorrectedGreenOMA2[,i]<-scale2[i]*GreenOMA[,i+1] 
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} 
 
### Two sample t-test to determine differentially methylated sites 
 
library(multtest) 
#Compute t-test test statistic 
liver.results<-mt.teststat(beta,targets$Diagnosis) 
#Compute adjusted degrees of freedom for unequal sample size 
rawp0.liver<-2*(1-pnorm(abs(liver.results))) 
df.func<-function(beta,class=targets$Diagnosis) { 
var1<-var(beta[class=="Cirrhosis HCC"]) 
var2<-var(beta[class=="Cirrhosis non-HCC"]) 
n1<-length(beta[class=="Cirrhosis HCC"]) 
n2<-length(beta[class=="Cirrhosis non-HCC"]) 
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1)) 
df 
} 
degrees.f<-apply(beta,1,df.func) 
##p values for t distn 
rawp0.liver<-2*(1-pt(abs(liver.results),degrees.f))  
code<-data.frame(GreenOMA$codeG) 
class<-targets$Diagnosis 
deltabeta<-numeric() 
for (i in 1:1547){ 
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))-
mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"])) 
} 
data<-cbind(code,deltabeta,rawp0.liver) 
code<-data.frame(GreenOMA$codeG) 
class<-targets$Diagnosis 
deltabeta<-numeric() 
for (i in 1:1547){ 
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))-
mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"])) 
} 
data<-cbind(code,deltabeta,rawp0.liver) 
 
###To identify sites with specific delta betas 
#Compute delta beta 
delbeta<-numeric() 
mu.HCCpos<-numeric() 
mu.HCCneg<-numeric() 
abs.delbeta<-numeric() 
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for (i in 1:1547){ 
mu.HCCpos[i]<-mean(as.numeric(beta[i,targets$Diagnosis=="Cirrhosis HCC"])) 
mu.HCCneg[i]<-mean(as.numeric(beta[i,targets$Diagnosis=="Cirrhosis non-HCC"])) 
delbeta[i]<-mu.HCCpos[i]-mu.HCCneg[i] 
abs.delbeta[i]<-abs(delbeta[i]) 
} 
 
index<-1:1547 
new.data<-cbind(index,mu.HCCpos,mu.HCCneg,delbeta,abs.delbeta,rawp0.liver) 
#sites of interest are those where both means>0.2 
ind<-numeric() 
ind.a<-numeric() 
for (i in 1:1547){ 
ind[i]<-ifelse(mu.HCCpos[i]>0.2 & mu.HCCneg[i]>0.2,1,0)} 
of.interest<-new.data[ind==1,] 
#sort by increasing values of absolute value of delta beta 
of.interest<-of.interest[order(of.interest[,5]),] 
 
#843 sites where both means >0.2 
#for testing about 0.17 
ind2<-numeric() 
for (i in 1:843){ 
ind2[i]<-ifelse(.15<of.interest[i,5] & of.interest[i,5]<.18,1,0)} 
sub2<-of.interest[ind2==1,] 
#site 946 
 
#for testing about .2 
ind3<-numeric() 
for (i in 1:843){ 
ind3[i]<-ifelse(.18<of.interest[i,5],1,0)} 
sub3<-of.interest[ind3==1,] 
#site 1051 
 
#for testing about .1 
ind4<-numeric() 
for (i in 1:843){ 
ind4[i]<-ifelse(.08<of.interest[i,5] && of.interest[i,5]<.12,1,0)} 
sub4<-of.interest[ind4==1,] 
# site 441 
 
#for testing about .5 
ind5<-numeric() 
for (i in 1:843){ 
161 
ind5[i]<-ifelse(.049<of.interest[i,5] && of.interest[i,5]<.055,1,0)} 
sub5<-of.interest[ind5==1,] 
#site 920 
 
######################################### 
######################################### 
######################################### 
 
## Generating Data that's significantly differently expressed: bivariate normal 
#Set seed so data is replicable 
set.seed(123) 
test<-as.character(deltabeta) 
### Change this site depending on site that data is being modeled after 
site<-946  
sig.green<-CorrectedGreenOMA2[site,] 
green.positive<-as.numeric(sig.green[targets$Diagnosis=="Cirrhosis HCC"]) 
mu.green.positive<-mean(green.positive) 
green.negative<-as.numeric(sig.green[targets$Diagnosis=="Cirrhosis non-HCC"]) 
mu.green.negative<-mean(green.negative) 
s2.green.positive<-var(green.positive) 
s2.green.negative<-var(green.negative) 
 
sig.red<-RedOMA[site,2:37] 
red.positive<-as.numeric(sig.red[targets$Diagnosis=="Cirrhosis HCC"]) 
mu.red.positive<-mean(red.positive) 
red.negative<-as.numeric(sig.red[targets$Diagnosis=="Cirrhosis non-HCC"]) 
mu.red.negative<-mean(red.negative) 
s2.red.positive<-var(red.positive) 
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s2.red.negative<-var(red.negative) 
cov.positive<-(-.6)*sqrt(s2.red.positive)*sqrt(s2.green.positive) 
cov.negative<-(-.6)*sqrt(s2.red.negative)*sqrt(s2.green.positive) 
library(MASS) 
## Differentially expressed CpG sites 
nreps<-3152 
set.seed(123) 
## Change ncol depending on sample size being tested 
red.pos.sig<-matrix(nrow=nreps,ncol=40) 
green.pos.sig<-matrix(nrow=nreps,ncol=40) 
red.neg.sig<-matrix(nrow=nreps,ncol=40) 
green.neg.sig<-matrix(nrow=nreps,ncol=40) 
for (i in 1:nreps){ 
## Change length of generated data depending on sample size 
positive.sig<-
mvrnorm(40,mu=c(mu.red.positive,mu.green.positive),Sigma=matrix(c(s2.red.positive,cov
.positive,cov.positive,s2.green.positive),nrow=2)) 
red.pos.sig[i,]<-positive.sig[,1] 
green.pos.sig[i,]<-positive.sig[,2] 
negative.sig<-
mvrnorm(40,mu=c(mu.red.negative,mu.green.negative),Sigma=matrix(c(s2.red.negative,c
ov.negative,cov.negative,s2.green.negative),nrow=2)) 
red.neg.sig[i,]<-negative.sig[,1] 
green.neg.sig[i,]<-negative.sig[,2] 
} 
beta1.positive<-red.pos.sig/(red.pos.sig+green.pos.sig) 
beta2.negative<-red.neg.sig/(red.neg.sig+green.neg.sig) 
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delta.beta<-numeric() 
sd.beta1.positive<-numeric() 
sd.beta2.negative<-numeric() 
for (i in 1:nreps){ 
delta.beta[i]<-mean(beta1.positive[i,])-mean(beta2.negative[i,]) 
sd.beta1.positive[i]<-sqrt(var(beta1.positive[i,])) 
sd.beta2.negative[i]<-sqrt(var(beta2.negative[i,])) 
} 
summary(delta.beta) 
summary(sd.beta1.positive) 
summary(sd.beta2.negative) 
 
###Combine data 
red.data<-cbind(red.pos.sig,red.neg.sig) 
green.data<-cbind(green.pos.sig,green.neg.sig) 
beta<-red.data/(red.data+green.data) 
 
##Change negative values to positive 
#Change ncol and limit of loop depending on sample size 
red.data.new<-matrix(nrow=nreps,ncol=80) 
green.data.new<-matrix(nrow=nreps,ncol=80) 
for (i in 1:nreps){ 
for (j in 1:80){ 
red.data.new[i,j]<-ifelse(red.data[i,j]<0,(-red.data[i,j]),red.data[i,j]) 
green.data.new[i,j]<-ifelse(green.data[i,j]<0,(-green.data[i,j]),green.data[i,j]) 
} 
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} 
beta.new<-red.data.new/(red.data.new+green.data.new) 
 
##Conduct KS test to ensure still follow biv norm 
mu.green<-apply(green.data.new,1,mean) 
s2.green<-apply(green.data.new,1,var) 
mu.red<-apply(red.data.new,1,mean) 
s2.red<-apply(red.data.new,1,var) 
red.data.norm<-numeric() 
green.data.norm<-numeric() 
for (i in 1:nreps){ 
red.data.norm[i]<-
ks.test(red.data.new[i,],"pnorm",mean=mu.red[i],sd=sqrt(s2.red[i]))$p.value 
green.data.norm[i]<-
ks.test(green.data.new[i,],"pnorm",mean=mu.green[i],sd=sqrt(s2.green[i]))$p.value 
} 
sum(ifelse(green.data.norm>0.05,1,0)) 
sum(ifelse(red.data.norm>0.05,1,0)) 
## This demonstrates that vast majority of generated CpG site still follow normal 
distribution 
##Conduct subsequent analysis on red.data.new, green.data.new,beta.new 
 
#################### 
#### T Test########### 
#################### 
library(multtest) 
#Compute t-test test statistic 
165 
##0 is HCC pos group; 1 is HCC neg group 
#Change these numbers depending on sample size 
#indicator<-rep(0:1,c(20,16)) 
indicator<-rep(0:1,c(40,40)) 
liver.results<-mt.teststat(beta.new,indicator) 
 
 
 
#Compute adjusted degrees of freedom for unequal sample size 
rawp0.liver<-2*(1-pnorm(abs(liver.results))) 
df.func<-function(beta.new,class=indicator) { 
var1<-var(beta.new[class==0]) 
var2<-var(beta.new[class==1]) 
n1<-length(beta.new[class==0]) 
n2<-length(beta.new[class==1]) 
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1)) 
df 
} 
degrees.f<-apply(beta.new,1,df.func) 
p0.liver<-2*(1-pt(abs(liver.results),degrees.f)) ##p values for t distn 
 
sig.level<-0.05 
type2<-numeric() 
not.sig.ttest<-p0.liver 
type2<-numeric() 
for (i in 1:nreps){ 
type2[i]<-ifelse(p0.liver[i]>sig.level,1,0) 
} 
type2error.ttest<-sum(type2)/nreps 
 
################## 
#####Bibikova###### 
####Filtered ttest##### 
################## 
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type2.bib<-numeric() 
for (i in 1:nreps){ 
#Change limits depending on sample size 
delta.beta<-abs(mean(beta.new[i,1:40])-mean(beta.new[i,41:80])) 
type2.bib[i]<-ifelse(not.sig.ttest[i]>sig.level | delta.beta<0.17,1,0) 
} 
type2error.bib<-sum(type2.bib)/nreps 
 
#################### 
#### LR Test######### 
#################### 
 
# Getting the derivative using R 
null.expression<-expression(n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-1)* 
log(input)+(q-1)*log(1-input)) 
dx.null<-deriv(null.expression,c('p','q')) 
# grr is the gradient for the null likelihood 
grr<-function(par,input) { 
 p<-par[1] 
 q<-par[2] 
 n<-length(input) 
 c(n*(gamma(p+q)*digamma(p+q)/gamma(p+q)-
gamma(p)*digamma(p)/gamma(p))+sum(log(input)), 
 n*(gamma(p+q)*digamma(p+q)/gamma(p+q)-
gamma(q)*digamma(q)/gamma(q))+sum(log(1-input)) 
 ) 
} 
# null function to be minimized 
null.function<-function(par,input) { 
 p<-par[1] 
 q<-par[2] 
 n<-length(input) 
 null.like<- n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-
1)*sum(log(input))+(q-1)*sum(log(1-input)) 
 -null.like 
 } 
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# Alternative function 
alt.function<-function(par,input1,input2) { 
 p1<-par[1] 
 q1<-par[2] 
 n1<-length(input1) 
 p2<-par[3] 
 q2<-par[4] 
 n2<-length(input2) 
 log.like<- n1*(log(gamma(p1+q1))-log(gamma(p1))-log(gamma(q1)))+(p1-
1)*sum(log(input1))+(q1-1)*sum(log(1-input1)) + n2*(log(gamma(p2+q2))-
log(gamma(p2))-log(gamma(q2)))+(p2-1)*sum(log(input2))+(q2-1)*sum(log(1-input2)) 
 -log.like 
 } 
 
null<-numeric() 
alt<-numeric() 
for (i in 1:nreps){ 
 null[i]<-optim(par=c(.5,.5),fn=null.function,gr=grr,input=beta.new[i,],method='Nelder-
Mead')$value 
#Change limits depending on sample size 
 alt[i]<-
optim(par=rep(.5,4),fn=alt.function,input1=beta.new[i,1:40],input2=beta.new[i,41:80],met
hod='Nelder-Mead')$value 
} 
like.test<--2*(alt-null) 
 
pvals.like<-pchisq(like.test,df=2,lower.tail=FALSE) 
#Type 2: say equal when not equal 
sig.like<-pvals.like 
type2.like<-numeric() 
for (i in 1:nreps){ 
type2.like[i]<-ifelse(sig.like[i]>sig.level,1,0) 
} 
type2error.like<-sum(type2.like)/nreps 
 
#################### 
#### Bstrap########### 
#################### 
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Red<-red.data.new 
Green<-green.data.new 
#Change limits depending on sample size 
Red.pos<-Red[,1:40] 
Red.neg<-Red[,41:80] 
Green.pos<-Green[,1:40] 
Green.neg<-Green[,41:80] 
teststat<-numeric() 
for (i in 1:nreps){ 
teststat[i]<-mean((Red.pos[i,])/(Red.pos[i,]+Green.pos[i,]))-
mean((Red.neg[i,])/(Red.neg[i,]+Green.neg[i,])) 
} 
#Number of bootstrap samples 
B<-2500 
 
b.teststat<-matrix(ncol=B,nrow=nreps) 
set.seed(123) 
for (b in 1:B) { 
#Change limits depending on sample size 
bsample<-sample(1:80,replace=TRUE) 
red<-Red[,bsample] 
green<-Green[,bsample] 
Red.positive<-red[,1:40] 
Green.positive<-green[,1:40] 
Red.negative<-red[,41:80] 
Green.negative<-green[,41:80] 
for (i in 1:nreps){ 
b.teststat[i,b]<-mean((Red.positive[i,])/(Red.positive[i,]+Green.positive[i,]))-
mean((Red.negative[i,])/(Red.negative[i,]+Green.negative[i,])) 
} 
 
} 
 
b.teststat.sort<-matrix(ncol=B,nrow=nreps) 
for (i in 1:nreps){ 
b.teststat.sort[i,]<-sort(b.teststat[i,]) 
} 
 
result<-numeric() 
for (i in 1:nreps){ 
result[i]<-ifelse(teststat[i]<b.teststat.sort[i,25]|teststat[i]>b.teststat.sort[i,975],1,0) 
} 
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asl<-numeric() 
for (i in 1:nreps){ 
asl[i]<-sum(ifelse(b.teststat[i,]>abs(teststat[i]) | b.teststat[i,]< -abs(teststat[i]),1,0))/B 
} 
sig.level<-0.05 
 
#Type 2: say equal when not equal 
sig.bstrap<-asl 
type2.bstrap<-numeric() 
for (i in 1:nreps){ 
type2.bstrap[i]<-ifelse(sig.bstrap[i]>sig.level,1,0) 
} 
type2error.bstrap<-sum(type2.bstrap)/nreps 
 
######################## 
##### Beta Test########### 
######################## 
 
## Differentially expressed CpG sites 
#Generate many observations to get more stable estimate 
set.seed(123) 
positive.sig<-
mvrnorm(3152,mu=c(mu.red.positive,mu.green.positive),Sigma=matrix(c(s2.red.positive,c
ov.positive,cov.positive,s2.green.positive),nrow=2)) 
red.positive<-positive.sig[,1] 
green.positive<-positive.sig[,2] 
negative.sig<-
mvrnorm(3152,mu=c(mu.red.negative,mu.green.negative),Sigma=matrix(c(s2.red.negative
,cov.negative,cov.negative,s2.green.negative),nrow=2)) 
red.negative<-negative.sig[,1] 
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green.negative<-negative.sig[,2] 
beta.positive<-red.positive/(red.positive+green.positive) 
beta.negative<-red.negative/(red.negative+green.negative) 
mu.beta.positive<-mean(beta.positive) 
s2.beta.positive<-var(beta.positive) 
a.positive<-mu.beta.positive*(mu.beta.positive*(1-mu.beta.positive)/s2.beta.positive-1) 
p.positive<-(1-mu.beta.positive)*(mu.beta.positive*(1-mu.beta.positive)/s2.beta.positive-
1) 
mu.beta.negative<-mean(beta.negative) 
s2.beta.negative<-var(beta.negative) 
a.negative<-mu.beta.negative*(mu.beta.negative*(1-mu.beta.negative)/s2.beta.negative-1) 
p.negative<-(1-mu.beta.negative)*(mu.beta.negative*(1-
mu.beta.negative)/s2.beta.negative-1) 
 
variance <- function(a, b) a * b/((a + b + 1) * (a + b)^2) 
mean.beta <- function(x,y) { 
xbar<-mean(c(x,y)) 
v<-var(c(x,y))*(length(c(x,y))-1)/length(c(x,y)) 
a <- xbar * (xbar * (1 - xbar)/v - 1) 
b <- (1 - xbar) * (xbar * (1 - xbar)/v - 1) 
var <- variance(a, b) 
list(xbar = xbar, alpha = a, beta = b, var = var) 
} 
 
set.seed(123) 
x.pos<-rbeta(3152,a.positive,p.positive) 
set.seed(123) 
x.neg<-rbeta(3152,a.negative,p.negative) 
 
combined <- mean.beta(x.pos, x.neg) 
#Compute Quantile value under null hypothesis of equality 
Q <- (qbeta(0.975, combined$alpha, combined$beta) - combined$alpha/(combined$alpha 
+ combined$beta))/sqrt(variance(combined$alpha, combined$beta)) 
set.seed(123) 
power <- numeric() 
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#Change n1 and n2 based on sample size  
n1 <- 40 
n2 <- 40 
set.seed(123) 
for (i in 1:3152) { 
x <- rbeta(n1, a.positive, p.positive) 
y <- rbeta(n2, a.negative, p.negative) 
Critical <- 0 + Q * sqrt(variance(a.positive, p.positive)/n1 + 
variance(a.negative,p.negative)/n2) 
power[i] <- ifelse(abs(mean(x) - mean(y)) > Critical, 1, 0) 
} 
type2error.beta<-1-sum(power)/3152 
 
#Type 2 error rates and parameter estimates (for use in calculating variance of beta 
distribution) 
type2error.ttest 
type2error.bib 
type2error.beta 
type2error.like 
type2error.bstrap 
a.positive 
p.positive 
a.negative 
p.negative  
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